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ABSTRACT 
 
MECHANISMS OF PERIPHERAL TRANSPLANTATION TOLERANCE 
LUÍS GRAÇA 
D.PHIL. TRINITY TERM 2002, PHYSIOLOGICAL SCIENCES 
 
 
A short-term treatment leading to long-term acceptance of transplanted 
tissues has been one of the major objectives in transplantation immunology. 
Non-depleting monoclonal antibodies, such as those targeting CD4, CD8 and 
CD154, have been shown effective in inducing transplantation tolerance. The 
cellular and molecular mechanisms that allow tolerance induction and 
maintenance are still largely unknown. A more precise identification of such 
mechanisms would allow the development of more robust tolerogenic 
strategies, and the generation of new diagnostic tools. 
 
This thesis demonstrates that transplantation tolerance induced by co-
stimulation blockade leads to a dominant and infectious form of tolerance 
maintained by CD4+ T cells. Co-stimulation blockade, when combined with 
co-receptor blockade, led to robust tolerance of fully mismatched skin 
allografts. Such tolerance was also dominant, manifest by linked-suppression 
and a dependence on regulatory CD4+ T cells.  
 
I examined the phenotype of T cells maintaining dominant tolerance, and 
concluded that these could be found within both the CD4+CD25+ and 
CD4+CD25- populations of tolerised mice, yet only among the CD4+CD25+ T 
cells of naïve animals. Such regulatory cells were found not only in the 
spleen of tolerised mice, but also in the tolerated tissue. Finally, I describe a 
strategy to eliminate the immunogenicity of “therapeutic” mAbs by temporarily 
interfering with their capacity to bind to cells. Further elucidation of 
mechanisms of transplantation tolerance, namely the identification of specific 
markers for regulatory T cells, may lead to significant advances on our 
understanding of T cell suppression and may greatly facilitate the clinical 
application of tolerogenic strategies. 
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i.p.  Intraperitoneal 
i.v.  Intravenous 
mAb  Monoclonal antibody 
MFI  Mean fluorescence intensity 
MHC  Major histocompatibility complex 
MST  Median survival time 
NK  Natural killer 
NMS  Normal mouse serum 
 v
NOS  Nitric oxide synthase 
PBL  Peripheral blood lymphocyte 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PE  Phycoerythrin 
PerCP Peridinin chlorophylla protein 
QR  Quantum red 
RA  Rheumatoid arthritis 
RT-PCR Reverse transcription PCR 
SAGE  Serial analysis of gene expression 
SEB  Staphylococcal enterotoxin B 
SPF  Specific pathogen free 
ST  Streptavidin 
ST-APC Streptavidin-allophycocyanin 
TCR  T cell receptor 
TCM  Central-memory T cell 
TE  Thymic epithelium 
TEM  Effector-memory T cell 
TGF  Transforming growth factor 
Th  T-helper 
TNF  Tumour necrosis factor 
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 CHAPTER 1 
 
INTRODUCTION 
 
 
Immunological tolerance to a foreign antigen or tissue can be defined as the 
state of unresponsiveness to the antigen, following prior contact with that 
antigen, where the host remains competent to mount an effective aggressive 
immune response against third-party antigens. The mammalian immune 
system is usually tolerant to the host’s own cells and molecules (self-
tolerance), except in pathological conditions designated as autoimmunity. It is 
then the normal function of the immune system to be able to generate 
aggressive immune responses against non-self constituents entering the 
body, particularly microbes and their products, whilst remaining harmless to 
the autologous components.  
 
The attainment of therapeutic tolerance has been considered the Holy Grail 
of immunology ever since the pioneering work of Medawar and colleagues 
(Billingham et al., 1953). This goal is not only important to enable successful 
allogeneic transplantation, but also to overcome unwanted immune 
responses to therapeutic proteins and gene products. This is the case for the 
majority of therapeutic monoclonal antibodies (mAbs) and correction of 
genetic defects by enzyme replacement and gene therapy. Immune 
responses against such therapeutic products shorten their half-life and utility.  
 
The main objective of this thesis’ work was to investigate how the immune 
system may become tolerised to therapeutic proteins and transplanted cells 
and organs. An understanding of the mechanisms involved, could enable us 
to manipulate the system more effectively. 
   1
 1. 1  Self-tolerance 
 
The immune system has evolved as a mechanism to protect the body against 
foreign infectious pathogens. However, in spite of being capable of detecting 
and destroying foreign microbes without prior experience, the immune 
system has to remain unresponsive against self-antigens. This 
unresponsiveness towards “self” is usually referred to as “self-tolerance”. 
There is therefore a balance between processes leading to aggression 
towards non-self and those enabling self-tolerance. Occasionally this balance 
is disturbed leading to immunodeficiency and susceptibility to infection on the 
one hand, and autoimmunity on the other. As a consequence, the capacity to 
maintain self-tolerance without compromising protective immunity must have 
been a major issue in natural selection. Thus, it is not surprising that several 
immune mechanisms have co-evolved so as to maintain both self-tolerance 
and immunity. The mammalian immune system of today shows a remarkably 
robust capacity for self-tolerance, in spite of its equally efficient performance 
in attacking foreign microbes – the latter creating a major hurdle for 
transplantation and the therapeutic administration of “foreign” proteins and 
genes.  
 
1.1.1  Central tolerance 
 
In order for the immune system to be capable of mounting an efficient 
immune response to any foreign pathogen, always evolving and 
consequently changing its antigenic content, antigen-specific receptors are 
generated by somatic rearrangement of germ-line gene segments 
(Tonegawa et al., 1974). In this way, a sufficient diversity of receptors is 
generated to allow the recognition of virtually any antigen generated by 
infectious agents. Naturally, many of those generated antigen receptors of T 
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 cells will bind to self. Without a censoring mechanism these autoreactive cells 
might then lead to autoimmune disease. 
 
The thymus is the organ where developing thymocytes, precursors of mature 
T cells, are generated and selected for their capacity to interact with self-
MHC and associated antigens. During thymic “education” thymocytes interact 
with thymic stroma, first in the outer cortex, and finally in the medulla. The 
thymic stroma provides survival factors to thymocytes expressing a T cell 
receptor (TCR) capable of binding self-MHC loaded with antigen. 
Thymocytes failing to engage in such interactions are committed to 
apoptosis. This process, known as positive selection, leads to a T cell 
repertoire where the TCRs are restricted to self MHC molecules (Zinkernagel 
and Doherty, 1974; Zinkernagel, 1974; Zinkernagel et al., 1978). However, 
due to similarities between different MHC alleles, and to the selection of T 
cells whose TCRs weakly interact with a MHC molecule, T cells can be 
activated by cells expressing non-self MHC. This phenomenon is one of the 
major factors determining transplant rejection of MHC mismatched tissues, 
being known as “direct presentation” (described below). 
 
“Positive selection” would lead by itself to the generation of many 
autoreactive T cells. It has been suggested that the fate of developing 
thymocytes depends on the avidity of the interaction they establish with the 
thymic stroma (Jameson et al., 1994; Sebzda et al., 1994; Alam et al., 1996). 
When a TCR interaction with peptide-loaded MHC results is of low or 
intermediate avidity, the cells are rescued from death by neglect due to 
receiving a survival factor. However, a high avidity interaction results in the 
delivery of an apoptotic signal leading to cell death. Such is the basis of 
thymic “negative selection”, a process evolved to purge the T cell repertoire 
of cells expressing TCRs which bind avidly to self-antigens presented by 
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 thymic antigen presenting cells (APCs) (Kappler et al., 1987; MacDonald et 
al., 1988; von Boehmer et al., 1989).  
 
Thymic negative selection gave support to the view that self-tolerance could 
be explained by the deletion of autoreactive T cell clones, an idea originally 
introduced by Burnet to explain aspects of antibody (Ab) production (Burnet, 
1957). Clonal deletion, or central tolerance, was based on the assumption 
that negative selection in the thymus could purge the immune system of any 
autoreactive T cells. Indeed, thymic selection has a major impact in shaping 
the repertoire of peripheral T cells, with more than two thirds of positively 
selected thymocytes being subsequently deleted by exposure to self peptides 
in the thymic medulla (Murphy et al., 1990). However, despite this, T cells 
with autoreactive TCRs are exported from the thymus and can be 
demonstrated to be present in the periphery (Ramsdell et al., 1989; 
Schonrich et al., 1992).  
 
1.1.2  Peripheral tolerance 
 
Not all autoreactive T cells are deleted or anergised in the thymus. It is 
possible to identify peripheral T cells with capacity to cause damage to self-
tissues from normal animals (Powrie and Mason, 1990; Fowell and Mason, 
1993). It is likely that the majority of such autoreactive T cells are specific for 
antigens that are not expressed in the thymus, or that are expressed at low 
levels. Consequently, there may be a number of fail-safe mechanisms 
operating to prevent autoimmune disease. Peripheral mechanisms such as 
deletion, anergy, ignorance and regulation are thought to offer a further level 
of control over autoreactive T cells in the periphery. Furthermore, there is 
evidence that the thymus can export regulatory T cells important for the 
maintenance of immune tolerance (Seddon and Mason, 2000).  
   4
 1.1.2.1 Peripheral deletion 
 
Clonal deletion of auto-reactive T cell clones is not exclusive to the thymus. 
Several experiments show that deletion can also occur in the periphery. In 
one such experiment, in vivo injection of the superantigen Staphylococcal 
enterotoxin B (SEB) led to transient proliferation of SEB reactive Vβ8+ T cells, 
followed by their deletion to numbers below those prior to treatment (Kawabe 
and Ochi, 1991; MacDonald et al., 1991). Similar results were obtained 
following administration of the superantigen Mls-1a (Webb et al., 1990; Jones 
et al., 1990), or in T cell transgenic mice specific for a male H-Y peptide in 
the context of MHC class I molecules (Zhang et al., 1992). 
 
However, peripheral T cell deletion is unlikely to account for the whole of 
peripheral tolerance. High doses of antigen are required for peripheral 
deletion, and even in such circumstances a residual population of antigen-
specific cells was seen to persist (Chen et al., 1995). Furthermore, it has 
been suggested that given the high degree of cross-reactivity of TCRs, self-
tolerance by deletion alone would create a major hole in the T cell repertoire 
(Mason, 1998). 
 
1.1.2.2  Ignorance and indifference 
 
Immune ignorance has been defined as the situation where T cells do not 
lead to immune reactivity towards their specific antigens, as such antigens 
are not encountered in an immunogenic form by T cells during their normal 
recirculation (Oldstone et al., 1991; Ohashi et al., 1991).  
 
It has been shown that naïve T cells do not circulate through non-lymphoid 
tissues (Mackay et al., 1990), and consequently lack the capacity to inflict 
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 damage in those tissues even when they are reactive against tissue specific 
antigens. In support of this hypothesis it was shown that transgenic mice 
expressing the MHC class I molecule H-2Kb in pancreatic islet β-cells (rat 
insulin promoter RIP-Kb mice) do not develop diabetes even when most of 
their CD8+ T cells express a Kb specific TCR (Heath et al., 1995). However, 
when primed with Kb-bearing skin grafts, as the skin transplants are rejected, 
the pancreatic islets become infiltrated and are ultimately destroyed (Heath et 
al., 1995). More recently it was shown that T cell replete mice lacking 
secondary lymphoid tissue fail to reject vascularised cardiac allografts, 
suggesting that alloimmune responses to vascularised organ transplants are 
not initiated in the graft itself (Lakkis et al., 2000).  
 
The danger model, proposed by Matzinger in 1994 (Matzinger, 1994), can be 
seen as a variation on the ignorance theme (Matzinger, 2001; Matzinger, 
2002). In brief, the danger model postulates that autoreactive cells present in 
the periphery do not cause damage for as long as signals of cell death or 
distress (“danger”) are absent. It differs from the immune ignorance model in 
that T cells remain unresponsive even when they have access to the antigen, 
providing there are no “danger” signals. In other words, the autoreactive T 
cells are indifferent rather than ignorant to the antigen. The finding of 
dominant regulation, discussed below, casts doubts on whether such a model 
is useful as a complete explanation for tolerance. Without doubt “danger” or 
“adjuvanticity” are important initiators of immune responses. However, there 
is now compelling evidence that regulatory T cells can prevent aggressive 
immune responses even in situations where danger is present (see below). 
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 1.1.2.3  Anergy 
 
T cell anergy was described as the functional state in which T cells remain 
viable but unable to respond to optimal stimulation through both the TCR and 
costimulatory molecules (Schwartz, 1996). The functional state of anergic T 
cells can be defined by their incapacity to proliferate or to produce interleukin-
2 (IL-2) (Lamb et al., 1983; Schwartz, 1990).  
 
Anergy was first described in studies with human T cell clones specific for 
influenza virus haemaglutinin peptides (Lamb et al., 1983). In such studies, 
incubation of T cells with high doses of the antigen resulted in T cell 
unresponsiveness to subsequent presentation of the peptide in normal 
stimulatory conditions (Lamb et al., 1983). Later, it was shown that anergy 
could be induced by antigen recognition in the absence of co-stimulation 
(Quill and Schwartz, 1987; Jenkins and Schwartz, 1987), the use of altered 
peptide ligands (Sloan-Lancaster et al., 1993; Sloan-Lancaster et al., 1994), 
or direct presentation by activated rat or human T cells which express MHC 
class II molecules (Lombardi et al., 1996; Taams et al., 1998).  
 
T cell anergy has also been described in vivo in several animal models. 
Initially it was reported following transplantation tolerance induced by anti-
CD4 mAbs (Qin et al., 1989; Alters et al., 1991). But in vivo T cell anergy was 
also decribed following injection of cells expressing a self-superantigen (Mls-
1a) into mice (Rammensee et al., 1989), following aqueous peptide antigen 
administration in mice (Burstein et al., 1992), in double transgenic mice for a 
TCR and its surrogate self antigen (Schonrich et al., 1992; Jordan et al., 
2000), and in oral tolerance (Chen et al., 1994). 
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 Interestingly, anergic T cells were found capable to suppress proliferation of 
naïve T cells in vitro (Lombardi et al., 1994) and in vivo (Chai et al., 1999). 
However, the T cells used in both instances were rendered anergic following 
in vitro incubation with immobilised anti-CD3 mAb. There has been no report 
yet of suppressive function of T cells obtained following physiological in vivo 
induction of anergy by antigen stimulation. In any case, such observations 
support the “civil service model” proposed by Waldmann (Waldmann et al., 
1992), that postulates that antigen specific unresponsive cells can interfere 
with the generation of help by co-localising with other T cells and competing 
for elements in the microenvironment (such as adhesion molecules or 
cytokines). As a consequence by preventing adequate “help” from being 
generated the anergic cells could suppress the proliferation and effector 
function of the naïve T cells. 
 
1.1.2.4  Regulatory T cells 
 
The existence of regulatory T cells, at that time named suppressor T cells, 
was first suggested in the early 70s following the observation that it was 
possible to transfer T cell unresponsiveness between animals (Gershon and 
Kondo, 1970; Droege, 1971). At that time CD8+ T cells were believed to 
contain the population of suppressor T cells. However, interest in the 
phenomenon faded as many experimental systems proved hard to sustain, 
and the results difficult to explain. As a consequence the field was brought 
into disrepute and the term “suppressor T cells” became a taboo word for 
immunologists (Bloom et al., 1992; Green and Webb, 1993).  
 
However, in recent years, several different groups have clearly established 
the existence of CD4+ T cells with suppressive properties, now named 
regulatory T cells (reviewed in Maloy and Powrie, 2001; Sakaguchi, 2000; 
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 Shevach, 2000; Waldmann and Cobbold, 2001). First, indirect evidence for 
the existence of T cells capable of suppressing autoimmune responses 
resulted from studies with mice thymectomised at day 3. Such animals 
developed autoimmune diseases such as oophoritis (Nishizuka and 
Sakakura, 1969), thyroditis (Kojima et al., 1976), or gastritis (Kojima et al., 
1980), that could be prevented by adoptive transfer of thymocytes or 
splenocytes from normal syngeneic animals. With the development of 
methods allowing specific depletion or sorting of T cell subsets it became 
possible to further characterise the phenotype of regulatory T cells that could 
prevent the onset of autoimmune diseases or gut immunopathology upon 
adoptive transfer into susceptible animals and also in therapeutically induced 
tolerance. Initially Sakaguchi identified the regulatory capacity among the 
CD5+ T cells (Sakaguchi et al., 1985), while in experimentally induced 
tolerance regulatory activity was present among the CD4+ T cells (Hall et al., 
1985). The CD4+ cells have been further subdivided: first the regulatory 
capacity was found to be within the CD4+CD45RClow compartment in the rat 
(Powrie and Mason, 1990; Fowell and Mason, 1993) or the CD4+CD45RBlow 
compartment in mice, and later within the CD4+CD25+ compartment 
(Sakaguchi et al., 1995; Asano et al., 1996). Read et al has shown, by 
comparing the regulatory capacity of CD4+CD25+CD45RBlow and CD4+CD25-
CD45RBlow that only the first population could suppress colitis in scid mice 
co-transferred with CD4+CD45RBhigh T cells (Read et al., 2000). It can thus 
be concluded that CD25 is a more useful marker than CD45RB. However, it 
was shown that CD4+CD25-CD45RClow T cells can prevent diabetes in 
lymphopenic rats, although the regulatory capacity of these cells was inferior 
to the potency of CD4+CD25+CD45RClow (Stephens and Mason, 2000). More 
recently an equivalent subset of CD4+CD25+ regulatory T cells was isolated 
from humans, and suppressive capacity was confirmed in vitro, by inhibition 
of proliferation of target T cells (Ng et al., 2001; Dieckmann et al., 2001; 
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 Jonuleit et al., 2001; Stephens et al., 2001; Levings et al., 2001; Taams et al., 
2001; Baecher-Allan et al., 2001). 
 
Other markers, such as L-selectin (CD62L) (Herbelin et al., 1998) or CD38 
(Read et al., 1998) have been suggested as possible surface markers of 
regulatory cells. However they were not shown to be useful markers to further 
subdivide the CD4+CD25+ regulatory T cell population (Read et al., 2000).  
 
It is still unclear whether regulatory T cells constitute a specific lineage 
originating in the thymus. Recent evidence has suggested that thymocytes 
are more potent than splenocytes in preventing autoimmunity in lymphopenic 
mice (Saoudi et al., 1996). Furthermore, thymectomised PVG rats treated 
with sublethal irradiation develop autoimmune thyroiditis that can be 
prevented by adoptive transfer of CD4+CD45RClow T cells or CD4+CD8- 
thymocytes from syngeneic donors. However, when thyroids were ablated in 
utero with I131, peripheral T cells, but not thymocytes, lost the capacity to 
prevent thyroiditis (Seddon and Mason, 1999a). Such result suggests that 
regulatory T cells develop within the thymus, and once exported to the 
periphery require contact with the antigen in order to keep their regulatory 
function. It was also shown that it is possible to induce allospecific tolerance 
by grafting allogeneic thymic epithelium (TE) into athymic (nude) mice at 
birth. The grafted mice reconstitute normal numbers of T cells and accept 
skin grafts syngeneic with the TE, being competent to reject third-party 
allografts (Modigliani et al., 1995). In addition, when CD4+ T cells from the TE 
chimeras were transferred into immunocompetent syngeneic hosts, such 
mice became themselves tolerant for TE-type allografts (Modigliani et al., 
1995). Taken together, these results led to the notion that the production of 
regulatory T cells may be a further property of the thymus (Seddon and 
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 Mason, 2000). Significantly, a role for the thymus in transplantation tolerance 
induced with non-depleting mAbs has never been shown (see below). 
 
1.1.2.5  Functional characteristics of regulatory T cells 
 
The functional characteristics of natural regulatory T cells still remain to be 
elucidated.  
 
Most studies have used inhibition of T cell proliferation as the readout of T 
cell suppression. Such studies have been used to confirm the suppressive 
capacity of T cells rendered anergic following incubation with immobilised 
anti-CD3 mAb (Lombardi et al., 1994), or regulatory T cell clones (Tr1) 
(Groux et al., 1997), or more recently CD4+CD25+ T cells (reviewed in 
(Sakaguchi, 2000; Shevach et al., 2001).  
 
In the first case, anergic T cells were shown to inhibit antigen specific T cell 
proliferation in vitro, providing the antigen recognised by both the anergic T 
cells and these specific T cells being suppressed was present in the same 
APC (Lombardi et al., 1994). The Tr1 clones were also shown capable of 
inhibiting proliferation of CD4+ T cells in response to antigen (Groux et al., 
1997). CD4+CD25+ T cells required activation prior to their suppressive 
activity. Following such antigen specific activation, their suppressive activity 
was antigen non-specific (Thornton and Shevach, 2000). Inhibition mediated 
by CD4+CD25+ cells was not dependent on cytokines or other soluble factors, 
but required direct cellular contact (Takahashi et al., 1998; Thornton and 
Shevach, 1998).  
 
Other in vitro studies have suggested that anergic or CD4+CD25+ regulatory 
T cells exerted their suppressive function by down-regulating the expression 
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 of MHC class I and the co-stimulatory molecules CD80 and CD86 on 
dendritic cells (DCs) (Vendetti et al., 2000; Cederbom et al., 2000). As a 
consequence the DC would become “decommissioned” for T cell activation 
(Fairchild and Waldmann, 2000). Such concept is particularly appealing 
considering that DCs were shown capable of acting as a temporal bridge 
between helper T cells, and CD8+ T cells (Ridge et al., 1998; Bennett et al., 
1998; Schoenberger et al., 1998). It is tempting to establish a parallel and 
predict that DCs may also act as a temporal bridge between T cells with 
suppressive function and the T cells being suppressed. This could be 
achieved by modulation of the maturation state of the DC, as it has been 
reported that immature DCs have tolerogenic properties (Jonuleit et al., 2000; 
Dhodapkar et al., 2001; Roncarolo et al., 2001). The recent identification of a 
method to induce the differentiation of DCs from embryonic stem cells 
(Fairchild et al., 2000) may allow confirmation that by modifying the 
maturation state of DCs one can render them tolerogenic. 
 
Alternatively, it was suggested that suppression mediated by CD4+CD25+ T 
cells require direct interaction between the suppressive T cell and the T cell 
being suppressed, as it could operate with fixed APCs or in the absence of 
APCs (Takahashi et al., 1998; Thornton and Shevach, 2000). It is not clear at 
this moment whether regulatory T cells induce suppression via DC 
modulation in addition to a direct suppressive effect on other T cells, or 
whether the two mechanisms are distinct regulatory circuits.  
 
Following the identification that CTLA-4 is constitutively expressed on the 
majority of CD4+CD25+ regulatory T cells, different groups investigated 
whether such molecule could be an important mediator of T cell regulation. 
Indeed, by using anti-CTLA4 neutralising mAbs it was shown, both in vitro 
and in vivo, that in the presence of such mAbs suppression mediated by 
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 CD4+CD25+ T cells was abrogated (Read et al., 2000; Takahashi et al., 
2000). Such results were not confirmed in other experiments (Ng et al., 2001; 
Dieckmann et al., 2001; Jonuleit et al., 2001; Stephens et al., 2001; Levings 
et al., 2001; Taams et al., 2001; Baecher-Allan et al., 2001; Shevach, 2001; 
Graca et al., 2002b; Chapter 5). It is possible that some of the effects seen 
when anti-CTLA4 mAbs are used, result from their effect on the effector cell 
population rendering them more sensitive to antigen mediated signals 
(Hurwitz et al., 2002; Egen and Allison, 2002). However, recently Read et al 
found that when CD4+CD45RBhigh T cells from CTLA-4-/- mice were co-
transferred with wild-type CD4+CD25+ T cells, into T cell-deficient mice, these 
mice were protected from inflammatory bowel disease (IBD). However, when 
the CD4+CD45RBhigh T cells from CTLA-4-/- mice were injected in the 
absence of CD4+CD25+ T cells, or when both populations were co-
administered together with anti-CTLA4 mAb, the recipient mice developed 
IBD (S. Read, personal communication). Such results suggest that, in 
addition to possible effects of anti-CTLA4 mAb on effector cells, the same 
mAbs may have an effect on regulation by CD4+CD25+ T cells, at least in 
relation to specific situations. 
 
Several cytokines were also suggested as being key factors mediating T cell 
suppression. Much of the evidence supporting the suppressive role of key 
cytokines derived from studies of “immune deviation” discussed below. 
 
1.1.2.6  Immune deviation: the Th1 – Th2 (and Th3 / Tr1) paradigm 
 
It was shown that terminally differentiated CD4+ T cells could be functionally 
divided according to the cytokines they produce: T helper 1 (Th1) cells that 
produce IL-2, interferon-γ (IFN-γ) and tumour necrosis factor-α (TNF-α); and 
the Th2 cells, which produce IL-4, IL-5, IL-6, IL-10, and IL-13 (Mosmann et 
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 al., 1986; Mosmann and Coffman, 1989). Naïve T cells, also named Th0, are 
believed to have the potential to differentiate towards any of the above 
mentioned fates (reviewed in O'Garra, 1998). Th0 cells are consequently 
non-polarised and capable of secreting low levels of Th1 or Th2 type 
cytokines. At the onset of an immune response the microenvironment in 
which the cells are found determines the direction in which they polarise, 
which is further reinforced by the effect of the cytokines the cells produce in 
driving differentiation towards that same type while inhibiting differentiation 
towards the opposing cell type (Gajewski and Fitch, 1988; Fiorentino et al., 
1989; McKnight et al., 1994; Sad and Mosmann, 1994). 
 
It has been suggested that autoimmunity and allograft rejection are immune 
responses dependent on Th1 cells, that could be suppressed by “deviating” 
the immune response towards the Th2 type of behaviour (Waldmann and 
Cobbold, 1993; Abbas et al., 1996). This hypothesis was supported by 
evidence of an absence of Th1 type cytokines, and presence of Th2 type 
cytokines, in animals demonstrating long-term graft survival (Takeuchi et al., 
1992; Hancock et al., 1993; Mottram et al., 1995; Sayegh et al., 1995). 
Furthermore, in animal models of gut immunopathology and autoimmune 
disease, a Th1 type of response seem to correlate with the pathology, that 
could be abrogated by deviating the response towards Th2 (Powrie and 
Mason, 1990; Saoudi et al., 1993; Kuchroo et al., 1993; Powrie et al., 1994b; 
Powrie et al., 1994a).  
 
However, a number of studies have suggested that tolerance could not 
simply be explained by immune deviation towards Th2 type responses. 
Although it was shown that prolongation of graft survival could be achieved 
by administration of Th2 type cytokines (Levy and Alexander, 1995; Takeuchi 
et al., 1997), other studies found no evidence for Th2 involvement in 
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 promoting long-term graft survival (Krieger et al., 1996; Plain et al., 1997). 
Furthermore, Th2 cells were shown capable of inducing autoimmune disease 
(Lafaille et al., 1997; Pakala et al., 1997) and to mediate allograft rejection 
(Chan et al., 1995; VanBuskirk et al., 1996; Zelenika et al., 1998). 
Furthermore, in transplantation tolerance induced by non-depleting anti-CD4 
and anti-CD8 mAbs, the frequency of Th1 and Th2 cells, as determined by 
limiting dilution analysis, was shown to be similar in tolerised and rejecting 
mice (Cobbold et al., 1996).  
 
The role of Th2 type cytokines in immune tolerance has been extensively 
studied, but no consensus has yet been reached as there are several 
contradictory reports. Antibodies targeting IL-4 were shown to abrogate 
transplantation tolerance (Donckier et al., 1995; Davies et al., 1996b; 
Onodera et al., 1997), although in one of these studies the effect was only 
partial (Davies et al., 1996b). However, in other studies transplantation 
tolerance was shown to be IL-4 independent (Hall et al., 1998; Chapter 5), as 
was prevention of gut immunopathology by CD4+CD45RBlow cells (Powrie et 
al., 1996). 
 
Several groups have used mAbs to neutralise IL-10, showing a role for this 
molecule in immune tolerance (Asseman et al., 1999; Hara et al., 2001; 
Kingsley et al., 2002). However, injection of anti-IL10 mAb failed to break 
anti-CD4 induced transplantation tolerance (Davies et al., 1996b; Graca et 
al., 2002b; Chapter 5).  
 
More recently, a CD4+ T cell clone producing IL-4, IL-10 but also tranforming 
growth factor β (TGF-β) and capable of suppressing autoimmune 
encephalomyelitis (EAE) in mice was described (Chen et al., 1994). Such 
clone was named Th3. Another T cell clone capable of suppressing gut 
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 immunopathology induced following transfusion of CD4+CD45RBhigh splenic T 
cells into SCID mice was defined as T regulatory 1 (Tr1) (Groux et al., 1997). 
Such cells can be generated in vitro following stimulation in the presence of 
IL-10, have a low proliferative capacity, produce high levels of IL-10, 
moderate levels of TGF-β, low levels of IL-2 and IL-4, and are capable of 
suppressing the proliferation of CD4+ T cells in vitro (Groux et al., 1996). 
Consistent with a role for these types of cells in vivo was the finding that 
prevention of EAE, or other immunopathology triggered by CD4+CD45RChigh 
cell transfusion into lymphopenic mice, could be abrogated following 
administration of anti-IL10 and anti-TGFβ mAb (Doetze et al., 2000; Kitani et 
al., 2000; Read et al., 2000). The relationship between Th3 and Tr1 CD4+ T 
cell populations, if any, is not yet clear (reviewed in Roncarolo and Levings, 
2000). It is also unclear whether Th3/Tr1 cells bear any relationship to the 
naturally occurring CD4+CD25+ T cells, as they do not seem to share an 
obvious mechanism of action (Roncarolo and Levings, 2000). A direct 
comparison of genes expressed by Th1, Th2 and Tr1 T cell clones suggested 
that Th2 and Tr1 cells may be very closely related (Zelenika et al., 2002). 
 
1.1.2.7  In vitro and in vivo assays of regulatory T cell function 
 
The development of reliable in vitro systems have been useful in the 
elucidation of many immune mechanisms. However, recent findings raise 
doubts on whether current assays are adapted for the study of T cell 
regulation. The most popular of the assays used measures the capacity of 
putative regulatory cell population to inhibit proliferation of target T cells. 
Such assays have been used to assess the regulatory capacity of anergic T 
cells (Lombardi et al., 1994), Tr1 clones (Groux et al., 1996), or more recently 
CD4+CD25+ T cells (Thornton and Shevach, 1998; Takahashi et al., 1998; Ng 
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 et al., 2001; Dieckmann et al., 2001; Jonuleit et al., 2001; Stephens et al., 
2001; Levings et al., 2001; Taams et al., 2001; Baecher-Allan et al., 2001).  
 
Recently it was shown in the host laboratory that in vitro proliferation of CD4+ 
T cells and IFN-γ secretion can be inhibited by co-culture with antigen specific 
Th1, Th2 or Tr1 clones (Zelenika et al., 2001). Although inhibition of 
proliferation mediated by Th1 cells could be abrogated by addition of 
inhibitors of nitric oxide synthase (NOS), suppression mediated by Th2 and 
Tr1 clones was NOS independent (Zelenika et al., 2001). Interestingly, when 
suppressive capacity of the same T cell clones was assessed by in vivo 
capacity to prevent skin graft rejection, only the Tr1 clone was found to have 
regulatory properties (Zelenika et al., 2002). 
 
Furthermore, Chun-Yen Lin, also in the host laboratory, conclusively 
demonstrated that when allo-specific CD8+ T cells are injected into tolerant 
mice, they proliferate and survive to the same extent as in non-tolerant mice. 
The only apparent difference between the two cases is that when transfused 
into tolerant mice the allo-specific CD8+ T cells fail to produce IFN-γ, generate 
cytotoxic T cells (CTL) and reject grafts (Lin et al., 2002; Lin, 2002). In other 
words, it appears that the in vivo function of regulatory T cells is not inhibition 
of proliferation or abrogation of T cell help, but rather they act by “disarming” 
the effector T cells. Preliminary results suggest that the same conclusions 
can be extended to suppression of CD4+ T cells (Lin, 2002). 
 
When taken together, these results question whether the currently available 
in vitro tests are adequate for the study of T cell suppression. It is possible, 
due to the uncertainties about the mechanism of action of regulatory T cells, 
that in vitro assays still do not include all the factors relevant for the study of 
T cell regulation. Until in vitro assays are further refined I believe the in vivo 
   17 
 experimental systems to be more reliable for the study of this complex 
phenomenon. 
 
1.2  Therapeutically induced tolerance 
 
Induction of therapeutic tolerance (Figure 1.1) has been one of the major 
aspirations of immunologists. This is not only important for transplantation, 
and the treatment of autoimmune diseases, but also to overcome immune 
responses that target molecules therapeutically introduced in the patient. 
Currently, the prevention of transplant rejection is achieved by administration 
of immunosuppressive drugs, with their associated side effects. 
 
Such immunosuppressive regimens target the whole immune system. 
However, an elective ablation of only the alloreactive clones, if feasible, offers 
a way of preventing graft rejection while sparing host’s immunocompetence. 
One possible approach to achieving this involves the establishment of mixed 
hematopoietic chimerism or macro-chimerism by transfer of a high dose of 
donor bone marrow cells (Ildstad and Sachs, 1984; Wekerle and Sykes, 
1999; Wekerle et al., 2000). This permits in vitro monitoring of the tolerant 
state by sampling lymphocytes from the host and testing their reactivity 
against donor-type cells. Such “functional” assays may be impracticable, 
inconvenient and not always reliable, as it might prove difficult to deplete all 
alloreactive T cell clones, and any expansion of residual cells might give rise 
to delayed transplant rejection. Furthermore, the practical logistics 
concerning myeloablation and bone marrow transplantation prior to organ 
grafting, may preclude the application of this method to cadaveric 
transplantation.  
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 Receives Graft 
no therapy
Graft rejected
Receives Graft 
Short-course antibody therapy
Graft accepted
Receives fresh graft
and third party graft
Graft accepted
Third-party graft rejected
 
 
Figure 1.1 Demonstration of tolerance in antibody treated animals. Mice accept a second 
challenge with a graft of the same type, but readily reject third party grafts. Alloreactive cells, 
as demonstrated by proliferation assays, are present at any time point. 
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 The complementary strategy aims to control alloreactive cells in a different 
way. It is based on the induction of a dominant tolerance state and its 
hallmark is the emergence of regulatory CD4+ T cells (Waldmann and 
Cobbold, 1998). Unlike tolerance by deletion, alloreactive T cells may still be 
demonstrated, but grafts are accepted indefinitely. Furthermore, tolerance 
can be very robust and resists the adoptive transfer of large numbers of cells 
with the potential to mediate graft rejection – the reason why it is termed 
dominant (Figure 1.2) (Qin et al., 1990; Scully et al., 1994). The regulatory 
cells can even do more than just “suppress”: if they are allowed to coexist 
with the naïve cells, they have the capacity to recruit new regulatory CD4+ T 
cells from that naïve pool. After this recruitment, the initial regulatory T cells 
can be removed experimentally and one observes that the new regulators 
can maintain tolerance themselves (Qin et al., 1993). This process can be 
repeated experimentally for several cell transfers, and has therefore been 
named “infectious tolerance” (Figure 1.3) (Qin et al., 1993; Chen et al., 1996; 
Cobbold and Waldmann, 1998). 
 
1.2.1  mAbs as dominant tolerance inducing agents 
 
Short courses of therapeutic antibodies have been shown to lead to long-
term acceptance of foreign grafts in several experimental systems (reviewed 
in Waldmann and Cobbold, 1998). The first examples of peripheral tolerance 
induced with monoclonal antibodies were reported in 1986 (Benjamin and 
Waldmann, 1986; Gutstein et al., 1986). In these experiments tolerance to 
foreign immunoglobulins was achieved after a short-term treatment with 
depleting anti-CD4 antibodies. It was soon demonstrated that depletion of 
CD4+ cells was not required for tolerance induction, as similar results were 
found using F(ab’)2 fragments (Benjamin et al., 1988; Carteron et al., 1988; 
Carteron et al., 1989), non-depleting isotypes (Qin et al., 1990) or non-
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 depleting doses of synergistic pairs of anti-CD4 antibodies (Qin et al., 1987).  
Treatment with anti-CD4 antibodies was also shown to lead to long-term 
acceptance of skin grafts differing by  “multiple-minor” antigens (Qin et al., 
1990), even in pre-sensitised recipients (Marshall et al., 1996). The same 
results were also demonstrated for heart grafts across MHC barriers (Chen et 
al., 1992; Onodera et al., 1996) or concordant xenografts (Chen et al., 1992). 
 
Further demonstrations of transplantation tolerance were later reported with 
anti-LFA-1 antibodies, alone (Benjamin et al., 1988) or in combination with 
anti-ICAM-1 (Isobe et al., 1992), and also with anti-CD2 and anti-CD3 
antibodies (Chavin et al., 1993). 
 
More recently, co-stimulation blockade of CD28 (Lenschow et al., 1992), 
CD40L (CD154) (Parker et al., 1995) or both in combination (Larsen et al., 
1996b) has been shown effective. These findings have recently been 
extended to non-human primates. In one study, long-term survival of renal 
allografts was achieved following blockade of CD40L alone (Kirk et al., 1999). 
Another group achieved prolonged islet allograft acceptance after a similar 
treatment (Kenyon et al., 1999). Interestingly, the association of tacrolimus or 
steroids to the therapeutic regime abrogated tolerance (Kirk et al., 1999). 
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 Tolerant mouse 
Receives fresh graft
Receives lymphocytes from non-tolerant mice
Graft accepted!
Tolerant mouse 
Receives fresh graft
T cells are depleted
Receives lymphocytes from non-tolerant mice
Grafts rejected
 
Figure 1.2 Demonstration of dominant tolerance. This requires the demonstration of 
tolerance being imposed on cells with the ability to reject a graft in the absence of regulatory 
cells. 
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 Tolerant mouse  
Receives fresh graft
Receives lymphocytes from non-tolerant mice
Tolerant mouse T cells are depleted in the
first week after lymphocyte transfer
Grafts rejected
Tolerant mouse 
Receives fresh graft
Receives lymphocytes from non-tolerant mice 
Tolerant mouse T cells are depleted 4 -6
weeks after lymphocyte transfer
Grafts accepted
Figure 1.2 protocol could now demonstrate
that new cells now enforce dominant tolerance
 
Figure 1.3 Demonstration of infectious tolerance. This requires the demonstration that cells 
with the ability to reject are converted into the regulatory type after coexistence with cells 
from a tolerant animal. 
   23 
 1.2.2  Infectious tolerance    
 
Models of transplantation tolerance induced with anti-CD4 or anti-CD40L 
antibodies have shown that tolerant mice do not reject the grafts even after 
the adoptive transfer of fresh lymphocytes from a non-tolerant animal (Qin et 
al., 1990; Scully et al., 1994; Graca et al., 2000). Spleen cells from animals 
made tolerant to skin and heart grafts using anti-CD4 or anti-CD40L 
antibodies could regulate naïve T cells, and in so doing, rendering them 
regulatory in their own right (Qin et al., 1993; Chen et al., 1996; Graca et al., 
2000). Using transgenic mouse strains carrying specific cell surface markers 
in their lymphocytes, it was possible to selectively eliminate the host-type T 
cells from the tolerant animal (Qin et al., 1993; Graca et al., 2000). If this cell-
depletion was performed immediately after cell transfer, the tolerant state 
was broken and indicator grafts were readily rejected by the transferred non-
tolerant lymphocytes (Qin et al., 1993; Graca et al., 2000). If, however, the 
host cells were allowed to coexist with the adoptively transferred set for 4 – 6 
weeks, then tolerance was maintained even after the depletion of the host 
cells (Qin et al., 1993; Graca et al., 2000). The remaining cells were 
nevertheless fully competent to reject an unrelated graft. Not only were they 
unable to reject a graft from a similar donor, but they could now regulate 
another population of spleen cells from a non-tolerant animal in a similar 
transfer experiment (Qin et al., 1993). This effect, named “infectious 
tolerance”, provides compelling evidence for the existence of regulatory T 
cells: the regulatory cells from a tolerant animal can suppress the aggressive 
action of graft-reactive T cells and induce members of that population to 
become regulatory as well.  
 
A further important finding underlining the significance of infectious tolerance 
comes from the demonstration of a phenomenon named “linked suppression” 
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 (Figure 1.4). In the original experiment (Davies et al., 1996a) CBA/Ca mice 
were rendered tolerant to B10.BR skin grafts (different in multiple minor 
transplantation antigens) with non-depleting anti-CD4 and anti-CD8 
treatment. These mice readily rejected a third-party CBK skin graft (CBA/Ca 
mice transgenic for the MHC class I antigen Kb) even if simultaneously 
grafted with a fresh B10.BR skin into the same graft bed. However, when 
tolerised mice were transplanted with (CBK x B10.BR)F1 skin grafts, 
harbouring simultaneously the tolerated and the third-party antigens, rejection 
was delayed or absent. Furthermore, mice that had accepted the (CBK x 
B10.BR)F1 skin grafts, accepted CBK skin transplants at a later time point. 
The same phenomenon was recently demonstrated for anti-CD40L antibody 
induced tolerance (Honey et al., 1999), and tolerance induced following 
donor bone marrow infusion (Bemelman et al., 1998). 
 
1.2.3  T cell regulation 
 
Evidence for the existence of regulatory T cells does not come exclusively 
from studies of transplantation tolerance. Regulatory T cells have been found 
in several autoimmunity models (reviewed earlier and in Mason and Powrie, 
1998; Roncarolo and Levings, 2000). Even among the T cell population of 
normal individuals, T cells with the capacity of causing autoimmune disease 
have been identified, as well as regulatory cells that prevent this pathological 
auto-aggression (Powrie and Mason, 1990; Fowell and Mason, 1993). It is 
therefore likely that, in addition to thymic tolerance, peripheral tolerance 
mechanisms operate to safeguard tolerance to extra-thymic antigens.  
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Mouse tolerant to B 
Receives (BxC)F1 graft
(BxC)F1 graft accepted
Receives C graft
C graft rejected
C graft accepted
(BxC)F1
B
C
Mice: type A
(AxC)F1
Mouse tolerant to B
Receives (AxC)F1 graft
(AxC)F1 graft rejected
 
Figure 1.4 Demonstration of linked suppression. This requires the demonstration that 
tolerant animals accept grafts where a third party antigen is present in cells that also have 
the tolerated antigens (BxC)F1, but reject third party grafts (C) if the tolerated antigen absent 
from the graft cells (even if a concomitant tolerated-type graft (B) is given). The animals that 
accept the grafts with the “linked” third party antigen (BxC)F1 should accept later grafts of the 
third party (C). 
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 The phenotype of these regulatory cells, and their proposed mechanisms of 
action is not yet totally clear. Although it is possible to induce transplantation 
tolerance with mAbs in thymectomised mice (Qin et al., 1987; Honey et al., 
1999), there is evidence suggesting that regulatory cells in some 
autoimmunity models are a defined lineage originating in the thymus 
(reviewed by Seddon and Mason, 2000). This lineage was shown to have 
some distinctive surface markers: they are included in the CD45RClow 
population of CD4+ cells in the rat (Fowell and Mason, 1993), or in the 
CD45RBlow in the mice (Powrie et al., 1996). It also seems that expression of 
the IL-2 receptor α-chain (CD25) is a good indicator of the presence of a 
putative regulatory CD4+ cell that further subdivide the CD45RBlow population 
(Sakaguchi et al., 1995; Read et al., 2000). Given that CD25 seems to be a 
marker of suppressor cells it may seem paradoxical that an antibody 
targeting CD25 is licensed for use as immunosuppressive agent in clinical 
transplantation (reviewed in Waldmann and O'Shea, 1998). A theoretical risk 
for a therapy that targets CD25 expressing cells might be the loss of potential 
to induce tolerance to the graft, as well as a possible disruption of normal 
regulatory mechanisms that prevent autoimmunity. It may be relevant to note 
that mice treated with the anti-CD25 mAb PC61 were more effective in 
rejecting tumour cells (Shimizu et al., 1999). 
 
It is hoped that purification and cloning of the elusive regulatory T cells will 
allow a better understanding of their biology. 
 
1.2.4  Tolerance and cell death 
 
During immune responses, large numbers of activated T cells are generated. 
The majority of them are eliminated by apoptosis (Murali-Krishna et al., 
1998). Two distinct forms of apoptotic cell death associated with the 
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 termination of T cell responses have been described (reviewed in Lenardo et 
al., 1999). Passive cell death occurs at the later stages of immune 
responses, when activated T cells are deprived of T cell growth cytokines. As 
a consequence of apoptosis by cytokine withdrawal, the pool of reactive T 
cells shrinks following an immune response (Jones et al., 1990; Kuroda et al., 
1996). The second form of apoptosis was named activation induced cell 
death (AICD), and occurs during active proliferation of T cells, which have 
undergone one or more rounds of cell division and during G1 or S phase of 
the cell cycle (Lenardo, 1991; Boehme and Lenardo, 1993; Lissy et al., 
1998). AICD was shown to be IL-2 dependent (Lenardo, 1991), with IL-2-/- 
mice developing a lymphoproliferative disease with accumulation of 
lymphocytes in secondary lymphoid tissue, infiltration of several organs and 
overproduction of cytokines and autoantibodies (Schorle et al., 1991; Sadlack 
et al., 1995). A similar phenotype was also described for mice deficient in the 
IL-2 receptor α chain (CD25) (Willerford et al., 1995). In addition, apoptosis 
also seems to be mediated by members of the tumour necrosis factor (TNF)-
receptor family, such as Fas (CD95) (Zheng et al., 1995; Dhein et al., 1995). 
 
There are now many examples where evidence is found for alloreactive T cell 
death in response to tolerance induction to transplanted tissue without the 
need for intended chimerism. For example, two interesting recent papers 
demonstrate that tolerance induction with therapeutic anti-CD40L mAbs 
requires cell death (Li et al., 1999; Wells et al., 1999). In fact, blockade of 
activation induced cell death (AICD) either by using transgenic mice resistant 
to apoptosis (Wells et al., 1999), or by using Cyclosporin-A (CsA) (Li et al., 
1999) resulted in graft rejection in animals subjected to antibody blockade of 
CD28 and CD40L.  
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 In spite of the importance of AICD in anti-CD40L transplantation tolerance, 
regulatory cells also play a role in its maintenance. In fact, tolerance induction 
with therapeutic anti-CD40L results in linked-suppression (Honey et al., 1999) 
and infectious tolerance (Chapter 3 and Graca et al., 2000). Thus, regulatory 
CD4+ T cells emerge, following tolerance induction, and actively enforce a 
dominant tolerance state. 
 
One can safely speculate that amplification of regulatory cells and induction 
of AICD are probably general mechanisms exploited in the different 
tolerance-inducing strategies. It is likely, although not yet demonstrated, that 
anti-CD4 therapeutic mAbs also require some cell death for the induction of 
transplantation tolerance. Supporting this hypothesis, it was recently shown 
that treatment of diabetic NOD mice with non-depleting anti-CD4 mAb can 
lead to apoptosis of diabetogenic T cells (Phillips et al., 2000). In these 
experiments, besides physical elimination of aggressive clones the 
tolerogenic treatment leads to the development of protective regulatory T 
cells. With regard to the role of apoptosis in transplantation tolerance induced 
with non-depleting anti-CD4 mAbs, it was recently shown that tolerance so 
achieved is independent of the Fas (CD95), so ruling out that pathway 
(Honey et al., 2000b). When all the above experimental results are taken 
together, it seems likely that in all tolerance inducing strategies some cell 
clones may remain fully committed towards an aggressive phenotype and 
their physical (AICD) or functional (anergy) deletion is required if tolerance 
induction is to be successful. 
 
Information is lacking on whether therapeutic protocols targeting deletion of 
alloreactive clones, such as those based on macrochimerism (Wekerle et al., 
2000), also encourage the emergence of regulatory cells. In this respect, it is 
important to note that when a small dose of T cell depleted bone marrow (<4 
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 x 105 cells) was administered to mice, under the cover of non-depleting anti-
CD4 mAbs, it led to dominant tolerance, mediated by CD4+ T cells 
(Bemelman et al., 1998). However, when the dose of bone marrow is 
increased (>4 x 105 cells), the outcome is tolerance by deletion of alloreactive 
clones (Bemelman et al., 1998). High dose bone marrow mediated deletion of 
alloreactive clones was shown to be Fas independent (Honey et al., 2000a). 
Even a high dose of bone marrow should be equivalent to a low dose for 
sparse antigens. I would predict a low frequency of regulatory CD4+ T cells to 
these residual antigens. In another study, the role of Fas/FasL in 
transplantation tolerance induced by co-stimulation blockade (using a 
combination of anti-CD40L mAb and human-CTLA4-Ig fusion protein), a 
similar result was observed (Trambley et al., 2001). It was shown that 
tolerance is independent of Fas/FasL signalling, as graft survival in tolerised 
lpr mice (deficient in Fas) or gld mice (deficient in FasL) is not compromised.   
 
1.2.4  Tolerance and T cell homeostasis 
 
The number of T cells in a normal adult immune system is largely stable, in 
spite of constant input of newly formed cells from the thymus, clonal 
expansion of peripheral cells, and cell death. The control of cell numbers in 
the immune system is one of the least known aspects of the whole 
immunology (reviewed in Freitas and Rocha, 2000).  
 
It has been suggested that homeostatic control of T cell numbers is a 
consequence of competition for limited resources as yet to be identified 
(Freitas and Rocha, 2000). Supporting this hypothesis it was shown that 
different populations of CD8+ TCR transgenic T cells compete with each 
other and with non-transgenic CD8+ T cells in bone marrow chimeras, 
parabiosis, and adoptive transfers into T cell deficient mice (Freitas et al., 
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 1996). In these experiments the steady state size of each population was 
dependent on the presence of other populations and on the time the different 
populations started to co-exist. A similar competition effect had been 
previously reported for different transgenic B cell populations (Freitas et al., 
1995). Interestingly, different types of lymphocytes have been shown to 
behave independently, i.e. without competing with each other, suggesting the 
existence of different types of “niches” that are occupied by different types of 
lymphocytes. This is the case of B and T cells: B cell deficient mice have 
normal T cell numbers (Kitamura et al., 1991), and mice without T cells have 
a normal number of B lymphocytes (Mombaerts et al., 1992). It is therefore 
likely that B and T cells exploit different resources. Also αβ and γδ T cells 
seem to be independently regulated: in the absence of one type of these 
populations the other is not expanded (Mombaerts et al., 1991). However, 
CD4+ and CD8+ T cells are likely to exploit the same resources of common 
“niches” being co-regulated. In the absence of any of the two T cell subsets, 
the other expand leading to a normal number of αβ T cells (Rocha et al., 
1989; Zijlstra et al., 1990; Rahemtulla et al., 1991; Cosgrove et al., 1991). 
 
Interestingly naïve and memory/activated T cells seem to have independent 
homeostatic control (Tanchot and Rocha, 1995; Tanchot et al., 1997). Mice 
manipulated in order to contain only naïve CD8+ T cells, in spite of the 
available space, only have half of the normal number of CD8+ T cells, and 
vice-versa (Tanchot and Rocha, 1995). In addition, the continuous thymus 
output of naïve T cells do not replace resident memory T cells (Tanchot et al., 
1997).  
 
It has been known that when T cells are adoptively transferred into 
lymphopenic hosts they undergo homeostatic driven proliferation (Bell et al., 
1987; Rocha et al., 1989). Such proliferation is largely antigen non-specific, 
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 although some low-affinity TCR interactions may be required as suggested 
by dependence on MHC expression by the host. In fact, the peripheral T cell 
survival and homeostatic proliferation can be driven by the same peptide 
ligands that mediate positive selection in the thymus (Ernst et al., 1999; 
Goldrath and Bevan, 1999). Given the dependency of homeostatic expansion 
on self-antigens it is perhaps not surprising that many animal models of 
autoimmune diseases are lymphopenic. It may be that homeostatic 
proliferation is a major factor determining susceptibility to autoimmunity 
(Theofilopoulos et al., 2001).  
 
Recent studies have suggested a role for CD4+ regulatory T cells in 
controlling T cell homeostasis (Annacker et al., 2000; Annacker et al., 
2001b). It has been shown that both CD4+CD25- and a fraction of the 
CD4+CD25+ T cells do expand when injected into RAG2-/- mice (Annacker et 
al., 2001b). Such in vivo results contrast with the poor proliferative capacity of 
CD4+CD25+ cells in vitro (Takahashi et al., 1998; Thornton and Shevach, 
1998). But in in vivo experiments only ~10% of the injected CD4+CD25+ T 
cells underwent proliferation, involving 10 – 11 rounds of division, such that 
the progeny contributed to more than 99% of the cell pool once a steady 
state was reached (Annacker et al., 2001b). Nonetheless, in co-transfer 
experiments CD4+CD25+ T cells were shown to be capable of controlling the 
expansion of CD4+CD45RBhigh T cells (Annacker et al., 2001b).  
 
Most in vivo studies of T cell suppression in autoimmunity use lymphopenic 
mice where T cell populations (such as the CD4+CD45RBhigh T cells) cause 
disease upon transfer. Preliminary evidence suggests that in some of these 
experimental systems disease is prevented by abrogating homeostatic 
expansion of the putative aggressive CD4+CD45RBhigh T cells, for example 
by adoptive transfer of a larger number of such cells (Barthlott et al., 2002). It 
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 will therefore be important to develop in vivo assays for regulatory T cell 
function in the absence of homeostatic proliferation. In the case of 
transplantation tolerance it has been demonstrated conclusively that 
regulation of alloreactive cells is independent of their proliferation. Lin et al, in 
the host laboratory, have shown that TCR transgenic CD8+ T cells when 
injected into tolerised or naïve mice proliferate to the same extent (Lin et al., 
2002). However, only the cells injected into the tolerised mice are “disarmed”, 
failing to produce IFN-γ, generate CTL and reject grafts (Lin et al., 2002). 
 
1.3  Experimental models of transplantation 
 
In the work described in this thesis, I focus on mechanisms of transplantation 
tolerance in mice transplanted with skin grafts. 
 
Studies of transplantation offer important advantages when compared with 
other experimental systems of adult immune tolerance, such as animal 
models of autoimmune diseases. One of the main advantages is the capacity 
to control the time when the immune system encounters the antigen, as well 
as the type of antigen provided. Furthermore, the identity of the antigens 
involved in transplant rejection is generally better characterised than the 
identity of antigens that initiate a destructive autoimmune process. It is thus 
likely that experimental transplantation tolerance offers a better opportunity to 
study antigen specificity of the cells inducing and maintaining the tolerant 
state. 
 
Transplant rejection or tolerance does not depend exclusively on the degree 
of mismatch between the host and the donor. Different strains of mice have a 
distinct behaviour concerning the capacity to reject or become tolerant to 
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 transplants (Davies et al., 1997; Trambley et al., 2000). The genetic basis of 
strain variability is still unknown.  
 
The capacity to accept a transplant also depends on the graft itself. 
Vascularised grafts are, in general, more easily accepted than non-
vascularised ones such as skin. Also, different organs have been shown to 
have different requirements for being tolerised (Zhang et al., 1996; Jones et 
al., 2001; Trambley et al., 2000). Liver acceptance is relatively easy to 
achieve, with many liver allografts being spontaneously accepted without any 
treatment in permissive strains (Qian et al., 1994). Kidney allografts are also 
occasionally spontaneously accepted in rodents, although not as consistently 
as liver (Zhang et al., 1996). In contrast, pancreatic islets and heart allografts 
are usually rejected in the absence of therapeutic intervention. However, skin 
grafts are even more difficult to tolerise as some treatments capable of 
preventing rejection of heart allografts are ineffective in inducing long term 
survival of skin allografts (Pearson et al., 1993; Pearson et al., 1994; 
Cavazzana-Calvo et al., 1995; Isobe et al., 1996). 
 
In the experiments described in this thesis I have used skin transplants with 
different mismatches as they allow regular observation for rejection, and 
being the most difficult organ to tolerise constitute a stringent experimental 
system. 
 
1.4  Mechanisms of transplant rejection 
 
Transplant rejection is absolutely dependent on T cells. This can be shown 
experimentally as nude mice do not reject skin allografts until they are 
reconstituted with immunocompetent T cells (Rosenberg et al., 1987). The 
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 rejection process is initiated by T cell activation by non-self transplantation 
antigens (Rosenberg and Singer, 1992).  
 
Transplantation antigens have been classically divided in two groups: the 
major and the minor alloantigens. The major transplantation antigens consist 
of MHC class I and class II molecules, while minor antigens are all other allo-
peptides (Sherman and Chattopadhyay, 1993). Host T cells can recognise 
alloantigens through two different pathways: the direct pathway, consisting of 
direct interaction of host T cells with allo-MHC molecules on the surface of 
donor cells; and the indirect pathway, that involves the recognition of 
peptides derived from donor major and minor transplantation antigens 
processed and presented on host MHC class II molecules on the surface of 
host APCs (Gould and Auchincloss, 1999).  
 
In transplantation, as in other immune responses, activation of naïve T cells 
require presentation by DCs that are capable of providing costimulatory 
signals (Fairchild and Waldmann, 2000). The role of DCs in promoting graft 
rejection was initially established concerning direct presentation, as thyroid 
allografts depleted of APCs were accepted permanently (Lafferty et al., 1975; 
Lafferty et al., 1976). Similar results were obtained following depletion of 
APCs from pancreatic islet allografts (Faustman et al., 1984). Furthermore, 
when the number of DCs in cardiac grafts was increased by prior treatment 
with Flt3-ligand, graft rejection was accelerated (Steptoe et al., 1997). 
 
Given the evidence for a crucial role of the direct pathway in transplant 
rejection, CD8+ T cells were long considered to be the critical effector cells, 
often requiring CD4+ T cell help (Rosenberg and Singer, 1992).  However, in 
vivo use of depleting anti-CD4 and anti-CD8 mAbs demonstrated that both 
CD4+ and CD8+ T cells could contribute to graft rejection, and reject grafts 
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 independently (Cobbold et al., 1986). This finding suggested that any 
protocol for inducing transplantation tolerance would need to target both 
major T cell populations.  
 
It was also assumed that while CD4+ T cells participated in the rejection of 
MHC class II mismatched grafts, CD8+ cells were the main contributors for 
rejection of MHC class I mismatched allografts. Such a conclusion was 
derived from studies of mice mutated for expression of MHC class I or II 
molecules. Using these mutants as bone marrow donors, it was observed 
that the injected cells were rejected by CD4+ or CD8+ cells depending on 
whether they were respectively expressing MHC class II or class I (Korngold 
and Sprent, 1985). However, subsequent studies have proven that in some 
cases rejection of MHC class I mismatched allografts was dependent on 
CD4+ T cells (Morton et al., 1993; Wise et al., 1999). 
 
As described previously, during the course of an immune response, CD4+ T 
cells can differentiate along, at least, two different pathways: the Th1 and 
Th2. Th1 cells express IFN-γ and IL-2 that, in the context of graft rejection, 
can lead to clonal expansion and activation of CD8+ T cells, but also to 
recruitment and activation of macrophages driving a delayed type 
hypersensitivity allo-reaction (Valujskikh et al., 1998). Th1 cells may also 
become directly cytotoxic by the expression of FasL on their surface 
(Rosenberg and Singer, 1992; Kagi et al., 1996; Le Moine et al., 2002). 
 
Th2 cells were also shown to be capable of mediating graft rejection 
(Zelenika et al., 1998). Although Th2 cells do not become directly cytotoxic by 
expressing FasL (Matesic et al., 1998), they can recruit and activate 
eosinophils in a process mediated by IL-5, which can lead to graft rejection 
(Le Moine et al., 1999a; Le Moine et al., 1999b; Goldman et al., 2001). 
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 Another pathway through which CD4+ T cells can lead to graft rejection is by 
providing help to allo-specific B cell clones, driving the production of 
alloantibodies (Baldwin et al., 2001). This type of immune response is 
dependent on the indirect presentation pathway (Pettigrew et al., 1998). 
When alloantibodies bind to transplanted cells they can lead to cell killing 
through different mechanisms, such as activation of the complement 
cascade, antibody-dependent cell cytotoxicity (ADCC) mediated by natural 
killer (NK) cells, and activation mediated by cross-linking of Fc receptors on 
graft infiltrating macrophages, neutrophils and eosinophils (reviewed in 
(Baldwin et al., 2001). The role of alloantibodies can be demonstrated by 
graft rejection in nude rats injected with allospecific hyperimmune serum 
(Gracie et al., 1990). It has also been shown that a prolongation of cardiac 
allograft survival can be achieved when specific B cell tolerance is induced 
following CsA plus donor-specific blood transfusion pretreatment (Yang et al., 
2000). 
 
In summary, due to the many redundant mechanisms that lead to transplant 
rejection, a protocol for the therapeutic induction of transplantation tolerance 
must be aimed at an upstream target (or targets) on which the other 
components are dependent. In this respect, tolerance induction to fully 
mismatched skin grafts (described in Chapter 4) is particularly relevant, as an 
effective control of all rejection pathways is required. 
 
1.5  Therapeutic induction of transplantation tolerance: How can the 
present knowledge translate to the clinic? 
 
Current immunosuppressive agents, although the best option available, are 
far from being ideal drugs. However, their known efficacy in preventing acute 
allograft rejection makes it ethically difficult to displace them in clinical trials of 
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 potential tolerogenic drugs. CsA is known to hinder tolerance induction with 
therapeutic mAbs (Li et al., 1999). Is it wise though to give transplanted 
patients an experimental therapeutic regime in the absence of CsA?  
 
One reason why CsA exerts a tolerance-blocking effect is due to its capacity 
to interfere with AICD (Li et al., 1999). In fact, both CsA and sirolimus 
(FK506) are calcineurin inhibitors that block transcriptional activation of the 
IL-2 gene in response to antigen stimulation. As lymphocytes are prevented 
from being activated, AICD does not occur. In that respect the new 
immunosuppressive drug rapamycin might be a good alternative. It does not 
interfere with activation and AICD. It rather functions by arresting the cell 
cycle, rendering lymphocytes insensitive to proliferative signals. Therefore, 
although CsA prevents tolerance induction with anti-CD40L antibodies, 
rapamycin does not affect, and can even facilitate, tolerance induction in this 
experimental system (Li et al., 1999). One can predict that also anti-CD4 
tolerance induction might be achieved in spite of concomitant administration 
of rapamycin, if given at the appropriate dose and time. 
 
In any case, development of diagnostic tests for tolerance is required to 
translate experimental results into clinical practice. Currently, abrogation of 
tolerance is not diagnosed until the tissue is damaged, both in autoimmunity 
and transplantation. Safe clinical trials of experimental tolerogenic regimens 
will be greatly facilitated when tolerance can be monitored in vitro, allowing 
the use of conventional immunosuppressive drugs as soon as there is 
evidence of tolerance failure. In this respect, the study of cellular and 
molecular characteristics of therapeutic induced tolerance might identify cell 
populations, or gene transcripts, whose presence or absence correlates with 
the maintenance of tolerance. 
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 1.6 Aims of the thesis 
 
The present thesis describes studies of therapeutic transplantation tolerance 
induced with mAbs. As immunogenicity of therapeutic monoclonal antibodies, 
such as some of the ones used experimentally, may induce artefacts, a 
strategy to overcome this problem was also studied.  
 
1. Anti-CD154 (CD40 ligand) therapeutic mAbs have been shown to 
be effective in the induction of transplantation tolerance. Chapter 3 
describes a study to confirm that CD4+ regulatory T cells are 
induced following anti-CD154 tolerance induction, and lead to a 
state of dominant tolerance where infectious tolerance can be 
demonstrated. 
 
2. As a consequence of the findings implicating CD4+ regulatory T 
cells in transplantation tolerance induced with non-depleting mAbs 
targeting co-receptors (such as CD4 and CD8) or co-stimulatory 
molecules (as CD154), it was investigated whether a combination 
of both types of mAbs leads to more robust transplantation 
tolerance. The results are described in Chapter 4. 
 
3. CD4+CD25+ T cells have been implicated as the main regulatory T 
cells involved in the maintenance of self-tolerance. Chapter 5 
describes experiments establishing that regulatory T cells 
mediating dominant transplantation tolerance are contained in both 
the CD4+CD25+ and CD4+CD25- populations, although the two 
populations are distinct in terms of gene expression. It is also 
described that CD4+CD25+ T cells with the capacity to prevent 
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 allograft rejection by non-tolerant cells can be isolated from naïve 
mice. 
 
4. It has been known, and confirmed in experiments described in 
Chapter 5, that regulatory T cells that mediate transplantation 
tolerance can be isolated from the spleen of tolerised animals. In 
Chapter 6 a group of experiments demonstrates that regulatory T 
cells with the capacity to maintain dominant transplantation 
tolerance are present in tolerated skin allografts.  
 
5. Therapeutic mAbs, such as the CAMPATH-1H, are commonly 
used in the treatment of human pathology. As foreign proteins with 
the ability to bind to cells of the body, mAbs elicit immune 
responses leading to a reduction of their efficiency unless 
immunosuppressive drugs are co-administered. Such antiglobulin 
responses may also limit the usefulness of mAb in some 
experimental systems where a long-term effect or repeated 
administration of the mAb is desired. It has been shown that mAbs 
with mutations that prevent their cell binding activity induce 
tolerance to their cell binding form (Gilliland et al., 1999). Chapter 7 
describes the characteristics of a mAb that was constructed with its 
binding site occupied by an epitope-like peptide (mimotope). Such 
mAb has the capacity to induce tolerance to itself as well as to the 
wild type mAb. Furthermore, it has the capacity to spontaneously 
acquire cell-binding capacity and mediate its biological effect, 
without hindrance to the development of tolerance. Such mAb 
constructs, by having a biological effect without eliciting anti-
globulin responses are useful for animal studies, such as some 
experiments described in Chapter 5.  
   40 
 CHAPTER 2 
 
MATERIALS AND METHODS 
 
2.1  Experimental animals 
 
All mice were bred in a specific pathogen free (SPF) facility at the Sir William 
Dunn School of Pathology, Oxford, U.K. Age and sex matched groups of 
animals were used in experiments, unless otherwise stated. Animals from 
strains listed in Table 2.1 were used. 
 
Mouse Strain Haplotype References 
CBA/Ca H-2k + CBA “minors”  
BALB/c H-2d + BALB “minors”   
C57/BL10 H-2b + Black 10 “minors”  
B10.BR H-2k + Black 10 “minors”  
CP1-CBA/Ca H-2k + CBA “minors” 
Transgenic for human-CD52 
expressed on T cells 
(Gilliland et al., 1999) 
RAG1 -/--CBA/Ca H-2k + CBA “minors” + RAG1-/-  (Zelenika et al., 1998) 
Table 2.1 Strains of mice used in experiments described in the thesis 
 
2.2  In vivo Techniques 
 
All procedures were carried out in accordance with the UK. Home Office 
Animals (Scientific Procedures) Act of 1986.  
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 2.2.1  General anaesthesia 
 
Mice were anaesthetised using a cocktail of 10 mg/ml metomidate (Hypnodil, 
Janssen Pharmaceutical, Tilburg, The Netherlands) and 2 µg/ml fentanyl 
(Sublimaze, Janssen Pharmaceutical, Tilburg, The Netherlands), diluted in 
sterile water. Anaesthetic was injected i.p., 0.12 ml per 20 g body weight. 
 
2.2.2  Skin grafting 
 
Skin grafts were performed according to a modified technique of Billingham et 
al (Billingham et al., 1953). Briefly, full thickness tail skin (1 cm x 1 cm) was 
transplanted onto a vascularised graft bed on the lateral thoracic flank. Grafts 
were placed with the direction of hair growth opposite to that of the recipient. 
The grafts were covered with paraffin gauze (Smith and Nephrew, UK), which 
was kept in place by wrapping the mice in cotton gauze (Johnson and 
Johnson, USA) and then plaster of Paris (Gypsona, Smith and Nephrew, 
UK.). The casts were secured to the scruff of the neck with autoclips (Becton 
Dickinson,UK.). Casts were removed 8 days after skin grafting. Skin grafts 
were considered rejected when no viable donor tissue was visible.  
 
2.2.3  Transfer of tolerated skin grafts 
 
Tolerated skin allografts were collected 100 to 120 days following transplant 
and tolerisation protocol. They were washed in phosphate sulphate buffered 
saline (PBS; Oxoid Ltd., U.K. Cat. No.: BR14) and grafted, as described 
above, on the lateral flank of new hosts. 
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 2.2.3  Thymectomy 
 
Mice were thymectomised between 4 and 6 weeks of age according to a 
modified technique of Monaco et al (Monaco et al., 1966). Briefly, a 
longitudinal incision was made in the ventral surface of the neck and the pre-
tracheal fascia exposed. A glass tube was inserted through the pre-tracheal 
fascia into the anterior mediastinum. The thymus was removed as two intact 
lobes by the application of negative pressure through the glass tip. The 
incision was closed using VetBondTM (3M, Minneapolis, USA). 
 
2.2.4  Lymphocyte depletion in vivo 
 
In vivo CD8+ lymphocyte depletion was achieved by intraperitoneal co-
injection of 1 mg of each of the lytic anti-CD8 mAbs, YTS 156.7 and YTS 
169.4 (see Table 2.2). CD4+ lymphocyte depletion was achieved by 
intraperitoneal co-injection of 1mg of each of the lytic anti-CD4 mAbs, YTA 
3.1.2 and YTS 191.2 (see Table 2.2). Depletion of the total lymphocyte 
population was achieved by intraperitoneal injection of a cocktail of 1 mg of 
each of the lytic anti-CD8 mAbs, plus the anti-CD4 mAbs, as above. 
Injections were carried out 3 and 2 days prior to using the mice in the 
indicated experiments. T cells from CP1-CBA transgenic mice were depleted 
using an intraperitoneal injection of 0.25 mg of anti-human CD52 mAb 
CAMPATH-1H. 
 
2.2.5 Induction of transplantation tolerance 
 
Tolerance was induced in CBA/Ca or CP1-CBA/Ca mice by treatment with 1 
mg YTS177.9 and 1 mg YTS105.18 at days 0, 2, and 4 after B10.BR skin 
transplantation (Chapters 5 and 6). Alternatively with 1 mg MR1 at days 0, 2, 
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 and 4 following B10.BR skin transplantation (Chapter 3). Or with a 
combination of the three mAbs administered at the same days following 
C57/B10 skin transplantation (Chapter 4). 
 
2.2.6  Adoptive transfer of splenocytes 
 
Spleens were dissected from donor mice and macerated through a 70 µm 
filter (Becton Dickinson,UK. Cat. No.: 352350) in R10 medium (see section 
2.4.1). Cells were centrifuged at 1300 rpm (Sorvall RT 6000D) for 10 minutes 
at room temperature; these conditions were standard when washing cells. 
Erythrocytes were lysed by 5 seconds incubation with 0.9 ml sterile water 
followed by addition of 100 µl PBS 10x concentrated, then washed in PBS, 
1% w/v BSA and passed through another 70 µm filter into a new tube to 
remove erythrocyte ghosts. Cells were counted in Trypan Blue (Sigma) using 
a haemocytometer. Cells were re-suspended in PBS at the desired cell 
density and 0.2 ml cell suspension was injected into the lateral tail vein of 
mice heated using an infra-red lamp (IMS, UK) to allow vasodilatation.  
 
2.2.7  Statistics 
 
Significant differences in skin graft survival were analysed using the non-
parametric Mann-Whitney U test and the log rank method by computer 
software Prism version 3.02 (GraphPad Software Inc.).  
 
2.3  Monoclonal Antibodies 
 
The mAbs used in this thesis are listed in Table 2.2. Constructs based on 
CAMPATH-1H linked to its mimotope are described in detail in Chapter 7. 
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 Name Isotype Specificity Reference 
YTS 177.9.6.1 Rat IgG2a Mouse CD4 (Qin et al., 1990) 
YTS 105.18.10 Rat IgG2a Mouse CD8 (Qin et al., 1990) 
YTA 3.1.2 Rat IgG2b Mouse CD4 (Qin et al., 1987) 
YTS 191.2 Rat IgG2b Mouse CD4 (Cobbold et al., 1984) 
YTS 156.7.7 Rat IgG2b Mouse CD8 (Cobbold et al., 1984) 
YTS 169.4.2 Rat IgG2b Mouse CD8 (Cobbold et al., 1986) 
11B11 Rat IgG1 Mouse IL-4 (Ohara and Paul, 1985) 
JES5.2A5 Rat IgG1 Mouse IL-10 (Sander et al., 1993) 
PC61 Rat IgG1 Mouse CD25 (Lowenthal et al., 1985) 
CAMPATH-1H Human IgG1 Human CD52 (Riechmann et al., 1988) 
CAMPATH-1G Rat IgG2b Human CD52 (Dyer et al., 1989) 
187.1 Rat IgG1 Mouse Ig kappa (Yelton et al., 1981) 
M5/114 Rat IgG2b Mouse MHC II  
(I-Ab,d,q,I-Ed,k) 
(Bhattacharya et al., 1981) 
MR1 AH IgG3 Mouse CD154 (Noelle et al., 1992) 
YCATE55 Rat IgG1 Canine CD8 (Cobbold and Metcalfe, 1994) 
KT3 Rat IgG2a Mouse CD3 (Tomonari, 1988) 
4F10 AH IgG1 Mouse CTLA-4 (Walunas et al., 1994) 
YNB46-HG1 Human IgG1 Human CD4 (Isaacs et al., 1997) 
Table 2.2 mAbs used in this thesis. AH, Armenian hamster. 
 
2.3.1  Preparation of monoclonal antibodies 
 
mAbs were produced by culture in hollow-fibre bioreactors designed for 
generating high yields of concentrated antibodies (see website: 
http://www.molbiol.ox.ac.uk/pathology/tig/mprod.html). Briefly, cells were 
grown on semi-permeable hollow-fibres to allow free exchange of 
metabolites, but not proteins, with the medium being pumped through the 
fibres. The mAbs containing supernatants was harvested and further 
processed as described in Sections 2.3.1.1 and 2.3.1.2. 
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 2.3.1.1 Purification of monoclonal antibodies by ammonium sulphate 
precipitation 
 
Ammonium sulphate precipitation was carried out according to a standard 
protocol for mAbs purification (Cooling et al., 1994). Ammonium sulphate was 
added to the culture supernatant to make a 50% w/v saturated solution. This 
was stirred continuously overnight at 4 ºC, centrifuged, and the supernatant 
discarded. The pellet was re-suspended in a minimal amount of distilled 
water (~ 10% starting volume) and dialysed against PBS. The protein 
concentration was determined by measuring the optical density at 280 nm. 
The purity of the preparation was assessed by native gel eletrophoresis 
(PhastGel, Pharmacia, St. Albans, U.K. Cat. No.: 17-0517-01) according to 
the manufacturer’s instructions. The mAb preparations were aliquoted and 
stored at –30 ºC.  
 
2.3.1.2  Ion Exchange Purification  
 
2.3.1.2-A  Reagents 
 
10x stock of buffer A: 
       Malonic Acid          104 g 
       NaOH                 60 g 
       Betaine              20 g 
       Make up to 2 litres with endotoxin free water. 
     pH 5.2 - pH 5.4 at 25 ºC  
       Sterile filter to 0.2 µm and store at 4 ºC  
 
Buffer B (1x): 
       Make 1x buffer A, but containing 0.5M NaCl   
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 2.3.1.2-B Procedure 
Antibody preparation was dialyzed into 1x Malonate buffer (buffer A). Any 
precipitate was spun out and discarded. Supernatant was measured for 
OD280 and adjusted to between 1 and 20 mg/ml buffer A. Fast Flow SP-
Sepharose (Pharmacia Biotech, Sweden, Cat. No.: 17-0729-01) was washed 
three times (by centrifugation for 2 mins at 2000 rpm) in buffer A. The 
antibody previously dialysed into buffer A was incubated with the correct 
volume of SP-Sepharose (1 ml gel for 20 mg antibody) for 1 hour at room 
temperature, with gentle rotation. The supernatant was then removed (and 
checked to establish whether the antibody had been adsorbed by running 
analytical gel). The gel was washed three times with buffer A (each wash at 
least 5 gel volumes). The antibody was eluted by adding 1 gel volume of 
buffer B, rotated at room temperature for 5 minutes, centrifuged, and the 
supernatant collected. The process was repeated and the eluted volumes 
pooled. The protein concentration and purity was checked as stated above 
(section 2.3.1.1). 
 
2.3.1.3 Biotinylation of monoclonal antibodies 
 
mAb purified using ammonium sulphate precipitation (Section 2.3.1.1) or ion 
exchange purification (Section 2.3.1.2) was dialysed against sodium 
bicarbonate buffer, pH 9.3 (8.65 g anhydrous NaHCO3 + 8.6 g Na2CO3 per 
litre of distilled water). Fresh Sulfo-NHS-LC-Biotin (Pierce, USA, Cat. No.: 
21335), 1 mg/ml in water, was added to a final concentration of 37 µg per mg 
of mAb and incubated on ice for 2 hours. The biotinylated mAb was dialysed 
against PBS overnight to remove excess biotin. Bovine serum albumin (BSA; 
Sigma, UK; Cat. No.: A-9647) was added to 1% w/v, and sodium azide to 
0.1% w/v. Aliquots were stored at 4 ºC and –80 ºC. 
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 2.3.1.4 Fluorescin isothiocyanate conjugation of monoclonal 
antibodies 
 
mAb purified using ammonium sulphate precipitation (Section 2.3.1.1) and 
ion exchange purification (Section 2.3.1.2) was dialysed into 0.1M sodium 
bicarbonate buffer and the concentration adjusted to 5 mg/ml. Fresh 
fluorescein isothiocyanate (FITC; Sigma, UK; Cat. No.: F7250), 1 mg/ml in 
dimethylsulphoxide (DMSO; Sigma, UK; Cat. No.: D5879), was added to a 
final concentration of 40 µg per mg of mAb and incubated at room 
temperature for 2 hours with occasional mixing. The FITC-conjugate was 
dialysed against PBS overnight. The protein concentration in mg/ml was 
determined using: [OD280nm - (0.36 x OD493nm)]/1.4. The molar FITC/protein 
ratio determined using a nomogram (Wells et al., 1966) with 3-5 being 
preferred. BSA was added to a final concentration of 1% w/v and sodium 
azide to 0.1% w/v. Aliquots were stored at 4 ºC and –80 ºC. 
 
2.4 Tissue Culture 
 
2.4.1 Media and buffers 
 
R10 RPMI 1640 (Life Technologies, UK. Cat. No.: 21875-034) 
10% v/v Foetal Calf Serum (FCS) (Life Technologies, UK. Cat. No.: 
192-1005PJ) 
50 µg/ml Penicillin/Streptomycin (Life Technologies, UK. Cat. No.: 
15070-063) 
0.01M Hepes Buffer (Life Technologies, UK. Cat. No.: 15630-056) 
5 x 10-5M 2-Mercaptoethanol (BDH, UK. Cat. No.: 436022A) 
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IMDM  Hepes-free Iscove’s Modified DMEM (Life Technologies, U.K. Cat. 
No.: 041-91344P) 
7 mg/L adenosine 
7 mg/L cytidine 
7 mg/L guanidine 
7 mg/L uridine 
2.4 mg/L thymidine 
357 mg/L L-glutamic acid 
325 mg/L L-asparagine (free base) 
5660 mg/L NaCl 
IMDM 5% IMDM 
2mM L-glutamine (Life Technologies, U.K. Cat. No.:25030-024) 
5% v/v FCS (Life Technologies, U.K. Cat. No.:192-1005PJ) 
50 µg/ml Penicillin/Streptomycin (Life Technologies, UK. Cat. 
No.:15070-063) 
0.01M Hepes Buffer (Life Technologies, UK. Cat. No.: 15630-056) 
5 x 10-5M 2-Mercaptoethanol (BDH, UK. Cat. No.:436022A) 
 
2.4.2 Preparation of mouse T cell blasts by concavalin A activation 
 
A single cell suspension of murine splenocytes was prepared by macerating 
a spleen through a 70 µm filter. The cells were washed in R10, re-suspended 
in 20 ml R10 containing 2.5 µg/ml concavalin A (Con A) and incubated for 48 
hours at 37 ºC and 5% v/v CO2 prior to harvesting. 
 
   49 
 2.4.3 T cell activation with immobilized anti-CD3 
 
24-well plates (Corning, New York, USA) were pre-coated with 1 ml per well 
of 1 µg/ml KT3 in PBS for 1 hour at 37 ºC. A single cell suspension of T cells 
was counted in trypan blue, and 106 cells were transferred into each well in 1 
ml R10. The cells were incubated with the immobilized KT3 overnight at 37 
ºC (typically 16 hours). 
 
2.5 Cell separation by magnetic sorting (MACS)  
 
2.5.1 Solutions for magnetic sorting  
 
MACS buffer: PBS supplemented with 0.5 % w/v BSA and 2mM EDTA. pH 
7.2; Rinsing solution: PBS, 2mM EDTA. 
 
2.5.2 CD4+ T cell sorting 
 
Cells were obtained from spleens of adult CBA/Ca mice. A single-cell 
suspension was obtained by passing the splenocytes through a 70 µm cell 
strainer (BD Biosciences, Oxford, U.K) and the erythrocytes were depleted by 
water lysis. Cells were pelleted a further time and re-suspended at 1x107 
cells per 90 µl in MACS buffer and 10 µl of MACS CD4 (L3T4) Microbeads 
(Miltenyi Biotec, Germany; Cat. No.:492-01). The cells were incubated with 
the microbeads for 15 minutes on ice. Cells were then washed once with 10 
ml MACS buffer and re-suspended at 108 cells/ml. Magnetic sorting by 
autoMACSTM (Miltenyi Biotec, Germany; Cat. No.:201-01) was performed 
according to the manufacturer’s manual using POSSEL program. 
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 2.5.3 CD4+CD25+ and CD4+CD25- T cell separation 
 
Single cell suspension from adult CBA/Ca spleens were first enriched for 
CD4+ cells by negative selection of CD8+ cells, MHC class II+ cells, and B 
cells by incubation with the mAbs M5/114, 187.1, and YTS 156.7, and 
subsequent incubation with 1ml goat-anti-rat IgG Dynabeads (Dynal Biotech, 
Oslo, Norway; Cat. No.: M450) for 3x108 cells and magnetic removal. For 
separation of CD4+CD25+ T cells, the CD8, class II, and B cell-depleted 
single-cell suspension was incubated 45 min at 4°C with anti-CD25 (7D4) 
biotin 1:100 in PBS, 1% w/v BSA, 5% v/v HINRS, and 0.1% w/v sodium 
azide. Following washing, the cells were incubated 15 min at 4°C with 2 µl 
streptavidin-microbeads (Miltenyi Biotech) per 107 cells, and positively 
selected over two columns using autoMACS POSSELD program. CD4+CD25- 
cells were sorted from the negative fraction obtained following CD4+CD25+ 
cell separation, by incubation with 100 µl streptavidin-microbeads per 107 
cells, and subsequent negative selection of any remaining CD25+ cells using 
autoMACS POSSELS program. Finally, CD4+CD25- were obtained following 
a positive selection step with anti-CD4 microbeads as described above. All 
sorted fractions were labeled with CD8 (YTS156.7)-FITC, CD25 (PC61)-PE, 
and CD4 (H129.19)-CyCr; and assessed in a flow cytometer. Typical purity of 
CD4+ and CD4+CD25- T cells was >98%, and purity of CD4+CD25+ T cells 
>90%.  
 
2.6  Flow cytometric analysis (FACS) 
 
2.6.1 Conjugated antibodies used in this thesis 
 
All commercial conjugated antibodies used were from BD Pharmingen, San 
Diego, CA, USA, except for CAMPATH-1H phycoerythrin (PE) conjugated 
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 (from Serotec, Oxford, UK). They are represented in Table 2.3. In addition to 
these mAbs, home grown mAbs conjugated with biotin or FITC were used 
(see Table 2.2). Streptavidin-PE (Sigma, UK, Cat. No. S3402) and 
streptavidin-allophycocyanin (ST-APC; BD Pharmingen, Cat. No. 13049A) 
were used as secondary reagents. 
 
Antigen Fluorochrome Clone Isotype Cat. No. 
CD3ε APC 2C11 AH IgG1 01089A  
CD4 PE H129.19 Rat IgG2a 01065A 
CD4 CyCr H129.19 Rat IgG2a 01068A 
CD4 PerCP H129.19 Rat IgG2a 0106PA 
CD8 PE 53-6.7 Rat IgG2a 01045A 
CD8 CyCr 53-6.7 Rat IgG2a 01048A 
CD8 PerCP 53-6.7 Rat IgG2a 0104PA 
CD25 PE PC61 Rat IgG1 01105A 
CD25 Biotin 7D4 Rat IgM 01092D 
CD44 PE IM7 Rat IgG2b 01225A 
CD45RB PE 16A Rat IgG2a 01145A 
hCD52 PE CAMPATH-1 Rat IgG2b MCA1642PE 
CD152  PE 4F10 AH IgG1 09385A 
Table 2.3 Commercially available conjugated antibodies used in this thesis. 
AH, Armenian hamster; CyCr, Cy-Chrome; PerCP, Peridinin chlorophyll-a 
protein. 
 
2.6.2 Four-colour cytometry (surface staining) 
 
Cells stained during this thesis were splenocytes and peripheral blood 
lymphocytes (PBL). Red blood cells were removed from splenocytes and 
PBL samples by water lysis (900 µl of water followed, 5 seconds later by 100 
µl 10x PBS) at room temperature prior to staining. Samples were then 
washed at 4 ºC in 200 µl washing buffer (PBS, 0.1% w/v BSA, 0.1% w/v 
sodium azide). Cells were re-suspended, using a plate shaker, in 50 µl mAb 
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 diluted appropriately in blocking buffer (PBS, 5% heat-inactivated normal 
rabbit serum (HINRS), 1% w/v BSA, 0.1%w/v sodium azide). The mAbs used 
were directly conjugated with fluorescent markers or with biotin. Cells were 
incubated in the dark at 4 ºC for 45 minutes and then washed twice in 200 µl 
wash buffer. If a biotinylated primary reagent was used cells were re-
suspended, using a plate shaker, in 50 µl secondary reagent (ST-APC or ST-
PE, see 2.6.1) diluted appropriately (usually 1:100) in wash buffer and 
incubated in the dark at 40C for a further 45 minutes. Cells stained with a 
biotin conjugated and a secondary reagent were washed once in 200 µl 
IMDM, 0.1% w/v BSA, 0.1%w/v sodium azide to wash multivalent streptavidin 
conjugates and once in 200 µl wash buffer. The cells were mixed in 100 µl 
PBS, 1% w/v BSA, 0.1% w/v sodium azide + 4% v/v formaldehyde. Fixed 
samples could be stored 4 ºC in the dark for a number of days. Samples 
were analysed using a FACScan (Becton Dickinson, UK) with dual laser 
(488nm and 633nm) excitation in combination with data acquisition and cross 
beam colour compensation using CellQuest 3.1 version software (Becton 
Dickinson, UK).  
 
2.6.3 Four colour cytometry (intra-cytoplasmic staining) 
 
Cells were stimulated for 5 hours with 50ng/ml Phorbol 12-myristate 13-
acetate (PMA; Sigma, U.K.; Cat. No.: P8139) plus 500ng/ml ionomycin 
(Sigma, U.K.; Cat. No.: I-0634) in phenol red free-R10 at 37 ºC, with the 
addition of 10 µg/ml Brefeldine A (Sigma, U.K.; Cat. No.: B-7651) in the last 
three hours. After washing with washing buffer twice, cells were re-
suspended, using a plate shaker, in 100 µl mAb diluted appropriately in 
blocking buffer. The mAbs used were directly conjugated with flourescent 
markers or with biotin (section 2.3.1). Cells were incubated in the dark at 40C 
for 30 minutes and then washed twice in 200 µl wash buffer. If a biotinylated 
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 primary reagent was used cells were re-suspended, using a plate shaker, in 
100 µl secondary reagent (ST-APC) diluted appropriately in wash buffer and 
incubated in the dark at 4 ºC for a further hour. Cells stained with a biotin 
conjugated and a secondary reagent were washed once in 200 µl IMDM, 
0.1% w/v BSA, 0.1%w/v sodium azide to quench multivalent streptavidin 
conjugates and once in 200 µl wash buffer. The cells were mixed in 50 µl 
PBS, 1% w/v BSA, 0.1% w/v sodium azide and 50 µl 4% v/v formaldehyde for 
15 minutes. Cells were then washed and permeabilized with PBS plus 0.5% 
saponin (Sigma, U.K.; Cat. No.: S-2149) for 20 minutes. Cells were pelleted 
and re-suspended in 100 µl saponin buffer with intracellular mAbs (section 
2.7.3.1) and incubated for 30 minutes at 4 ºC. The cells were extensively 
washed with saponin buffer twice and followed by washing buffer once. The 
cells were mixed in 50 µl PBS, 1% w/v BSA, 0.1% w/v sodium azide + 50 µl 
4% v/v formaldehyde. Samples were analysed by flow cytometry as stated 
above. 
 
2.6.4 Detection of PC61 mAb in mouse serum 
 
Serum PC61 was determined by inhibition of binding of anti-CD25 (PC61) PE 
conjugated detected by flow cytometry. CD25+ Con A blasts were incubated 
with the experimental serum diluted 1/5 in PBS, 1% w/v BSA for 30 min at 
4°C, followed by addition of anti-CD25 (PC61) PE-conjugated, as well as 
anti-CD4 CyCr. The experimental serum samples were compared with serum 
from untreated animals, and serum spiked with mAb to known 
concentrations. Three-colour FACSCaliber analysis was performed using 
CellQuest software. 
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 2.7 Enzyme-Linked ImmunoSorbant Assays (ELISAs) 
 
2.7.1 Analysis of CAMPATH-1H antiglobulin titres in mouse serum 
 
For detection of anti-CAMPATH-1H antibodies, flat bottom 96 well microtitre 
plates were coated with CAMPATH-1H, diluted to 10 µg/ml in coating buffer 
(0.1M NaHCO3 pH 8.6), by incubation for 1 hour at room temperature with 
100 µl per well. The coated plates were then blocked with 200 µl per well 
blocking buffer (PBS, 1% w/v BSA, 0.1% w/v sodium azide) for 1 hour at 
room temperature or overnight at 4 ºC. Following removal of the blocking 
buffer, serum samples were added in duplicate, diluted 1:20 in wash buffer 
(PBS, 0.1% w/v BSA, 0.1% w/v sodium azide). In each plate a positive 
control (hyper-immune serum) and a negative control (normal mouse serum - 
NMS) were included, also in duplicate. A two fold serial dilution of each of 
these samples were performed. The plates were incubated for 1 hour at room 
temperature, with a final volume of 50 µl per well. Bound antiglobulins were 
detected with 50 µl per well peroxidase conjugated anti-mouse IgG (Sigma, 
UK, Cat. No. A-9309), diluted 1:1,000 in wash buffer. Plates were incubated 
for 1 hour at room temperature. Plates were washed with PBS, 0.05% v/v 
Tween between each step. Following the final wash, the assay was 
developed using 100 µl substrate buffer (1 mg/ml o-phenylenediamine 
dihydrochloride in 0.025M citrate, 0.05M Na2HPO4, 0.04% H2O2) per well. 
This reaction was stopped at an appropriate time by adding 50 µl 1M H2SO4 
per well. The absorbance at 492 nm was read using a microplate reader 
(Labsystems Multiskan Plus, Labsystems, Finland) with the negative control 
as a blank. 
 
   55 
 2.7.2 Detection of human mAb in mouse serum 
 
96-well plates were coated with 10 µg/ml affinity-purified goat anti-human 
IgG, Fcγ-specific (Jackson Laboratories, USA, Cat. No. 109-005-098) in 0.1M 
NaHCO3, and blocked with 50 µl PBS, 1% w/v BSA, as described above. 
Following removal of the blocking buffer, serum samples were added in 
duplicate, diluted 1:20 in wash buffer, together with standards with known 
concentrations of human IgGγ1 and NMS as a negative control. A two fold 
serial dilution of each of these samples was performed. The plates were 
incubated for 1 hour at room temperature, with a final volume of 50 µl per 
well. Bound human antibodies were detected by 1-hour incubation at room 
temperature with 50 µl per well biotin conjugated affinity-purified goat anti-
human IgG, Fcγ-specific (Jackson Laboratories, USA, Cat. No. 109-065-098), 
diluted 1:10,000 in wash buffer, followed by 30 minutes incubation with 
extravidin-peroxidase (Sigma, UK, Cat. No.: E-2886) diluted 1:1,000 in wash 
buffer. The assay was developed and analysed as described above. 
 
2.7.3 In vitro binding to CAMPATH-1 antigen 
 
96-well plates were coated with 10 µg/ml BHK.CAM17.5, a fusion protein with 
the CAMPATH-1 antigen (Gilliland et al., 1999), in 0.1M NaHCO3, and 
blocked with 50 µl PBS, 1% w/v BSA, as described above. Following removal 
of the blocking buffer, mAb samples (CAMPATH-1H, MIM-IgG1, AG-MIM-
IgG1, p61-IgG1, and anti human-CD4: negative control) were added in 
duplicate diluted to 50 µg/ml in wash buffer. A two fold serial dilution of each 
of these samples was performed. The plates were incubated for 1 hour at 
room temperature, with a final volume of 50 µl per well. Bound human 
antibodies were detected by 1-hour incubation at room temperature with 50 µl 
per well peroxidase conjugated affinity-purified goat anti-human IgG, Fcγ-
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 specific (Jackson Laboratories), diluted 1:10,000 in wash buffer, followed by 
30 minutes incubation with extravidin-peroxidase (Sigma, UK) diluted 1:1,000 
in wash buffer. The assay was developed and analysed as described above. 
 
2.7.4 Detection of JES5 and 11B11 mAbs in mouse serum 
 
96-well plates were coated with 10 µg/ml JES5 or 11B11 in 0.1M NaHCO3, 
and blocked with 50 µl PBS, 1% w/v BSA, as described above. Serum 
samples from the JES5 and 11B11 treated mice, as well as normal mouse 
serum (negative control) and serum spiked to known concentrations of the 
mAbs (positive control), were diluted 1/20 in PBS, 1% w/v BSA containing 
either recombinant IL-10 (10 ng/ml) or recombinant IL-4 (2 ng/ml), and pre-
incubated for 60 min at room temperature before being transferred into the 
JES5- or 11B11-coated plates, where the samples were incubated for a 
further 60 min. After washing with PBS, 0.05% Tween, the plates were 
incubated 60 min with anti-IL10 (SXC-1) biotin or anti-IL-4 (BVD6-24G2) 
biotin (both from BD Biosciences, UK). The plates were then incubated with 
extravidin-peroxidase (Sigma-Aldrich, U.K.) for 30 min, and developed with 
substrate buffer and absorbance at 492 nm analysed with a microplate 
reader (Labsystems, Finland).  
 
2.7.5 Detection of 4F10 mAb in mouse serum 
 
96-well plates were coated anti-hamster IgG (HIG-29) (BD Biosciences) and 
blocked as described above. Serum from 4F10 treated mice, as well as 
normal mouse serum (negative control) and serum spiked to known mAb 
concentrations (positive control), was diluted 1/20 in PBS 1% w/v BSA and 
incubated for 1 hour at room temperature in the coated plates. After washing 
with PBS 0.05% v/v Tween, any bound hamster mAb was detected with 
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 biotin-conjugated HIG-29 (BD Biosciences). The plates were then incubated 
with extravidin-peroxidase, developed and analysed as described above. 
 
2.8 Detection of antibody binding to CAMPATH-1 Ag by surface 
plasmon resonance (BIAcore) 
 
The experiments were performed at 25 ºC, using a BIAcore 2000 apparatus 
(Biacore AB, UK), and a flow rate of 10 µl/min unless stated otherwise. 
Proteins were covalently coupled to the carboxymethylated dextran matrix on 
CM5 sensor chip (Biacore AB, UK, Cat. No.: 0371) using amine coupling as 
suggested by the manufacturer. Before activating the surface of the sensor 
chip, the best pH to bind the coating Ab, at which > 10,000 response units of 
protein bind electrostatically, was assessed injecting 25 µg/ml goat anti-
human IgG, Fcγ-specific (Jackson Laboratories) in 10mM sodium acetate at 
different pH (4.0, 4.5, 5.0, 5.5) over the flow cell. The best pH was found to 
be 5.0. The chip surface was activated by injecting 70 µl 0.05M N-ethyl-N-
(dimetylaminopropyl) carbomide (EDC) and 0.2M N-hydroxisuccinimide 
(NHS). Then, 70 µl of the coating Ab in 10mM sodium acetate pH 5.0, was 
injected at the same rate. Any remaining active carboxyl groups were 
subsequently blocked with a 70 µl injection of 1M ethanolamine 
hydrochloride, pH 8.5. The coated chip was regenerated by sequential 3 
minute injections of 5mM NaOH and 0.1M glycin-HCL, pH 2.5. 70 µl of 
BHK.CAM17.5 (the fusion protein containing CAMPATH-1 Ag) at 10 µg/ml in 
HBS-EP (10mM HEPES pH 7.4, 150 mM NaCl, 3mM EDTA and 0.005% v/v 
surfactant P20) was then injected at 5 µl/minute to confirm no background 
binding to the coated plate. The four flow-cells of the sensor chip were coated 
with 70 µl of CAMPATH-1H, MIM-IgG1, P61-IgG1 and the control anti-human 
CD4 mAb YNB46-HG1 (all at 25 µg/ml in HBS-EP) injected at 5 µl/minute. 
Subsequently, 70 µl of the ligand, BHK.CAM17.5, was injected 
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 simultaneously in all flow cells and binding was monitored. Different 
concentrations of BHK.CAM17.5 (from 1 µg/ml to 800 µg/ml were tested). 
Between experiments the sensor chip was regenerated as described above. 
Following the Ab stripping, the flow cells were re-coated with the 
experimental Abs as described. Data was collected using BIAcore 2000 
control software and analysed using BIAevaluation 3.0 (BIAcore AB). 
 
2.9 SAGE libraries and differential analysis of gene expression 
 
The SAGE libraries were made by Sara Thompson. CD4+CD25+ and 
CD4+CD25- T cells were sorted from spleens of naive CBA/Ca mice and 
activated with overnight incubation with solid-phase anti-CD3 mAb (KT3), as 
described above. T cell populations were pelleted and re-suspended in 
Promega SV total RNA isolation system (Promega Z3100; Promega, 
Madison, WI) lysis buffer (175 µl / 2 x 106 cells), and total RNA was isolated 
according to the manufacturer’s instructions. First strand cDNAs were 
prepared from 1 µg of total RNA from each cell fraction using Superscript II 
(Life Technologies, Gaithersburg, MD). Reverse transcription was initiated 
using the anchoring primer 5’-GACTCGAGTTGACATCGAGG(T)20V-3’ with 
incorporation of the SMARTII oligonucleotide (Clontech, Palo Alto, CA) 5’-
AAGCAGTGGTAACAACGCAGAGTACGCGGG-3’ at the 5’ end. The cDNAs 
were pre-amplified with the forward 5’-AGTGGTAACAACGCAGAGTAC-3’ 
and reverse 5’-GACTCGAGTTGACATCGAG-3’ primers using the 
Advantage-GC cDNA PCR kit (Clontech) with 1M of the GC-Melt, following 
the manufacturer’s protocol. cDNAs were subjected to 16 cycles of pre-
amplification, 94°C for 30 s, 68°C for 7 min. The pre-amplification steps were 
monitored by PCR using various house-keeping and cytokine primers as 
tests. SAGE was performed using NlaIII as the anchoring enzyme, BsmF1 as 
the tagging enzyme, and SphI as the cloning enzyme, as described 
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 (Velculescu et al., 1995). DNA sequencing was performed using the 
Megabase 1000 (Molecular Dynamics, Sunnyvale, CA). Sequence analysis 
software SAGE 3.04 β was provided by K. W. Kinzler (Johns Hopkins 
Oncology Center, Baltimore, MD). A conservative estimate of the differential 
up-regulation of each gene within the given library, compared with a pool of 
other libraries, was calculated using a Bayesian statistics model (Zelenika et 
al., 2001). 
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 CHAPTER 3 
 
ANTI-CD40 LIGAND THERAPEUTIC ANTIBODIES INDUCE INFECTIOUS 
TRANSPLANTATION TOLERANCE 
 
Non-depleting anti-CD154 (CD40 ligand) monoclonal antibodies have 
proven effective in inducing transplantation tolerance in rodents and 
primates. In the induction phase anti-CD154 antibody therapy is known 
to enhance apoptosis of antigen reactive T cells. This may not, 
however, be the sole explanation for tolerance induced in this way. I 
show that tolerance is maintained through a dominant regulatory 
mechanism which, like that elicited with anti-CD4 antibodies, manifests 
as “infectious tolerance”. Tolerance induced with antibodies that target 
co-stimulatory molecules, like CD154, therefore involves not only the 
deletion of potentially aggressive T cells, but also a contagious spread 
of tolerance to new cohorts of graft-reactive T cells as they arise1.  
 
3.1  Introduction 
 
The main goal of transplantation research has been to induce tolerance by a 
short pulse of therapy. Long-term graft survival has been achieved in rodents 
through the use of non-depleting monoclonal antibodies such as anti-CD4, 
and anti-CD154 (Qin et al., 1990; Parker et al., 1995; Larsen et al., 1996b; 
Markees et al., 1998; Waldmann and Cobbold, 1998; Waldmann, 1999). The 
potential of anti-CD154 therapy to produce prolonged graft survival even 
across a full MHC mismatch in non-human primates (Kirk et al., 1999; 
Kenyon et al., 1999) has prompted an analysis of the mechanisms involved.  
 
                                            
1 Most of the results presented in this Chapter were published in (Graca et al., 2000). 
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 Treatment of mice with non-depleting anti-CD154 has been shown to be 
capable of prolonging graft survival of allogeneic hearts, but did not lead to 
indefinite graft survival (Larsen et al., 1996a). Such co-stimulation blockade 
resistant allograft rejection appears to be dependent on CD8+ T cells, 
apparently not tolerised following anti-CD154 treatment (Honey et al., 1999), 
CTLA4-Ig treatment (Newell et al., 1999), or both in combination (Trambley et 
al., 1999). The different susceptibility to tolerance induced co-stimulation 
blockade shown by CD4+ and CD8+ T cells may simply reflect their 
differential expression of co-stimulatory molecules.  
 
An additional concern with regard to the use of anti-CD154 in clinical trials 
has been raised following the report of thromboembolic complications 
following the use of one such mAb (5C8.33) in non-human primates (Kawai 
et al., 2000). Such complications were not observed in similar studies by 
another group (Kirk and Harlan, 2000b). CD154 has been shown to be 
expressed on activated platelets in vitro, and in vivo on platelets participating 
in thrombus formation (Henn et al., 1998), having a role on the stabilisation of 
arterial thrombi (Andre et al., 2002). It may be necessary to develop 
strategies allowing the tolerogenic action of anti-CD154 mAb without 
thromboembolic complications in humans. 
 
It has been a long held assumption that activation of T cells requires two 
signals (Bretscher and Cohn, 1970). Signal 1 is delivered by the CD3 
complex as a peptide – MHC complex is engaged by a specific TCR, in an 
interaction stabilised by the co-receptor molecules CD4 or CD8. Signal 2, 
also known as co-stimulation, is provided by the APC through CD80 and 
CD86 (ligands of CD28 on T cells) and CD40 (ligand of CD154). It has been 
postulated that both signals are required to induce T cell activation, while the 
delivery of signal 1 in the absence of signal 2 would result in cell death or its 
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 functional inactivation (Bretscher and Cohn, 1970; Lafferty and Cunningham, 
1975). In spite of several reports that cannot easily be explained by the two 
signal model of T cell activation it still remains an integral part of current 
immunological thought, with some authors postulating additional signals to 
reconcile the model with experimental results (Bretscher, 1999; Matzinger, 
1999; Matzinger, 2001). 
 
Two reports showed that activation induced cell death (AICD) of potentially 
aggressive T cells is an important feature of the induction phase of the 
prolonged graft survival with CD154 antibodies (Li et al., 1999; Wells et al., 
1999). These results may be interpreted in the light of the two signal model 
described above, as a consequence of blocking signal 2 when signal 1 is 
provided, giving rise to AICD and tolerance by purging the T cell repertoire of 
alloreactive cells. When apoptosis was impaired, in those studies, 
alloreactive clones were not deleted and tolerance could not be achieved.  
 
Previous work in our group has established that the CD4+ T cell population in 
mice could indeed be tolerised by CD154 antibodies, in circumstances where 
the CD8+ population had been removed by prior antibody ablation (Honey et 
al., 1999), as such treatment cannot efficiently control the behaviour of CD8+ 
cells that express low levels of CD154 (Trambley et al., 1999; Honey et al., 
1999). In such circumstances it was found that tolerised mice demonstrate 
“linked suppression” to third party antigens (Honey et al., 1999). This result 
cannot easily be explained without considering the emergence of CD4+ 
regulatory T cells following the tolerising mAb treatment. 
 
In a similar experimental system I further analysed the maintenance phase of 
tolerance, and uncovered a role for a contagious process of tolerance 
(infectious tolerance). Infectious tolerance has been observed following 
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 tolerance induction with non-depleting CD4 mAb in skin and marrow 
transplants over multiple-minor histocompatibility barriers, and heart 
transplants across complete MHC histocompatibility barriers (Waldmann and 
Cobbold, 1998). In this Chapter I describe how tolerance, once it has been 
induced by CD154 antibodies, cannot be broken by the adoptive transfer of 
large numbers of naïve non-tolerant T cells. When these naïve cells are 
allowed to coexist with the “regulatory” population for 6 weeks, they become 
tolerant themselves, so exhibiting “infectious tolerance”. These results lead 
me to conclude that tolerance induced with CD154 antibodies involves not 
just the deletion of alloreactive T cells but also maintenance through a 
contagious spread of tolerance to new graft-reactive T cells as they arise. 
 
3.2  Results 
 
3.2.1  The experimental setting 
 
I used CD8-depleted mice treated with CD154 antibodies to produce 
tolerance to B10.BR skin grafts which differ over multiple minor 
histocompatibility antigens.  This model has proven useful in previous 
descriptions of infectious tolerance with CD4 antibodies, and many 
parameters of cell dose and potency in adoptive transfers studies have been 
well characterised (Davies et al., 1996b). Previous studies have 
demonstrated that regulatory cells involved in CD4-antibody induced 
transplantation tolerance are themselves CD4+ (Qin et al., 1993). I wished to 
be able to distinguish any such CD4+ regulatory T cells from naïve CD4 T 
cells that could reject grafts. I therefore used CBA/Ca mice transgenic for the 
human CD52 gene, expressed under the control of the CD2 promoter, as the 
tolerised host, and normal CBA/Ca mice as a source of naïve non-tolerant T 
cells for adoptive transfer. It was thus possible to identify and specifically 
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 deplete host T cells using the CD52 specific CAMPATH-1H mAb (Gilliland et 
al., 1999). These transgenic mice, named CP1-CBA, are histocompatible with 
CBA/Ca mice, as was confirmed by acceptance of reciprocal skin grafts 
(Figure 3.1). Furthermore, when grafted with B10.BR skin (differing by 
multiple minor histocompatibility antigens), both transgenic and CBA/Ca 
strains rejected at a comparable rate  (Figure 3.1). In order to study infectious 
tolerance I needed to be sure that once host T cells had been ablated by the 
CAMPATH-1H antibody, they would not replenish from the thymus. For that 
reason I used adult-thymectomised (ATx) CP1-CBA mice. Such ATx mice 
depleted of T cells with 0.1 mg of CAMPATH-1H mAb accept B10.BR skin 
grafts indefinitely (Figure 3.2A). Analysis of PBLs from CAMPATH-1H treated 
mice by flow cytometry confirms that T cells are depleted to less than 1% 
(Figure 3.2B and 3.2C). This enabled me to use the CAMPATH-1H mAb to 
ablate T cells of the tolerant transgenic host whenever I wished, allowing me 
to determine the impact of their prolonged co-existence with naïve CBA/Ca T 
cells.  
 
In this study, ATx, CD8+ cell depleted CP1-CBA were tolerised to B10.BR 
skin under the cover of three doses of the non-depleting anti-CD154 mAb 
MR1, administered on days 0, 2 and 4 with respect to time of transplantation 
as previously described (Honey et al., 1999).  
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Figure 3.1 CP1-CBA and CBA/Ca mice are histocompatible. Adult CP1-CBA mice reject 
B10.BR skin grafts readily (■, n=4), but do not reject CBA/Ca skin transplants (▼, n=6). 
Similarly, CBA/Ca are able to reject B10.BR skin grafts (?, n=8), while accepting CP1-CBA 
skin transplants (?, n=6). 
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Figure 3.2 CP1-CBA mice reject B10.BR skin grafts at a similar rate to CBA/Ca, but not after 
T cell depletion with CAMPATH-1H mAb. A, Adult CP1-CBA (?, n=4) mice reject B10.BR 
skin grafts at a rate comparable with CBA/Ca (?, n=8) recipients. Adult ATx CP1-CBA 
donors treated with 0.1 mg of CAMPATH-1H mAb prior to B10.BR skin grafting permanently 
accept these grafts (■, n=5, median survival time (MST) >100 days). B, PBLs were analysed 
by flow cytometry following staining with CAMPATH-1H-FITC, CD8-PE and CD4-CyCr. CP1-
CBA mice T cells are double positive for either CD4 or CD8 and CAMPATH-1H. C, Euthymic 
CP1-CBA mice treated with 0.1 mg of CAMPATH-1H show depletion of both CD4+ and CD8+ 
T cells 7 days after treatment.  
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 3.2.2  Anti-CD154 mAb induces dominant transplantation tolerance 
 
I investigated whether anti-CD154 induced tolerance was dominant by testing 
if the CP1-CBA mice tolerised to B10.BR skin as described above could 
resist the adoptive transfer of spleen cells from naïve CBA/Ca mice (Scully et 
al., 1994). 90 days after tolerance induction, CP1-CBA tolerant mice were 
injected intravenously with 50x106 spleen cells from naïve CBA/Ca mice, and 
received a fresh B10.BR skin graft the following day. The naïve cells did not 
“break” tolerance, as both the new and old skin grafts were accepted 
indefinitely (Figure 3.3A). However, in control groups in which mice received 
MR1 treatment in the absence of a first skin graft, or where, at the time of 
cell-transfer, the host T cells had been depleted with CAMPATH-1H antibody, 
B10.BR skin grafts were readily rejected (see Figure 3.3A). The levels of 
donor T cell chimerism, and of host T cell depletion, were analysed by flow 
cytometry of PBLs (Figure 3.3B). These observations indicate that although 
naïve T cells did engraft, they were prevented from rejecting transplanted 
B10.BR skin by tolerised host T cells.  
 
3.2.3  Anti-CD154 mAb induces infectious transplantation tolerance 
 
As dominant-tolerance induced with CD4 antibodies has been shown to 
involve “infectiousness” – tolerant cells imposing tolerance on naïve cells  
(Qin et al., 1993; Cobbold and Waldmann, 1998; Waldmann, 2001) – I 
investigated whether infectious tolerance had been induced by anti-CD154 
therapy. “Indicator” CP1-CBA mice which had been adult thymectomised, 
and depleted of CD8+ T cells were tolerised to B10.BR skin grafts as above. 
After tolerance had been confirmed by graft maintenance for 90 days, 50x106 
spleen cells from naïve CBA/Ca mice were transferred intravenously into 
these tolerant mice, which then received a second B10.BR skin graft the
   68 
 0 25 50 75 100 125
0
50
100
Time/days
%
 G
ra
ft 
su
rv
iv
al
A B 3.3%
16.5%
0.4%
CAMPATH-1H
CD8
5.8% 15.6%
1.3%CD4
CAMPATH-1H
 
Figure 3.3 Anti-CD154 treatment of CD8 depleted mice induces dominant tolerance that is 
not broken by adoptive transfer of naïve spleen cells. A, Adult ATx and CD8 cell depleted 
CP1-CBA transgenic mice received a B10.BR skin graft (multiple minor histocompatibility 
differences) at day -90, with three doses of 0.67 mg of the non-depleting anti-CD154 mAb 
MR1 i.p. at days -90, -88 and -86 to induce tolerance. At day 0 mice from groups designated 
?, ? and ◆ received 50x106 spleen cells i.v. from naïve CBA donors. All mice received a 
fresh B10.BR skin graft the following day and were monitored for graft rejection. Tolerant 
mice that received naïve spleen cells accepted the grafts indefinitely (?, n=7, MST>100), as 
did tolerant mice receiving no naïve cells (■, n=6, MST>100 days, p<0.28). The absence of 
rejection was not due to the persistence of MR1 mAb as all animals in the control group that 
received the tolerising MR1 treatment in the absence of an initial skin graft rejected the graft 
(?, n=6, MST=15 days). The transferred cells were competent to reject the B10.BR skin, as 
mice depleted of their own T cells with 0.1 mg of CAMPATH-1H i.p. prior to cell transfer and 
skin grafting also rejected (◆, n=5, MST=19 days). B, PBLs were analysed by flow cytometry 
following staining with CAMPATH-1H-FITC, CD8-PE and CD4-CyCr. Host lymphocytes, from 
CP1-CBA transgenic mice, are CAMPATH-1H+. The CBA/Ca T cells that were adoptively 
transferred were CAMPATH-1H-ve. It was therefore possible to monitor the efficiency of cell 
transfer by flow cytometry of the CD4 and CD8 populations of CAMPATH-1H-ve cells. An 
example of a mouse from group ? is shown where ~25% of CD4+ and almost all of CD8+ T 
cells are from the donor (the host had been CD8 depleted). 
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 following day. This dose of spleen cells is well in excess of the dose needed 
to get rapid graft rejection in this model (Davies et al., 1996a). When host 
cells were depleted with the CAMPATH-1H mAb on the day following the 
adoptive transfer, the naïve CBA/Ca cells were fully competent to reject the 
new skin graft, as well as the original one (Figure 3.4A). However, if the naive 
CBA/Ca cells were allowed to co-exist with the tolerant cells for 6 weeks, 
before depletion of host cells with CAMPATH-1H mAb, and challenged with a 
third B10.BR skin graft on the day following depletion, all three B10.BR skin 
grafts were accepted indefinitely (Figure 3.4A). Flow cytometry confirmed 
donor T cell chimerism, as well as effective host T cell depletion  (Figure 
3.4B). 
 
3.3  Discussion 
 
Taken together with previous findings of linked suppression in this model of 
transplantation tolerance (Honey et al., 1999), these results indicate that 
therapy with anti-CD154 in this context has a more profound impact than can 
be explained just by deletion of potentially aggressive T cells by AICD (Wells 
et al., 1999; Li et al., 1999). The notion of the need for AICD arose from 
transplants across MHC barriers, and it is conceivable that AICD may not be 
essential in tolerance across multiple minor differences (Li et al., 1998), 
although this remains to be established. Equally, although infectious 
tolerance can be shown to operate across MHC barriers when tolerance is 
induced with CD4 antibodies, it has not been formally demonstrated with 
CD40L antibodies. Whether or not AICD is operational in tolerance achieved 
across multiple minor differences, I must conclude that a population of CD4+ 
regulatory T cells emerges from amongst the antigen-reactive T cells, and 
that these are responsible for the maintenance phase of tolerance. They do
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Figure 3.4 Anti-CD154 treatment induces infectious transplantation tolerance. A, 
Transplantation tolerance to B10.BR skin was induced in ATx CP1-CBA transgenic mice with 
MR1 mAb as described before. Mice from the group designated ■ (n=6) did not receive 
naïve cells. 50x106 spleen cells from naïve CBA donors were adoptively transferred into the 
animals of all other groups at day 0 (90 days after tolerance induction), followed by a fresh 
B10.BR skin graft at day 1. In group ? (n=13), where host transgenic T cells were depleted 
at day 1 with 0.1 mg of CAMPATH-1H mAb i.p., both fresh and old skin grafts were rejected 
(MST=13 days). In group ◆ (n=5), the CBA lymphocytes were allowed to co-exist with the 
CP1-CBA cells for 6 weeks, after which host-T cells cells were depleted with CAMPATH-1H 
and a further B10.BR skin grafted (MST>150). There was no statistically significant 
difference in graft survival for this group when compared with the groups that did not receive 
naïve CBA spleen cells (■, n=6), or in which the CP1-CBA cells were not depleted (?, n=7). 
There is a significant difference between the groups depleted at day 1 (?) and day 45 (◆) 
after transfer (p<0.006). In animals receiving multiple grafts the most recent one was always 
the first to be lost and the one considered in the analysis of data. B, PBLs were stained with 
CAMPATH-1H-FITC, CD8-PE and CD4-CyCr and analysed by flow cytometry, as before, to 
confirm the efficiency of depletion and cell transfers. An example of a mouse from group ◆, 
45 days after CAMPATH-1H depletion is shown, where the presence of CAMPATH –1H-ve T 
cells of donor origin can be seen while the host T cells are less than 1%. 
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 so not just by actively suppressing rejection, but also by imposing tolerance 
on naïve cells through infectious tolerance. 
 
There are two possible mechanisms by which these regulatory cells may 
arise. One (two-population model) is that these regulatory cells are already 
present in the T cell pool as a distinct sub-population. If they were less 
susceptible to AICD than potentially aggressive cells they would persist after 
anti-CD154 therapy and thus the ratio between regulators and aggressors 
would be altered to favour tolerance. A variant of this first model might 
require that AICD of the potentially aggressive T cells permits the graft to 
survive long enough for a regulatory CD4+ cell population to expand and then 
dominate. The other possible mechanism (single-population model) is that 
potentially aggressive T cells which failed to die from AICD might have 
changed function to become regulators as a consequence of the antigen 
recognition in a tolerogenic environment. I cannot, at present, distinguish 
between these two possibilities. 
 
To exert infectious tolerance such regulatory T cells would need to influence 
naïve T cells. This could occur either by influencing the local 
microenvironment of antigen presentation where both types of cells 
(regulatory and naïve) were in close proximity, or alternatively by 
decommissioning APCs so that they present to naïve T cells for tolerance 
rather than immunity. 
 
These results show that common characteristics can be found following 
tolerance induction with mAb targeting co-stimulatory molecules (such as 
CD154) or mAb targeting the co-receptor molecules CD4 and CD8 (reviewed 
in Waldmann and Cobbold, 1998). It is even likely that other tolerance 
inducing regimens like vitamin D3 and mycophenolate mofetil, although not 
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 yet studied with the same detail, will also share the same characteristics of 
dominant tolerance, infectious tolerance and linked suppression as they give 
rise to CD4+ regulatory T cells (Gregori et al., 2001). As a consequence, it 
may be possible to explore synergistic effects of such tolerance inducing 
agents, as described in the next chapter, in order to achieve an even more 
robust tolerance. 
 
One can speculate that any therapeutic intervention allowing peaceful 
coexistence between foreign antigen, some of it presented indirectly by host 
APCs, and CD4+ T cells can result in the expansion of regulatory T cells and 
dominant transplantation tolerance. It may even be that in the absence of 
inflammation or “danger”, where effector mechanisms are not deployed, the 
outcome is the expansion of regulatory T cells. This hypothesis is consistent 
with the finding described in Chapter 7 concerning the immunogenic and 
tolerogenic properties of mAb variants. There I show that two mAbs with the 
same sequence except for a single amino-acid mutation that renders one of 
the mAbs non-lytic have different properties. The mAb that do not kill cells is 
not immunogenic, being remarkably tolerogenic. In other words, absence of 
danger may drive tolerance. This would not be tolerance by indifference as 
suggested in Matzinger’s danger theory (Matzinger, 1994), but dominant 
tolerance enforced by regulatory T cells and capable of resisting subsequent 
“dangerous” encounters with the tolerated antigens, and even third-party 
“linked” antigens. 
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CHAPTER 4 
 
INDUCTION OF DOMINANT TRANSPLANTATION TOLERANCE TO FULLY 
MISMATCHED SKIN GRAFTS WITH NON-DEPLETING ANTIBODIES 
 
 
Non-depleting therapeutic antibodies, such as those targeting CD4, CD8 
and CD154 (CD40 ligand) have been shown effective in inducing 
tolerance to fully mismatched kidneys, heart and islet grafts, or to 
multiple minor antigens disparate skin grafts. A non-depleting antibody 
regimen capable of inducing tolerance to fully mismatched skin grafts 
has remained elusive. This Chapter reports that a combination of non-
depleting antibodies to CD4, CD8 and CD154 is capable of inducing 
tolerance to fully mismatched skin transplants in euthymic mice. 
Tolerised animals accept subsequent skin grafts of the tolerated type 
while remaining fully competent to reject skin grafts of unrelated 
donors. Tolerance so induced appears to be dominant and mediated by 
CD4+ T cells, reflected as a T cell dependent resistance of rejection 
mediated by transfused naïve lymphocytes and as “linked suppression” 
toward third party antigens associated with the tolerated set. This state 
of dominant tolerance is remarkably powerful, leading to tolerance of 
any third party antigens genetically associated with the tolerated set.  
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 4.1  Introduction 
 
The Holy Grail of transplantation research has been the achievement of life-
long tolerance, following a short treatment, and without significant long-term 
immunosuppression. Therapeutic non-depleting mAbs have been shown 
effective in inducing tolerance to fully mismatched kidneys, hearts and 
pancreatic islets (Chen et al., 1992; Lenschow et al., 1992; Isobe et al., 1992; 
Nicolls et al., 1993; Yin and Fathman, 1995b; Onodera et al., 1996; Kirk et 
al., 1999; Kenyon et al., 1999) and to skin grafts mismatched for multiple 
minor histocompatibility antigens (Qin et al., 1990). However, complete 
tolerance to the most challenging of allografts, the fully mismatched skin 
grafts, and defined by acceptance of repeat transplants, has remained 
elusive and considered a most stringent test for any tolerance inducing 
regimen. The two experimental protocols that have come closest to inducing 
tolerance to fully mismatched skin grafts have been either the combination of 
non-depleting anti-CD4 and anti-CD8 mAbs, or the combination of anti-
CD154 and CTLA4-Ig with indefinite survival of fully mismatched skin grafts 
being obtained in both cases (Larsen et al., 1996b; and S.P. Cobbold, 
unpublished). Both tolerance inducing regimens elicit the emergence of CD4+ 
regulatory T cells capable of suppressing rejection by transfused non-tolerant 
T cells (dominant tolerance) and inducing the non-tolerant T cells to become 
themselves tolerant (infectious tolerance) (Qin et al., 1993; Graca et al., 
2000). Operational tolerance of fully mismatched skin grafts has been 
obtained with the use of depleting mAbs (Cobbold et al., 1990), induction of 
macrochimerism (Wekerle and Sykes, 2001), or a combination of non-
depleting mAbs with immunossupressive drugs (Li et al., 1999). 
 
Based on evidence presented in the previous chapter, that either mAbs 
targeting co-receptor or mAbs specific for co-stimulatory molecules can 
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 induce dominant tolerance mediated by CD4+ regulatory T cells, I decided to 
investigate whether the combination of those mAbs would synergise leading 
to a more robust tolerant state. Indeed, I found that a combination of non-
depleting mAbs targeting CD4, CD8 and CD154 synergise to enable 
dominant tolerance to be achieved for fully mismatched skin grafts. Tolerised 
mice retain the capacity to reject unrelated skin grafts, while being disabled 
from rejecting repeat grafts of the tolerated type. Tolerance so induced 
appears to be dominant and mediated by CD4+ regulatory T cells, as 
expected from the known characteristics of tolerance induced by co-receptor 
or co-stimulatory blockade (Qin et al., 1993; Graca et al., 2000; Waldmann 
and Cobbold, 2001). A remarkably powerful form of linked suppression is 
readily demonstrated in tolerant mice, which is able to spread to third party 
antigens if these are genetically associated with the tolerated antigen set, 
and most surprisingly with the host antigens. This suggests that the repertoire 
of regulatory T cells which recognise “donor” antigens processed by host 
APCs, cross reacts significantly with that recognising third-party antigens (full 
mismatches) presented in association with host-type MHC. 
 
4.2  Results 
 
4.2.1  Non-depleting antibodies to CD4, CD8 and CD154 synergise to 
induce tolerance to fully mismatched skin grafts 
 
A short treatment with a combination of non-depleting CD4, CD8 and CD154, 
but not a combination of any two of the mAbs, is capable of inducing 
tolerance to fully mismatched skin grafts. Adult euthymic CBA/Ca mice were 
transplanted with C57/B10 skin and treated with a short course of non-
depleting CD4 (YTS 177), CD8 (YTS 105) and CD154 (MR1) mAbs. Mice 
treated with a combination of the three mAbs accepted the tolerated skin 
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 grafts indefinitely, as did most of the animals treated with anti-CD4 + anti-
CD8. All mice treated with other mAb combinations readily rejected the skin 
grafts (Figure 4.1A).  
 
At day 100 following tolerance induction, mice with surviving grafts received a 
fresh C57/B10 skin graft, as did animals treated with all three mAbs in the 
absence of the initial skin grafts (Figure 4.1B). No rejection was observed in 
the group rendered tolerant to C57/B10 skin by treatment with the three 
mAbs, a result which cannot be consequence of persistence of the mAbs in 
circulation, as the control group injected with the same mAbs, but in the 
absence of an initial graft, readily rejected the transplanted skin. Mice pre-
treated with just CD4 and CD8 mAbs, in spite of prolonged acceptance of 
initial allografts, rejected both fresh and old grafts following the secondary 
graft challenge.  Mice tolerised with the three mAbs remained fully competent 
to reject third-party BALB/c skin transplants, at a similar rate to non-tolerant 
animals.  
 
4.2.2  Non-depleting antibodies to CD4, CD8 and CD154 induce 
dominant tolerance to fully mismatched skin grafts 
 
Treatment with either non-depleting CD4 and CD8 mAbs, or with CD154 and 
CD8 mAb can lead to dominant transplantation tolerance to skin grafts 
mismatched for multiple minor transplantation antigens (Qin et al., 1993; 
Graca et al., 2000). Such dominant tolerance is easily identified by the 
demonstration that transfusions of naïve syngeneic lymphocytes will not 
break the tolerant state. This was indeed seen to be the case when tolerance 
had been induced to fully mismatched skin, as tolerised animals transfused 
with a large number of naïve lymphocytes resisted graft rejection.  
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Figure 4.1 Tolerance induction to fully mismatched skin grafts. A, CBA/Ca mice were treated 
with 3 doses of 1 mg of the anti-CD4, anti-CD8 and anti-CD154 non-depleting mAbs over 1 
week following C57/B10 skin transplantation at day 0. Only mice treated with the three mAbs 
(?, n=6, MST>100d) and anti-CD4 + anti-CD8 (?, n=26, MST>100d) showed indefinite graft 
survival (P<0.05 to any other group). All grafts from mice treated with anti-CD4 + anti-CD154 
(●, n=6, MST=21.5d), anti-CD8 + anti-CD154 (◆, n=6, MST=14d) and untreated controls (■, 
n=10, MST=10d) were rejected. B, After 100 days, mice with surviving skin allografts 
received fresh C57/B10 skin transplants. In animals treated with the three mAbs no 
rejections were observed (?, n=6, MST>100d). Mice treated with only anti-CD4 and anti-
CD8 rejected the skin allografts (?, n=10, MST=46d, P=0.011 vs. ?). The control group 
treated with the same three mAbs (as ?) in the absence of initial transplant rejected the skin 
grafts (◆, n=5, MST=16d). BALB/c skin was transplanted at day 140 onto mice tolerised with 
the three mAbs (?, n=6, MST=16d) and the control mice treated with the mAbs in the 
absence of an initial graft (?, n=5, MST=15d). 
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 Adult thymectomised CP1-CBA mice were tolerised to C57/B10 skin grafts, 
by treatment with the three mAbs over the first week following 
transplantation. At 100 days following tolerance induction, the CP1-CBA mice 
received a transfusion of 20x106 splenocytes from naïve CBA/Ca mice, as 
well as a fresh C57/B10 skin graft. Figure 4.2A shows that where 20x106 
non-tolerant splenocytes were transfused into T cell depleted hosts the grafts 
were readily rejected. Rejection at a similar rate was observed when host T 
cells were depleted from tolerised CP1-CBA mice one day following the 
transfusion with naive splenocytes. However, when host T cells were allowed 
to co-exist with the transfused splenocytes, graft rejection was significantly 
delayed. The extent of the delay was not due to the persistence of the 
therapeutic mAbs as control animals treated with the same mAb combination, 
but in the absence of an initial skin graft, readily rejected C57/B10 skin grafts 
even without being transfused with naive CBA/Ca splenocytes. Figure 4.2B 
shows that when non-tolerant splenocytes co-exist with tolerised T cells for 
45 days, their ability to reject fresh C57/B10 skin grafts was significantly 
reduced by comparison to those which have co-existed for just one day 
(MST=11d vs. 18.5d; P=0.018).  
 
The delay in graft rejection following the adoptive transfer of 20x106 
splenocytes from naïve mice is significant as I determined that as few as 
5x104 splenocytes from naïve CBA/Ca are sufficient to mediate C57/B10 skin 
graft rejection upon transfer into RAG1-/- mice (n=4, MST=23.5d; Figure 
4.2C). 
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Figure 4.2 Tolerised mice resist transfusion of non-tolerant cells. Adult thymectomised CP1-
CBA mice were tolerised to C57/B10 skin grafts as described. A, 100 days after initial 
transplantation (day -1) the animals from two groups (? and ?) were transfused with 20x106 
splenocytes from naïve CBA/Ca mice. The following day all mice were grafted with C57/B10 
skin, and one group depleted of host T cells with CAMPATH-1H (?). Animals from the 
depleted group readily rejected skin grafts (?, n=5, MST=12d) at rate comparable with non-
tolerant T cell depleted animals transfused with the same number of splenocytes (?, n=5, 
MST=12.5d), or animals treated with tolerogenic mAbs in the absence of initial skin graft, and 
not transfused (?). The animals whose T cells had not been depleted resisted transfusion 
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 showing delayed graft rejection (?). When their host T cells were depleted 45 days after 
transfusion, and another C57/B10 skin transplanted, grafts were rejected. B, Direct 
comparison of rejection rate following depletion of host T cells from tolerised mice, as 
described in (A). In mice from group ? the transfused non-tolerant splenocytes were allowed 
to coexist with tolerised T cells for only 1 day (n=5, MST=11d). In mice from group ? the 
coexistence was extended to 45 days (n=6, MST=18.5d, P=0.018). C, Number of 
splenocytes from naïve CBA/Ca capable to mediate C57/B10 skin graft rejection upon 
adoptive transfer into RAG1-/- mice. As few as 5x104 splenocytes can lead to allograft 
rejection. 
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 4.2.3  Tolerance is maintained by CD4+ regulatory T cells 
 
Dominant tolerance induced with either non-depleting CD4 and CD8 mAbs, 
or with CD154 mAb is maintained by CD4+ regulatory T cells (Qin et al., 
1993; Graca et al., 2000). We also confirmed that dominant tolerance 
induced with a combination of the three mAbs to fully mismatched skin grafts 
is mediated by CD4+ T cells.  
 
RAG1-/- mice were grafted with C57/B10 skin and transfused with 107 
splenocytes from CBA/Ca mice tolerised to C57/B10 skin 100 days earlier 
(Figure 4.3). Different groups of mice were depleted of CD4+ or CD8+ T cells 
with mAbs. All recipients of splenocytes from naïve donors rejected skin 
grafts regardless of depletion of either CD4+ or CD8+ cells, but rejection was 
significantly impaired when both populations of T cells were simultaneously 
depleted. However, where RAG1-/- mice were transfused with splenocytes 
from tolerised donors, rejection was only observed following depletion of 
CD4+ T cells, and at a delayed rate. The differences observed between the 
groups where “tolerant” splenocytes were depleted of CD4+ or CD8+ T cells is 
statistically significant (P<0.05).  
 
4.2.4  Non-depleting antibodies to CD4, CD8 and CD154 induce linked 
suppression to fully mismatched skin grafts 
 
Linked suppression has been a constant feature of dominant transplantation 
tolerance induced by treatment with non-depleting CD4 or CD154 mAbs 
(Davies et al., 1996a; Chen et al., 1996; Wong et al., 1997; Honey et al., 
1999). I found that the combination of the three mAbs induces a very 
powerful form of linked suppression across fully mismatched skin allografts.  
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Figure 4.3 Dominant transplantation tolerance is mediated by CD4+ T cells. RAG1-/-mice 
were transfused with 107 splenocytes from tolerant (filled symbols) or naïve donors (open 
symbols). CD4+ cells (circles), CD8+ cells (triangles), or both (diamonds), were depleted in 
different groups of mice. The difference in graft survival between groups where “tolerant” 
splenocytes were depleted of CD4+ or CD8+ T cells is statistically significant (? and ?, n=5, 
P<0.05). 
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 CBA/Ca mice were tolerised to C57/B10 skin grafts as described. Figure 4.4A 
shows graft survival for skin transplanted at 100 days. Mice grafted with 
(C57/B10 x BALB/c)F1 skin held their grafts indefinitely, while non-tolerant 
mice rejected their grafts. When mice were transplanted with both C57/B10 
and BALB/c skin in the same graft bed, the BALB/c graft was rejected, with 
two mice from this group subsequently rejecting the C57/B10 grafts (on days 
22 and 27, not represented in the figure). In a repeat experiment BALB/c 
rejection did not lead to C57/B10 rejection in any animal (n=5), and in all 
experiments where BALB/c and C57/B10 skin grafts were transplanted 
sequentially only BALB/c grafts were rejected (see Figure 4.1B). It is possible 
that in the two mice that had rejected the tolerated C57/B10 grafts, cross-
reactivity of T cells recognising antigens presented by donor APCs (direct 
presentation) overcame the effect of regulatory cells that were maintaining 
C57/B10 grafts.  
 
Surprisingly, tolerant mice grafted with (CBA/Ca x BALB/c)F1 skins rejected 
the grafts at a slower rate, with 3/6 of the mice accepting the grafts 
indefinitely (Figure 4.4A). Naïve CBA/Ca mice readily rejected (CBA/Ca x 
BALB/c)F1 or (CBA/Ca x C57/B10)F1 skin grafts.  
 
One of the potential therapeutic benefits of linked suppression is to build up 
tolerance to transplants of a third party type, by regrafting hosts tolerant to 
the second party with tissues exhibiting both the tolerated and the third-party 
antigens(Davies et al., 1996a; Chen et al., 1996; Wong et al., 1997). We 
confirmed that this was possible by transplanting BALB/c skin onto those 
CBA/Ca mice, pre-tolerised to C57/B10 skin, where  (C57/B10 x BALB/c)F1 
skin had survived 50 days (Figure 4.4B). All animals accepted the BALB/c 
skin. These results show how tolerance induced to fully mismatched skin 
grafts can be extended to third-party antigens. Most interestingly, grafts from 
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Figure 4.4 Linked suppression across fully mismatched skin transplants. CBA/Ca mice were 
tolerised to C57/B10 skin grafts as described. A, 100 days after tolerance induction (day 0 in 
the graph) mice were transplanted with (CBA/Ca x BALB/c)F1 (?, n=6, MST=80.5d), 
(C57/B10 x BALB/c)F1 (◆, n=6, MST>150d) skin grafts, or both BALB/c and C57/B10 skin 
grafts onto the same graft bed (only BALB/c graft survival represented: ?, n=5, MST=14d). 
Antibody treated mice not transplanted with tolerising skin were now grafted with C57/B10 
skin (?, n=6, MST=10.5d). Naive mice were transplanted with (C57/B10 x BALB/c)F1 (?, n= 
6, MST=10d), (CBA/Ca x BALB/c)F1 (∇, n=6, MST=12d), or (CBA/Ca x C57/B10)F1 (?, n=6, 
MST=12.5d) skin grafts. All tolerised mice grafted with (C57/B10 x BALB/c)F1 skin accepted 
the grafts (◆, P<0.001 to any other group except ?: non-significant), while mice grafted with 
(CBA/Ca x BALB/c)F1 skin showed a delayed rejection with half the mice accepting the grafts 
indefinitely (?, P<0.001). B, All mice from (A) that failed to reject either (C57/B10 x 
BALB/c)F1 (◆) or (CBA/Ca x BALB/c)F1 (?) skin grafts, accepted subsequent BALB/c skin 
grafts transplanted at day 150. The same mice that rejected (CBA/Ca x BALB/c)F1 (?) skin 
grafts, rejected subsequent BALB/c skin transplants. 
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 (CBA/Ca x BALB/c)F1 hybrid mice, where the host-type parent (CBA/Ca) had 
been crossed with the third-party (BALB/c), were also able to elicit a similar, 
albeit less powerful, effect than (C57/B10 x BALB/c)F1 grafts.  
 
4.3  Discussion  
 
It can therefore be concluded that a combination of non-depleting CD4, CD8 
and CD154 mAbs, but not a combination of any two of the mAbs, induce 
transplantation tolerance specific to the antigens present in the skin allograft 
at the time of treatment, without impairing immune responses to unrelated 
antigens (Figure 4.1). The treated mice are therefore tolerant and not 
immunosuppressed. Furthermore, mAbs targeting co-receptor molecules 
apparently synergise with mAbs targeting co-stimulatory molecules, and that 
CD4 blockade is more efficient that CD154 blockade in inducing tolerance, 
contrary to what would be predicted by a strict interpretation of the two signal 
model of T cell activation (Matzinger, 1999). 
 
The finding that non-depleting CD4 and CD8 mAb treatment leads to long-
term allograft survival, but cannot prevent rejection following a transplant 
rechallenge is intriguing. During the induction phase of tolerance it is possible 
that the T cell repertoire specific for directly presented antigens (on donor 
type APCs) is not efficiently deleted. It is known that dominant tolerance 
requires the persistence of the tolerated antigens in order to be maintained 
(Scully et al., 1994), and It is most unlikely that donor type APCs persist for a 
long period of time (Lechler and Batchelor, 1982). As a consequence, at the 
time of secondary skin transplantation, dominant tolerance towards directly 
presented antigens is probably absent, while tolerance to indirectly presented 
antigens persists. This effect cannot be seen in the context of minor antigens 
where there is no difference between direct and indirect presentation. It is 
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 possible (although speculative) that addition of anti-CD154 to the tolerizing 
protocol could allow a more complete depletion of the T cell repertoire 
specific for antigens presented on donor APCs, most likely by AICD (Wells et 
al., 1999; Li et al., 1999). According to this hypothesis, one would predict that 
a persistent source of donor type APCs, such as bone marrow 
transplantation or repeated donor type transfusions, should allow the 
maintenance of regulatory T cells capable of suppressing immune responses 
to repeat transplantation in mice treated with only anti-CD4 and anti-CD8. 
Another prediction is that if rejection of secondary grafts is prevented by 
conventional immunosuppressive drugs for the short time donor APCs are 
present, then tolerance will not be broken. It is important to note that this 
hypothesis is different from Matzinger’s danger theory (Matzinger, 1994). 
Although inflammatory stimuli may skew the balance between suppression / 
aggression towards the latter, the key issue is that direct presentation does 
not elicit regulatory cells unless there is a persistent source of donor APCs. 
When regulatory T cells are present, for example in the context of indirect 
presentation, usually “danger” cannot break tolerance. 
 
The results also suggest that in tolerant mice CD8+ T cells capable of 
rejecting the tolerated skin allografts persist, but are controlled by CD4+ 
regulatory T cells (Figure 4.3). Delayed rejection mediated by tolerated CD8+ 
T cells, when compared with rejection by naïve CD8+ cells, can be due to 
either the presence of some CD4- regulatory cells (not powerful enough to 
completely control rejection), or to deletion of a significant pool of alloreactive 
CD8+ T cells. I favour this last hypothesis, as activation induced cell death 
has been shown to contribute to mAb-induced transplantation tolerance 
(Wells et al., 1999; Li et al., 1999).  
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 The demonstration of dominant tolerance is compatible with a role for 
regulatory T cells, as it has been demonstrated for tolerance induced with 
non-depleting CD4 and CD8 mAbs (Qin et al., 1993), and with anti-CD154 
and CD8 mAbs (Graca et al., 2000).  
 
Furthermore, as tolerance can be induced in either euthymic (Figure 4.1), or 
adult thymectomised mice (Figure 4.2), I confirmed that the potential for this 
form of tolerance does resides in the periphery, and that any alloreactive T 
cells exported from the thymus are not able to break the tolerant state.  
 
Finally, it was shown that tolerance induced to fully mismatched skin grafts 
can be extended to skin of a third-type, by exposure of the immune system to 
a graft carrying both sets of antigens in their cells. Most interestingly, 
(CBA/Ca x BALB/c)F1 skin grafts, from syngeneic host-type mice crossed 
with third-party mice (whose cells harbour simultaneously autologous and 
third-party antigens), could also elicit a similar albeit less powerful outcome 
than (C57/B10 x BALB/c)F1 skin grafts (whose cells harbour simultaneously 
antigens of the tolerated type and third-party antigens). These observations 
contrast with findings from some studies where grafts mismatched for minor 
antigens were used (Davies et al., 1996a; Honey et al., 1999). In such 
experiments, syngeneic by third party F1 skin grafts were shown to be 
consistently rejected.  
 
Our results can be understood if we recognise that many donor proteins are 
presented on host APCs (indirect presentation) for priming of regulatory T 
cells (Wise et al., 1998; Yamada et al., 2001). It is possible that the two fully 
mismatched donor skin grafts (BALB/c and C57/B10) share sufficient 
polymorphic proteins so as to engage the abundant pool of regulatory T cells 
established following initial tolerisation of C57/B10 skin graft, when presented 
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 on host-type MHC. (CBA/Ca x BALB/c)F1 skin grafts would present many of 
these shared antigens through indirect presentation by H-2k on F1 APC. In 
contrast, BALB/c grafts would not be able to present “directly” to regulatory T 
cells, and so rejection would be advanced before regulation through indirect 
presentation had been harnessed. When tolerance is induced to some minor 
antigens, there may not be a sufficient overlap between the tolerised minor 
antigens, and the third-party antigens tested. In such conditions the balance 
would favour rejection (Davies et al., 1996a; Honey et al., 1999). It is, 
however, important to stress that skin grafts different in minor antigens are 
often not rejected, as it is the case of BALB/k skin grafts transplanted onto 
CBA/Ca (Davies et al., 1996a). Such phenomenon may also be due to “linked 
suppression” mediated by regulatory T cells maintaining peripheral self-
tolerance. 
 
The results presented in this chapter show that a combination of non-
depleting mAbs aiming for simultaneous co-receptor and co-stimulation 
blockade achieve tolerance in the most stringent of the mouse transplantation 
models. The observation of linked suppression offers the prospect of 
significant clinical application: it may be possible to identify sets of common 
transplantation antigens to which tolerance once induced would be 
permissive for acceptance, through linked suppression, of organs from 
diverse donors. Patients receiving such “prophylactic vaccines” prior to a 
transplant might tolerate a broader degree of genetic mismatch. A concern 
for clinical trials of mAb to induce tolerance to a transplanted organ is the risk 
of rejection where current drug immunosuppression is considered effective in 
the short-term. The concept of prophylactic tolerance induction to a limited 
set of common (shared) transplantation antigens could thus lessen the risk of 
rejection in experimental tolerance protocols. 
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 CHAPTER 5 
 
BOTH CD4+CD25+ AND CD4+CD25- REGULATORY T CELLS MEDIATE 
DOMINANT TRANSPLANTATION TOLERANCE 
 
 
CD4+CD25+ T cells have been proposed as the principal regulators of 
both self-tolerance and transplantation tolerance.  Although CD4+CD25+ 
T cells do have a suppressive role in transplantation tolerance, so do 
CD4+CD25- T cells although ten-fold less potent. Antibodies to CTLA-4, 
CD25, IL-10 and IL-4 were unable to abrogate suppression mediated by 
tolerant spleen cells, so excluding any of these molecules as critical 
agents of suppression. CD4+CD25+ T cells from naïve mice can also 
prevent rejection despite the lack of any previous experience of donor 
alloantigens. However, this requires many more naive than tolerised 
cells to provide the same degree of suppression. This suggests that a 
capacity to regulate transplant rejection pre-exists in naïve mice, and 
may be amplified in “tolerised” mice. Serial Analysis of Gene 
Expression (SAGE) confirmed that cells sorted into CD4+CD25+ and 
CD4+CD25- populations were distinct in that they responded to TCR 
ligation with very different programs of gene expression. Further 
characterization of the differentially expressed genes may lead to the 
development of diagnostic tests to monitor the tolerant state2. 
 
 
                                            
2 Some of the results presented in this Chapter were published in (Graca et al., 2002b). 
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 5.1  Introduction 
 
Ever since the description of classical transplantation tolerance by Medawar 
and his colleagues (Billingham et al., 1953), the attainment of clinical 
transplantation tolerance has been considered the Holy Grail of immunology. 
In rodents, the therapeutic administration of non-depleting monoclonal 
antibodies (mAb), such as the combination of anti-CD4 and anti-CD8, at the 
time of transplantation can lead to a robust form of peripheral tolerance (Qin 
et al., 1990; Qin et al., 1993; Davies et al., 1996a; Chen et al., 1996; 
Waldmann and Cobbold, 1998). The tolerant state so achieved, creates an 
environment in the host which can disarm non-tolerant naïve cells from 
rejecting the transplant (dominant tolerance), as well as enabling the 
emergence of novel regulatory cells from the naïve lymphocyte population 
(infectious tolerance). This has been observed not only with tolerance 
induced following co-receptor blockade of CD4 and CD8 (Qin et al., 1993), 
but also with tolerance resulting from co-stimulation blockade using non-
depleting anti-CD40L (CD154) mAb (Graca et al., 2000). Thus far, the 
regulatory cells mediating dominant tolerance have been identified as CD4+ T 
cells in all the models studied (Hall et al., 1985; Qin et al., 1993; Yin and 
Fathman, 1995a; Zhai and Kupiec-Weglinski, 1999; Waldmann and Cobbold, 
2001).  
 
In parallel studies, animal models of autoimmune disease and inflammatory 
bowel disease have provided compelling evidence of CD4+ regulatory cells 
that prevent immunopathology (Sakaguchi et al., 1985; Powrie and Mason, 
1990; Fowell and Mason, 1993; Mason and Powrie, 1998). The phenotype of 
these regulatory T cells has been further refined, so that 
CD4+CD25+CD45RBlow T cells are now considered the principal exponents 
(Sakaguchi, 2000; Shevach, 2000; Maloy and Powrie, 2001). These cells 
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 have been shown capable of regulating CD4+CD25- or CD4+CD45RBhigh non-
tolerant cells both in vitro and in vivo, preventing the onset of autoimmunity 
and gut immunopathology (Sakaguchi et al., 1995; Asano et al., 1996; 
Thornton and Shevach, 1998; Takahashi et al., 1998). They have also been 
shown capable of suppressing in vitro proliferation and IFN-γ secretion by 
CD8+ T cells (Piccirillo and Shevach, 2001). 
 
In order to establish the relationship, if any, between the T cells that regulate 
transplant rejection and those that regulate self-immunopathology we 
compared the suppressive ability of CD4+CD25+ and CD4+CD25- T cells from 
mice rendered tolerant to skin transplants, as well as from naïve mice with no 
previous experience of those particular transplantation alloantigens. We 
found that both CD4+CD25+ and CD4+CD25- cells from tolerant mice could 
mediate suppression, although the CD4+CD25- cells were required in larger 
numbers. However, as mice have ten times more CD4+CD25- than 
CD4+CD25+ T cells, we are led to conclude that regulatory cells within both 
populations are involved in suppression, perhaps acting in concert. In 
contrast, it was only the CD4+CD25+, but not the CD4+CD25-, cells from 
naïve mice that could prevent naïve splenocytes cells from rejecting a skin 
graft, although at least five-fold more cells were required than from tolerant 
donors. This could mean that tolerance inducing protocols either drive an 
expansion of regulatory T cells (both CD4+CD25+ and CD4+CD25-) or that 
they bring about selective deletion of non-tolerant cells, or indeed both – the 
outcome being a tolerance-permissive regulator to immune-effector ratio. 
These results appear to differ from previously published work (Hara et al., 
2001; Gregori et al., 2001) where only the CD4+CD25+ cells from tolerant 
animals have been shown to be regulatory. These differences may be 
apparent rather than real, simply reflecting minutiae of the protocols involved 
in the previous studies.  
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 Transcriptional profiling by SAGE (Velculescu et al., 1995) of CD4+CD25+ 
and CD4+CD25- T cells from naïve mice was used to establish that the two 
populations have very distinct gene profiles. These may reflect the differing 
functions of such populations, and, with further characterization, may provide 
diagnostics to allow monitoring of the contributions of each CD4+ 
subpopulation in circumstances where therapeutic tolerance is desirable. 
 
5.2  Results  
 
5.2.1  Spleen cells from “tolerized” mice abrogate skin graft rejection 
by spleen cells from naïve mice 
 
Regulatory cells that suppress graft rejection by naïve spleen cells can be 
found in the spleens of mice made tolerant to an allograft with therapeutic 
mAbs (Qin et al., 1993). We confirmed that 107 spleen cells from naïve 
CBA/Ca mice were, upon adoptive transfer, sufficient to reject B10.BR skin 
grafts in T cell depleted hosts (Davies et al., 1996b). An equal number of 
spleen cells from mice tolerant to B10.BR skin grafts could prevent graft 
rejection when co-administered with the naïve cells. 
 
Tolerance was induced in CBA/Ca mice by treatment with 3 mg of the 
combination of non-depleting CD4 and CD8 mAbs administered over one 
week following the transplantation of B10.BR skin grafts. I used CP1-CBA 
mice as T cell depleted hosts for cell transfusion (Gilliland et al., 1999). CP1-
CBA mice were thymectomised at 4 weeks of age, and depleted of T cells 
with CAMPATH-1H one week prior to cell transfer (designated as “empty” 
mice). The “empty” mice were transfused with 107 spleen cells from tolerant 
mice; 107 spleen cells from naïve CBA/Ca; or an equal number (107) spleen 
cells from both tolerant and naïve mice. All animals were grafted with B10.BR 
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 skin the following day. Rejection was only observed in those mice transfused 
with cells from naïve CBA/Ca (Figure 5.1). Spleen cells from tolerant mice not 
only failed to reject the skin grafts, but also abrogated rejection mediated by 
naïve T cells: so demonstrating dominant tolerance. Similar results were 
obtained in experiments where 2x107 and 4x107 spleen cells from both 
tolerant and naïve mice were transfused. I decided to use 107 spleen cells 
from naïve CBA/Ca as the target population to assess the number and 
phenotype of regulatory cells able to prevent rejection.  
 
5.2.2  CD4+CD25+ cells from naïve mice prevent graft rejection upon 
adoptive transfer 
 
I investigated whether the capacity to suppress transplant rejection pre-
existed in naïve mice. CD4+CD25+ and CD4+CD25- T cells were isolated from 
the spleens of naïve CBA/Ca mice. “Empty” CP1-CBA mice were injected 
with 107 unsorted spleen cells from naïve CBA/Ca, together with 106 of either 
CD4+CD25+ or CD4+CD25- T cells, also from naïve CBA/Ca. All mice were 
transplanted with B10.BR skin on the following day. Delayed graft rejection 
was observed in the group transferred with the CD4+CD25+ cells, with 6/10 of 
the mice showing indefinite graft survival (Figure 5.2). The animals injected 
with unsorted spleen cells alone rejected the skin grafts at a rate similar to 
the group receiving CD4+CD25- T cells. To rule out an artefact of the sorting 
procedure, a control experiment was performed where spleen cells from 
naïve CBA/Ca were sorted and subsequently remixed to the exact starting 
proportions. These cells failed to prevent skin graft rejection upon adoptive 
transfer (Figure 5.3).  
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Figure 5.1 Spleen cells from tolerant mice prevent rejection mediated by non-tolerant cells. 
CP1-CBA mice were thymectomised at 4 weeks of age, and depleted of T cells with 0.1mg 
CAMPATH-1H at days –7 and –8. (A) At day –1, these mice received an i.v. injection of 107 
(▲) or 2x107 ( ) spleen spleen cells from naïve CBA/Ca;107 (?) or 2x107 ( ) spleen cells 
from CBA/Ca mice tolerant of B10.BR skin grafts;107 or 2x107 spleen cells from the same 
naïve CBA/Ca donors, together with an equal number of spleen cells tolerant donors (▼ and 
); and a final group was not injected (?). All animals received a B10.BR skin graft on the 
following day (day 0). Only mice transfused with cells from naïve donors rejected the skin 
grafts, the rejection being slightly faster when more cells were transfused. The spleen cells 
from tolerant donors not only allowed indefinite graft survival, but were also able to suppress 
rejection mediated by the naïve cells injected at the same time.  
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Figure 5.2 CD4+CD25+ cells from naïve mice prevent graft rejection upon adoptive transfer. 
CD4+CD25+ and CD4+CD25- cells were sorted from spleens of CBA/Ca mice. “Empty” CP1-
CBA mice were injected i.v. with 106 of either CD4+CD25+ or CD4+CD25- cells together with 
107 unsorted spleen cells. All mice were transplanted with B10.BR skin the following day. 
The group injected with CD4+CD25- cells (▲, n=10, MST=19d) rejected the skin grafts at a 
similar rate as the control group where only 107 unsorted spleen cells were transferred (?, 
n=9, MST=18d). However, when the CD4+CD25+ cells were co-injected with the unsorted 
cells, graft rejection was significantly delayed, and several mice accepted the transplanted 
skin indefinitely (▼, n=10, MST>100, P<0.0001). This Figure represents pooled results from 
two different experiments. 
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 I confirmed that the CD4+CD25+ cells used in the present study have the 
principal phenotypic characteristics of the CD4+CD25+ regulatory cells 
described in the literature (reviewed in Shevach, 2000). By performing FACS 
staining we confirmed that approximately 10% of the splenic CD4+ T cells 
express CD25, and that the majority of the CD4+CD25+ cells constitutively 
express CTLA-4 and CD44, and are contained among the CD45RBlow T cells 
(Figure 5.4). The CD4+CD25- cells are predominantly CTLA-4 negative, and 
contained within the CD44- CD45RBhigh cell fraction, although ~20% are 
CD44+ CD45RBlow.  
 
5.2.3 CD4+CD25+ T cells from “tolerized” mice are more efficient than 
CD4+CD25- cells as mediators of dominant transplantation 
tolerance 
 
Having established that CD4+CD25+ T cells from naïve animals suppress 
graft rejection, I compared the potency of both CD4+CD25+ and CD4+CD25- 
populations from “tolerized” mice in preventing rejection. The CD4+CD25+ 
and CD4+CD25- populations were purified from the spleens of CBA/Ca mice 
made tolerant to B10.BR skin transplants 100 to 120 days earlier (Figure 
5.5A). Different numbers of CD4+CD25+ and CD4+CD25- T cells were 
transferred with the fixed number 107 of naïve spleen cells into “empty” CP1-
CBA recipients. All recipients received B10.BR skin grafts on the following 
day. When 105 CD4+CD25+ cells were transferred together with 107 spleen 
cells from naïve CBA/Ca a delay in graft rejection was observed, when 
compared with the groups transferred with the same number of CD4+CD25- 
cells, or with controls which had received naive spleen cells only (Figure 
5.5B). However, when the number of CD4+CD25- T cells was increased ten-
fold to 106, graft rejection was delayed to an extent comparable to the 105 
CD4+CD25+ group. No skin graft rejection by the naïve cells was observed in  
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Figure 5.3 Cell sorting procedure does not affect rejection capacity of cells. CD4+CD25+ and 
CD4+CD25- cells were sorted from naive CBA/Ca spleens, mixed together into the original 
proportion, and 107 injected iv into CP1-CBA mice, transplanted with B10.BR skin on the 
following day. All skin grafts were rejected (▼, n=6, MST=15.5d). Other empty CP1-CBA 
mice were transfused with the same number of cells, from the same naive CBA/Ca donors, 
either labeled with mAb and streptavidin-microbeads (▲, n=6, MST=26d) or in the absence 
of any manipulation (?, n=6, MST=21.5d). Differences in graft survival between the groups 
were not significant.  
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Figure 5.4 CD4+CD25+ T cells express CTLA-4, CD44 and low levels of CD45RB. Spleen 
cells from naïve CBA/Ca mice were stained ex vivo. Approximately 10% of the CD4+ 
population express CD25. The majority of the CD4+CD25+ cells constitutively express CTLA-
4 and CD44, and are contained among the CD45RBlow T cells. The CD4+CD25- cells are 
predominantly CTLA-4 negative, and contained among the CD44-CD45RBhigh cell fraction, 
although ~20% of these cells are CD44+CD45RBlow.  
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Figure 5.5 CD4+CD25+ T cells from tolerant mice are more efficient than CD4+CD25- cells as 
mediators transplantation tolerance. CD4+CD25+ and CD4+CD25- cells were sorted from the 
spleens of CBA/Ca mice tolerant to B10.BR skin transplants as described in Chapter 2. 
Different numbers of these cells were co-transferred i.v. with 107 unsorted spleen cells from 
naïve CBA/Ca into “empty” CP1-CBA mice. A, FACS profiles of the transferred CD4+CD25+ 
and CD4+CD25- cells. B, All mice were transplanted with B10.BR skin the day following cell 
transfer. When unsorted spleen cells were transferred in the absence of cells from tolerant 
mice, the grafts were readily rejected (?, n=11, MST=22d). A similar rate of rejection was 
observed when 105 CD4+CD25- cells were added (?, n=9, MST=22d). When the number of 
CD4+CD25- cells was increased to 106 (?, n=15, MST=89d), or when 105 CD4+CD25+ cells 
were transferred (▼, n=9, MST=42d), rejection was significantly delayed and several animals 
accepted the grafts indefinitely. No rejection was observed in the groups injected with 106 
CD4+CD25+ cells (▲, n=13, MST>100) or 107 CD4+CD25- cells (?, n=4, MST>100). This 
figure represents pooled results from three different experiments. 
   100 
 the groups transferred with 106 CD4+CD25+ or 107 CD4+CD25- T cells. These 
results suggest that both CD4+CD25+ and CD4+CD25- cells can mediate 
transplantation tolerance, the CD4+CD25+ T cells being ten times more 
potent than CD4+CD25- cells. However, as the number of CD4+CD25- T cells 
in tolerant mice is approximately ten times higher than that of CD4+CD25+ 
cells, it is likely that both populations have a significant role in maintaining 
transplantation tolerance.  
 
5.2.4  Regulatory potency of unsorted CD4+ cells suggests that 
CD4+CD25+ and CD4+CD25- T cells are both responsible for 
suppression of graft rejection 
 
I sought to study whether both CD4+CD25+ and CD4+CD25- T cells contribute 
to graft acceptance, by determining the minimum number of unseparated 
tolerised CD4+ cells (containing both CD4+CD25+ and CD4+CD25- 
subpopulations) capable of preventing graft rejection mediated by 107 
splenocytes from naïve CBA/Ca mice. The CD4+ cells were sorted from 
spleens of CBA/Ca mice tolerant to B10.BR skin grafts using magnetic 
microbeads, and different numbers of these cells were injected together with 
the fixed number of 107 splenocytes from naïve CBA/Ca mice into “empty” 
CP1-CBA recipients (Figure 5.6A). All animals received a B10.BR skin graft 
on the following day. When 105, or less, CD4+ spleen cells were transfused 
the outcome was rejection (Figure 5.6B). However, adoptive transfer of 
5x105, or more, CD4+ spleen cells from tolerant mice resulted in graft 
acceptance. In the CBA/Ca mouse strain ~10% of CD4+ cells co-express 
CD25, in both naïve and tolerant animals. On the basis of these figures we 
can calculate that it takes approximately 5x104 CD4+CD25+ cells combined 
with 4.5x105 CD4+CD25- cells from tolerant mice to suppress 107 naive 
spleen cells. However, we found that neither 105 CD4+CD25+ nor 106 
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Figure 5.6 CD4+ T cells from tolerant mice prevent rejection by spleen cells from naïve mice 
in a dose dependent way. Splenic CD4+ cells were sorted from CBA/Ca mice tolerant to 
B10.BR skin grafts, as described in Chapter 2, and injected i.v. with 107 spleen cells from 
naïve CBA/Ca mice into “empty” CP1-CBA mice. A, FACS profiles of the sorted CD4+ cells 
and the unsorted CBA/Ca spleen cells. B, All mice were grafted with B10.BR skin the day 
following adoptive cell transfer. The group injected with spleen cells in the absence of CD4+ 
cells from tolerant mice, readily rejected the skin grafts (?, n=5, MST=26d). The rejection 
rate was not significantly delayed in the groups where 5x104 (▼, n=5, MST=28d) or 105 (?, 
n=5, MST=37d) CD4+ cells were added to the 107 spleen cells from naïve CBA/Ca mice. 
However, when 5x105 (?, n=5, MST>100, P=0.0027) and 106 (?, n=5, MST>100, P=0.0027) 
CD4+ cells were added, the grafts were accepted indefinitely, these results being statistically 
significant when compared with the control group ?. 
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 CD4+CD25- cells alone could provide this degree of suppression (see Figure 
5.5). This suggests that the “unseparated” CD4+ cell population shows 
greater potency than the equivalent numbers of sorted CD4+CD25+ or 
CD4+CD25- T cells. Such a result could possibly reflect impairment of 
regulatory function from the cell-separation manipulations, or perhaps, the 
enhanced regulation from CD4+CD25+ and CD4+CD25- regulatory cells 
operating together. Further experiments are needed to clarify this. 
 
5.2.5  CD4+CD25+ regulatory T cells mediate infectious transplantation 
tolerance 
 
Infectious transplantation tolerance has been described as the capacity of 
tolerant T cells to induce regulatory function on a population of non-tolerant T 
cells upon coexistence in a tolerised animal (Qin et al., 1993; Cobbold and 
Waldmann, 1998). I decided to investigate whether tolerant T cells 
“infectiously” induce regulatory capacity within the CD4+CD25+ or CD4+CD25- 
cell population of non-tolerant T cells that are allowed to coexist for 6 weeks. 
The preliminary results suggest that regulatory function can be induced 
among the CD4+CD25+ T cells.  
 
CP1-CBA mice were tolerised to B10.BR skin grafts as described. At day 100 
all mice were transfused with 3.5x107 spleen cells from naïve CBA/Ca mice. 
Three weeks following adoptive cell transfer all mice were injected with 0.5 
mg of AG-MIM-IgG1 mAb. The objective of such treatment was to prevent 
antiglobulin response following subsequent administration of CAMPATH-1H, 
that was performed 21 days later (see Chapter 7). With such CAMPATH-1H 
treatment I was able to deplete the first cohort of tolerant T cells, with pre-
treatment with AG-MIM-IgG1 and using these mAb doses depletion of T cells 
can be extended for at least 60 days in euthymic mice (see Chapter 7, Figure 
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 7.10). On the same day of CAMPATH-1H depleting treatment all mice 
received a second B10.BR skin graft. Spleens from these mice were 
collected 4 weeks later and CD4+CD25+ and CD4+CD25- T cells were sorted 
as described, and adoptively transferred together with 107 unsorted spleen 
cells from naïve CBA/Ca into “empty” CP1-CBA hosts. Such test mice were 
grafted with B10.BR skin on the following day and monitored for transplant 
rejection. 
 
Mice transfused with 107 unsorted spleen cells alone rejected the skin grafts, 
as did mice where 2x106 CD4+CD25- T cells were added (Figure 5.7). 
However no skin graft rejection was observed in the group where 3x105 
CD4+CD25+ T cells were administered together with the unsorted spleen 
cells. Although this result suggests that infectious tolerance operates via 
induction of CD4+CD25+ regulatory T cells, the data lacks statistically 
significance due to the reduced number of animals per group. As a 
consequence, this observation requires confirmation in repeat experiments. 
 
5.2.6  CD4+CD25+ and CD4+CD25- cells differ in gene expression 
 
In order to validate the separation procedures adopted to isolate CD4+CD25- 
and CD4+CD25+ T cells, we examined the nature of genes expressed in each 
population, either resting or activated with solid-phase CD3 mAbs, using 
SAGE3. A differential analysis of the four SAGE libraries is displayed in 
Figure 5.8 as scatter plots comparing CD4+CD25- spleen cells with 
CD4+CD25+ spleen cells before and after stimulation.  A number of 
transcripts that do not differ between the two populations before activation 
are highlighted in Figure 5.8A. These include the housekeeping genes EF-1α 
and GAPDH, the T cell specific genes CD3δ and Ly116 (a Th1 marker), the 
                                            
3 The SAGE libraries were made by Sara Thompson. 
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Figure 5.7 CD4+CD25+ T cells mediate infectious transplantation tolerance. 3.5x107 spleen 
cells from naïve CBA/Ca mice were transfused into tolerised CP1-CBA recipients, and 
allowed to co-exist with the T cells of the tolerised mice for 6 weeks. After that time the 
CAMPATH-1H+ cells were depleted and the mice received an additional B10.BR skin graft. 
The transfused cells were allowed to expand for another 4 weeks, before spleens were 
removed and their cells separated into CD4+CD25+ and CD4+CD25- T cells. 3x105 
CD4+CD25+ T cells prevented B10.BR graft rejection when transfused into empty CP1-CBA 
mice together with 107 unsorted spleen cells from naïve CBA/Ca mice (▲, n=4, MST>100). 
Most of the skin grafts were rejected when the empty CP1-CBA mice were transfused with 
107 unsorted spleen cells alone (?, n=4, MST=41d), or in combination with 2x106 
CD4+CD25- T cells (▼, n=3, MST=48d). The difference in graft survival is statistically 
significant between the groups where naïve cells were transfused on their own or in 
combination with CD4+CD25+ T cells (P=0.0401), but not between any other groups.  
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 activation marker OX40, together with β2 microglobulin and MHC-I (K, D and 
L, although this latter tag is slightly higher in CD4+CD25- cells).  Very few 
tags appear to be specific to either one of the populations, but 28 tags are 
significantly up-regulated in CD4+CD25+ cells, most of which we have, as yet, 
been unable to assign to known genes, and 97 tags significantly up-regulated 
in CD4+CD25- cells. The majority of the latter tags (at least 58) map to 
transcripts normally considered housekeeping genes (shown in grey, and 
defined as being non-differential (ie. SD<Mean) across 16 other SAGE 
libraries, including ribosomal proteins and essential metabolic enzymes 
(Zelenika et al., 2001; Zelenika et al., 2002).  This relative loss of 
housekeeping transcripts is further exemplified after CD3 stimulation of the 
two populations (Figure 5.8B), and includes GAPDH, EF-1α and also β2 
microglobulin (while CD3δ, MHC-I and OX40 change little).  This apparent 
loss of housekeeping gene expression may be explained by the different 
capacities of the two populations to proceed through the cell cycle: it may be 
that CD4+CD25+ cells, which do not proliferate in response to TCR ligation, 
do not require many of the synthetic and metabolic enzymes, but express a 
set of new functional proteins without any cell division.  It is clear that 
CD4+CD25+ cells have indeed expressed at least 103 new transcripts as a 
result of their activation (Figure 5.8B) and are therefore behaving in a manner 
that is quite distinct from CD4+CD25- cells.  Most of these tags are unique 
amongst the SAGE libraries that have been constructed so far (Zelenika et 
al., 2001; Zelenika et al., 2002), and have not yet been assigned to known 
genes.  Although, I used SAGE results exclusively to confirm the 
distinctiveness of the CD4+CD25+ and CD4+CD25- T cells, I have thus far 
identified 4 novel candidate genes from the Celera Discovery System mouse 
gene database (marked as transcripts mCT5392, mCT2519, mCT6469 and 
mCT4200), whose roles are currently under investigation.  
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Figure 5.8 CD4+CD25+ and CD4+CD25- cells express different genes. A, Comparison of 
gene expression profile of CD4+CD25+ and CD4+CD25- cells sorted from naïve CBA/Ca 
mice. B, Comparison of gene expression profile of CD4+CD25+ and CD4+CD25- cells 
following activation with solid-phase anti-CD3 mAb. SAGE libraries were compared using 
scatter plots where each SAGE gene tag is represented by a point plotted at the coordinates 
corresponding to the tag frequency per 10,000 tags (note logarithmic scale).  Tags 
corresponding to genes whose expression is not differential are represented inside the 
diagonal area shown. Tags with a statistically differential expression (95% confidence of >1.2 
fold upregulation) are those plotted outside the diagonal area.  House keeping genes are 
defined as tags that are non-differentially expressed across a group of 20 SAGE libraries 
from different cell types (defined by SDev <= Mean) and are depicted in grey. For clarity, 
most of differentially expressed tags are represented in black, and the non-differential in 
white. The following gene transcripts were identified by their SAGE tags as follows: β2 
microglobulin, TTTTCAAAAA; CD3δ, AGACCGGAAG; EF-1α, AGGCAGACAG; GAPDH, 
GCCTCCAAGG; Ly116, GCAGTGGTTC; MHC-I (K; D; L), GATTGAGAAT; OX40, 
CTAGCAGCTG; mCT5392, CCCAGCATCC; mCT2519, AAGGCTATGT; mCT6469, 
CTTCTACCAA; mCT4200, GTGGCAGGAG. 
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 5.2.7  Dominant tolerance is not compromised by administration of 
mAbs targeting IL-10, IL-4, CTLA-4 and CD25 
 
There are several conflicting reports in the literature implicating particular 
cytokines and cell surface molecules in dominant tolerance. In some in vivo 
and in vitro studies, antibodies to CTLA-4 (4F10) and CD25 (PC61) have 
interfered with suppression (Takahashi et al., 2000; Read et al., 2000), 
although others did not find a role for CTLA-4 in vitro (Shevach et al., 2001). I 
could not implicate CTLA-4 in our readout of suppression (see below). Other 
studies have also described a role for IL-10, IL-4 and TGF-β in suppression 
by regulatory T cells, where high-doses of mAbs were used in an attempt to 
neutralize the effect of the target cytokines (Powrie et al., 1996; Davies et al., 
1996b; Asseman et al., 1999; Seddon and Mason, 1999b; Hara et al., 2001). 
I could not implicate IL-10 and IL-4 in my own studies.  
 
20x106 spleen cells from CBA/Ca mice tolerant to B10.BR skin were 
transfused into “empty” CP1-CBA mice, together with the same number of 
spleen cells from naïve CBA/Ca animals (as described in Figure 5.1). 
Separate groups of these animals were treated with high doses of anti-IL4 
mAb (11B11), anti-IL10 mAb (JES5) or both in combination; anti-CD25 mAb 
(PC61), anti-CTLA4 (4F10) or both in combination. One control group was 
treated with anti-canine CD8 (YCATE55), and another control group received 
naïve spleen cells in the absence of spleen cells from tolerant mice. The 
mAbs were administered in doses of 2mg at days –4, –2, 0, 5, and then 
weekly until rejection. The adoptive cell transfer was performed at day –1, 
and B10.BR skin transplants at day 0. Blood samples from all mice were 
collected at days 20 and 60 to determine the level of the injected mAbs in the 
sera. The serum concentration of the injected Abs, as determined by binding 
inhibition, was over 100 µg/ml in all PC61 treated mice (two mice injected 
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 with PC61 + 4F10 had serum levels between 1 µg/ml and 10 µg/ml at day 
60); all JES5 treated mice had serum concentrations of the mAb between 10 
µg/ml and 100 µg/ml; all 11B11 treated mice had serum concentrations of the 
mAb over 100 µg/ml (except 4 mice also injected with JES5 where the mAb 
concentrations were between 10 µg/ml and 100 µg/ml at day 20 and 60). The 
serum concentration of 4F10 was determined through an anti-hamster IgG 
ELISA. All mice had a serum concentration of hamster Ab between 1 µg/ml 
and 10 µg/ml at day 20, dropping to below 1 µg/ml at day 60.  
 
The group transferred with cells from naïve mice readily rejected the test skin 
grafts (Figure 5.9A). However, indefinite graft survival was observed in all 
other groups, suggesting that those particular targeted molecules do not play 
a critical role in dominant transplantation tolerance in this model. A similar 
experiment focussed on the naïve CD4+CD25+ population. I transferred 106 
sorted CD4+CD25+ spleen cells from naïve CBA/Ca mice, together with 107 
splenocytes from naïve CBA/Ca mice, as described. Some of the mice were 
treated with a combination of anti-CTLA4 and anti-IL10 mAbs in the doses 
mentioned above. Treatment with these mAbs did not result in any significant 
difference in tolerance induced by CD4+CD25+ cells (Figure 5.9B). A similar 
experiment with sorted CD4+CD25+ spleen cells from tolerised mice had a 
comparable result, with none of the mice treated with the mAbs rejecting their 
grafts.  
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Figure 5.9 Dominant tolerance operates in spite of treatment with high-dose mAbs targeting 
IL-10, IL-4, CTLA-4 and CD25. A, 20x106 spleen cells from naïve CBA/Ca were injected into 
“empty” CP1-CBA mice i.v., either alone (N) or together with the same number of spleen 
cells from CBA/Ca tolerant to B10.BR skin (N+T). Mice were injected i.p. with 2 mg of mAbs 
targeting CD25, CTLA-4, IL-4, IL-10 and canine CD8 (control) at days –4, –2, 0, 2, 5 and 
then weekly until rejection. Cells were injected i.v. at day –1, and all animals received 
B10.BR skin transplants at day 0. Animals transferred with 20x106 spleen cells from naïve 
CBA/Ca in the absence of mAb treatment, readily rejected the grafts (?, n=5, MST=21d). 
However, in all other groups grafts were accepted indefinitely (n=5, MST>100, P=0.0198 for 
▼, P=0.0017 for any other group). Blood samples were collected at days 20 and 60 to 
confirm the presence of the injected mAb in the sera. B, “Empty” CP1-CBA mice were 
transfused with 107 spleen cells from naïve CBA/Ca mice, alone (?, n=10, MST=21d) or in 
combination with 106 CD4+CD25+ spleen cells also from naïve CBA/Ca donors (▼ and ▲, 
n=5 in each group). All mice were transplanted with B10.BR skin on the following day. Some 
mice transfused with CD4+CD25+ T cells were treated with 2 mg of each of anti-IL10 and 
anti-CTLA4 as described above (▼). There was no significant difference in graft survival 
between the mAb treated and untreated groups. 
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 5. 3  Discussion 
 
One outstanding issue concerning in vivo suppression by CD4+CD25+ 
regulatory T cells concerns their antigenic specificity. Previous studies have 
established that dominant transplantation tolerance induced with non-
depleting mAb is antigen specific, as mice tolerised to one type of skin graft 
reject subsequent transplants of different types (Qin et al., 1990; Chen et al., 
1996; Chapter 4). Experimental transplantation offers the opportunity to 
assess the suppressive capacity of CD4+CD25+ regulatory T cells isolated 
from animals that had never experienced the transplantation antigens. When 
such experiments were performed I uncovered the capacity of CD4+CD25+ T 
cells from non-transplanted animals to prevent graft rejection mediated by 
unsorted splenocytes from the same donors (Figure 5.2). One interpretation 
for these results is that aggression and tolerance are the outcome of 
situations dictated by the numerical balance between regulatory and effector 
cells, and that by changing such balance one may alter the outcome of an 
immune response. 
 
This result differs from previously published data (Gregori et al., 2001; Hara 
et al., 2001; Taylor et al., 2001), however, in my experiments the number of 
CD4+CD25+ cells injected into each recipient was much higher than the 
numbers used in those studies. I suggest that the optimal regulator-effector 
ratio can only be reached when such high numbers of regulatory cells are 
transferred. In fact, one previous study demonstrated that purified 
CD4+CD25+ from naïve animals were incapable of making a graft versus host 
allogeneic response upon transfer into a mismatched immunodefficient 
recipient (Taylor et al., 2001). In another study, analyzing islet graft rejection, 
CD4+CD45RBlow cells from naïve donors could, when co-administered at an 
appropriate ratio, prevent graft rejection by CD4+CD45RBhigh cells (Davies et 
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 al., 1999). This is also consistent with the observation of Sakaguchi et al, that 
depletion of the CD25+ T cells increases the speed of first-set allograft 
rejection (Sakaguchi et al., 1995). 
 
The antigen specificity of the CD4+CD25+ T cells from naïve animals that 
suppress transplant rejection is currently unknown. CD4+CD25+ cells have 
been shown to inhibit the proliferation of CD4+CD25- cells to different 
alloantigens in vitro, as long as the CD4+CD25+ cells are themselves pre-
activated (Thornton and Shevach, 2000). It may be that their repertoire 
contains receptors directed towards self-antigens (Seddon and Mason, 
1999b). If so, then there is the possibility that self-reactive regulators mediate 
graft acceptance through “linked suppression” where they are brought into 
the local microenvironment of the alloreactive cell. Alternatively, the receptor 
repertoire of CD4+CD25+ T cells may show cross-reactivity to alloantigens 
present in the graft. Given the finding that suppression involves indirect 
presentation of antigen (Wise et al., 1998), the “alloantigens” in question are 
likely to be donor-type peptides presented in conjunction with host-type MHC. 
At this moment all the above hypotheses are possible, and the specificity of 
regulatory T cells remains a fundamental issue to resolve in the field of 
immune tolerance. 
  
By studying the regulatory potency of CD4+CD25+ and CD4+CD25- cells from 
tolerised mice I established that both populations can mediate transplantation 
tolerance, the CD4+CD25+ T cells being ten times more potent than 
CD4+CD25- cells from tolerised animals or CD4+CD25+ cells from naïve mice 
(Figure 5.5).   
 
These findings also contrast with previous reports describing a lack of 
regulatory capacity within the CD4+CD25- population in transplantation 
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 tolerance (Gregori et al., 2001; Hara et al., 2001). Although our experimental 
system is different to those used by Hara et al and Gregori et al in many 
respects, they may not have reached the appropriate cell doses of 
CD4+CD25- cells required for suppression. Experiments in animal models of 
autoimmunity have also described a regulatory role for CD4+CD25- peripheral 
T cells (Fowell and Mason, 1993; Stephens and Mason, 2000; Olivares-
Villagomez et al., 2000; Shevach, 2001). In one of these reports the 
difference in cell numbers between CD4+CD25+ and CD4+CD25- cells 
required to achieve equivalent suppression is comparable to our findings 
(Stephens and Mason, 2000). 
 
The observation that the potency of the CD4+CD25+ population seems to 
increase following induction of transplantation tolerance is intriguing. It is not 
clear at this time whether this is due to an expansion of the regulatory cells 
from pre-existing regulators, whether it results from de novo formation of 
regulatory cells, or whether this reflects selective inactivation or death of non-
tolerant cells, so shifting the functional bias of the population towards 
regulation. It is equally interesting that the CD4+CD25- population is only 
seen to regulate if derived from tolerant, but not naïve populations. It may be 
that some “tolerant” CD25+ regulatory cells lose the expression of CD25 and 
endow the CD4+CD25- population with new regulatory powers, as it has been 
suggested following homeostatic expansion of CD4+CD25+ T cells (Gavin et 
al., 2002). Alternatively, AICD previously reported to occur in the induction of 
transplantation tolerance (Wells et al., 1999; Li et al., 1999), may selectively 
remove effector cells from the CD25- population so unmasking residual 
regulatory cell activity. 
 
It is remarkable that the difference in regulatory potency between 
CD4+CD25+ and CD4+CD25- T cells from tolerised mice is about 10-fold, as 
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 the number of CD4+CD25- T cells in tolerant mice is approximately ten times 
higher than that of CD4+CD25+ cells. Taken these figures in consideration, it 
is likely that both populations have a significant role in maintaining 
transplantation tolerance. Such an hypothesis is further reinforced by the 
demonstration that the regulatory potency of unsorted CD4+ cells is greater 
than the equivalent number of each CD4+CD25+ and CD4+CD25- 
subpopulations (Figure 5.6).  
 
The cellular mechanisms underlying the well established phenomenon of 
infectious tolerance still remain to be elucidated. I investigated whether 
coexistence of spleen cells from naïve donors with regulatory T cells within 
tolerised mice could increase the suppressive potency of the CD4+CD25+ or 
CD4+CD25- cells, as seen following mAb induced tolerance. Although the 
described results still require confirmation, they suggest that by means of 
infectious tolerance the CD4+CD25+ T cells acquire a regulatory capacity 
superior to the one demonstrated by CD4+CD25+ cells from naïve mice, and 
comparable to the potency of cells with this phenotype from tolerised mice 
(Figure 5.7). The reciprocal population of CD4+CD25- T cells did not seem to 
acquire regulatory capacity as seen following mAb tolerisation. If confirmed, 
such results may suggest that tolerisation of the CD4+CD25+ and CD4+CD25- 
compartments may have different requirements. One can speculate that 
while the increased potency of CD4+CD25+ cells may be due to expansion of 
specific regulatory cells, the regulatory capacity found within the CD4+CD25- 
cells may be determined by another mechanism, such as deletion of 
aggressive cells. Infectious tolerance and mAb induced tolerance may 
explore diverse mechanisms for tolerance induction. 
 
When neutralizing mAb to IL-10, IL-4, CTLA-4 or CD25 were used, I failed to 
demonstrate a role for any of these molecules as being essential for 
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 regulatory function (Figure 5.9). Previous demonstrations of roles for these 
molecules in other experimental readouts suggest: (a) that regulation may 
involve diverse molecular mediators depending on the precise 
microenvironment where it operates; or (b) that dominant tolerance exploits 
multiple redundant suppressive pathways where blockade of any one would 
not impact the outcome; or (c) that some of the effects seen are on the 
effector population in rendering them more sensitive to antigen mediated 
signals – this may be a plausible explanation for the effects of CTLA-4 mAbs, 
which should in principle enhance signalling (Hurwitz et al., 2002; Egen and 
Allison, 2002); or (d) that regulation takes place within a compartment which 
the injected mAb cannot easily access, such as the transplanted skin graft 
itself (see Chapter 6).   
 
The present results confirm that where transplantation tolerance was induced 
with therapeutic mAbs the subpopulation most potent in maintaining 
tolerance are the CD4+CD25+ T cells. However, regulatory activity can also 
be demonstrated within the CD4+CD25- population. It is not clear whether this 
is a result of redundant tolerogenic strategies mediated by different cell 
populations, or whether it reflects the fact that a proportion of the regulatory T 
cell population does not express CD25 constitutively. Either way, the 
characterization of genes differentially expressed by CD4+CD25+ and 
CD4+CD25- cells may certainly contribute to a better understanding of their 
physiology, may provide new markers that better define regulatory T cells, 
and may lead to the development of diagnostic tests for monitoring T cell 
population changes in autoimmunity or therapeutic tolerance.  
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 CHAPTER 6 
 
IDENTIFICATION OF REGULATORY T CELLS IN TOLERATED ALLOGRAFTS 
 
 
Induction of transplantation tolerance with certain therapeutic non-
depleting monoclonal antibodies can lead to a robust state of peripheral 
“dominant” tolerance. Regulatory CD4+ T cells, which mediate this form 
of “dominant” tolerance can be isolated from the spleen of tolerant 
animals. In order to determine whether there were any extra-lymphoid 
sites that might harbour regulatory T cells their presence was sought in 
tolerated skin allografts and in normal skin. When tolerated skin grafts 
are re-transplanted onto T cell depleted hosts, graft infiltrating T cells 
exit the graft and recolonise the new host. These colonising T cells can 
be shown to contain members with regulatory function, as they can 
prevent non-tolerant lymphocytes from rejecting fresh skin allografts, 
without hindrance of rejection of third party skin. Such results suggest 
that T cell suppression of graft rejection is an active process that 
operates beyond secondary lymphoid tissue, and involves the 
persistent presence of regulatory T cells at the site of the tolerated 
transplant4.  
 
                                            
4 Most of the results presented in this Chapter were published in (Graca et al., 2002a). 
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 6.1  Introduction 
 
In recent years significant advances have been made in enabling the 
therapeutic induction of transplantation tolerance (Waldmann, 1999; Wekerle 
and Sykes, 2001; Knechtle, 2000; Kirk and Harlan, 2000a; Li et al., 2001; 
Waldmann, 2001). In rodents it is possible to induce a robust form of 
peripheral tolerance by treatment with non-depleting mAbs, such as the 
combination of anti-CD4 and anti-CD8, at the time of transplantation (Qin et 
al., 1990; Qin et al., 1993; Davies et al., 1996a; Chen et al., 1996; Waldmann 
and Cobbold, 1998; Waldmann and Cobbold, 2001). Tolerance so achieved 
is dependent on regulatory T cells that disarm non-tolerant naïve cells 
(dominant tolerance) and facilitate the emergence of novel regulatory cells 
from the naïve lymphocyte population (infectious tolerance) (Qin et al., 1993; 
Chen et al., 1996; Graca et al., 2000); Chapters 3 and 4). The regulatory cells 
which fulfill this role are known to be CD4+ (Qin et al., 1993), and contained in 
both the CD4+CD25+ and CD4+CD25- populations (Graca et al., 2002b; 
Chapter 5). 
 
Dominant transplantation tolerance has been shown capable to be extended 
to third-party antigens provided they are genetically linked to the tolerated 
ones in the same tissue (Davies et al., 1996a; Chen et al., 1996; Wong et al., 
1997; Honey et al., 1999; Chapter 4). This phenomenon, known as “linked 
suppression”, does not occur when the tolerated and third party antigens are 
provided in two separate skin grafts transplanted at the same time onto the 
same graft bed (Davies et al., 1996a; Honey et al., 1999; Chapter 4). It may 
be that regulatory T cells acting at the level of the graft itself mediate linked 
suppression. 
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 It has been repeatedly demonstrated that such regulatory T cells can be 
isolated from the spleens of tolerant mice (Qin et al., 1993; Zhai and Kupiec-
Weglinski, 1999; Waldmann and Cobbold, 2001; Chapter 5). Recent work 
has suggested that in tolerant rats T cells infiltrating tolerated kidneys are 
enriched for regulatory cells when compared with the splenic T cells (Sawitzki 
et al., 2001). The work described in this chapter shows that regulatory T cells 
which can mediate dominant transplantation tolerance are present within 
tolerated skin allografts. The presence of regulatory T cells in the tolerated 
transplanted tissue may indicate that they have a protective role within that 
tissue. 
 
6.2  Results  
 
6.2.1  The experimental system 
 
As the number of T cells that can be isolated from tolerated skin grafts is very 
low, it was necessary to develop an experimental system allowing expansion 
of rare resident T cells for analysis of their suppressive capacity in vivo 
(Figure 6.1).  
 
Tolerised CBA/Ca or CP1-CBA mice were used as donors of tolerated skin, 
100 to 120 days following tolerance induction with three doses of 1 mg of 
each of non-depleting CD4 and CD8 mAbs over one week. The experimental 
skin allografts were removed from the initial hosts and regrafted onto 
recipients without T cells (“empty” mice). These “empty” mice were either 
RAG1-/- mice, or adult thymectomised CP1-CBA mice T cell depleted with 
CAMPATH-1H mAb.  
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Figure 6.1 The experimental system. CBA/Ca or CP1-CBA were made tolerant to B10.BR 
skin grafts by treatment with non-depleting CD4 and CD8 mAbs. 100 days following 
tolerance induction the tolerated skin grafts, or autologous control skin, were removed and 
transplanted onto “empty” mice (either adult thymectomised and T cell depleted CBA-CP1 
mice, or RAG1-/--CBA mice). Following 30 days the mice were transfused with 107 
splenocytes from naive CBA/Ca mice, together with a fresh B10.BR skin graft. The possible 
outcomes are: rejection, when a non-tolerant pre-existing state permits the transfused cells 
to mediate graft rejection; or acceptance of the skin grafts, when tolerated grafts lead to a 
tolerance state that is non-permissive for graft rejection by the transfused splenocytes. 
   119 
 Cells were allowed to expand from the allograft for 30 days. At that time the 
mice were challenged with a fresh B10.BR skin graft, together with a 
transfusion of 107 splenocytes from naive CBA/Ca donors. The suppressive 
capacity of any regulatory T cells which may have emerged from tolerated 
allografts was assessed by their capacity to prevent skin graft rejection 
mediated by the transfused naïve splenocytes. 
 
6.2.2  Tolerated skin grafts can transfer dominant tolerance when re-
grafted onto new recipients 
 
I investigated whether tolerated skin from animals exhibiting dominant 
tolerance plays host to regulatory T cells. Here, I show that the re-grafting of 
tolerated B10.BR skin transplants into T cell depleted hosts leads to a 
dominant tolerant state, such that adoptively transferred splenocytes from 
naïve donors are prevented from rejecting fresh allografts (Figure 6.2). 
 
Tolerated B10.BR skin grafts, as well as control CBA/Ca skin, were re-grafted 
onto “empty” CP1-CBA mice. 30 days following the grafting of these empty 
CP1-CBA mice with tolerated B10.BR or control CBA/Ca skin grafts, all mice 
were transfused with 107 splenocytes from naïve CBA/Ca donors and 
challenged with a fresh B10.BR skin graft. Figure 6.2A shows that the group 
of mice transplanted with tolerated B10.BR skin grafts, was able to resist the 
rejection by naïve cells. However, groups transplanted with CBA/Ca skin from 
the same tolerant donors remained permissive for rejection, with a rate 
similar to the animals grafted with CBA/Ca skin from naïve donors, and to the 
control recipients that had not received any preparatory skin graft.  
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Figure 6.2 Tolerated skin grafts can transfer the tolerant state upon regraft. CP1-CBA mice 
were thymectomised at 4 weeks of age, and depleted of T cells with 0.25 mg CAMPATH-1H. 
A, At day –30, these mice were transplanted with tolerated B10.BR skin grafts from tolerant 
CBA/Ca (?), CBA/Ca skin from the CBA/Ca tolerant to B10.BR skin grafts (▲), or CBA/Ca 
skin from naïve donors (▼). A control group of mice did not receive any initial skin graft (?). 
All mice were transfused with 107 spleen cells from naïve CBA/Ca at day –1, and 
transplanted with a fresh B10.BR skin on the following day. Only mice with tolerated skin 
grafts resisted the challenge transfusion of non-tolerant splenocytes and accepted the 
B10.BR skin grafts indefinitely (?, n=5, median survival time (MST)>100d, P<0.002 to other 
groups). In all other groups the B10.BR skin grafts were rejected at a similar rate. B, Tolerant 
mice were grafted with both BALB/c (?) and B10.BR (▲) skin grafts in the same graft bed, 
60 days following challenge with naïve CBA/Ca splenocytes and a fresh B10.BR skin. Only 
BALB/c skin grafts were rejected (P<0.007). 
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 To confirm that tolerant animals were not globally immunosuppressed, I 
showed that the same recipient test animals remained permissive for 
rejection of third-party skin. BALB/c and fresh B10.BR skin were transplanted 
in the same graft bed of mice of the non-permissive group. Figure 6.2B 
shows that the third-party BALB/c skin grafts were promptly rejected while the 
B10.BR skin grafts were accepted indefinitely. 
 
Taken together, these results confirm that only the tolerated skin grafts, but 
not autologous skin from tolerant animals, had the capacity to transfer 
dominant tolerance. 
 
6.2.3  Tolerance is not due to microchimerism 
 
There is evidence implicating donor microchimerism as a mechanism 
capable of enhancing graft acceptance (Ko et al., 1999; Anderson and 
Matzinger, 2001). To investigate whether microchimerism was the 
explanation for tolerance induced by transfer of tolerated skin grafts, the 
experiment was repeated but this time grafting CBA/Ca mice with skin from 
(B10.BR x CBA/Ca)F1. Such skin grafts could contribute to the generation of 
donor-type microchimerism, with cells simultaneously carrying CBA/Ca and 
B10.BR antigens and being naturally tolerant, by deletion, to both sets of 
antigens (without B10.BR specific regulatory T cells). “Empty” CP1-CBA mice 
were transplanted with tolerated B10.BR skin grafts from tolerant CBA/Ca, 
another group with  (B10.BR x CBA/Ca)F1 skin grafts previously transplanted 
onto syngeneic F1 mice, and yet another group with fresh (B10.BR x 
CBA/Ca)F1 skin. In one control group, the empty CP1-CBA mice received no 
grafts. A i.v. infusion of 107 spleen cells from naïve CBA/Ca mice was 
administered to all CP1-CBA mice 30 days following grafting. All mice 
received a fresh B10.BR skin graft on the following day. Figure 6.3 shows 
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 that only the animals grafted with tolerated B10.BR skin from tolerant 
CBA/Ca were non-permissive for naïve cells to reject the B10.BR skin grafts. 
The empty mice, which had been grafted with (B10.BR x CBA/Ca)F1 skin, 
remained permissive and skin was rejected at rate similar to controls.  
 
6.2.4  Tolerance is due to regulatory T cells present in the skin graft  
 
To establish the role of putative regulatory T cells infiltrating the skin graft 
CP1-CBA mice, tolerised to B10.BR skin grafts, were used as donors of 
tolerated B10.BR skin. This enabled the use CAMPATH-1H mAb to deplete 
donor T cells present in the tolerated skin, once it had been re-transplanted. 
Figure 6.4 shows that when tolerated skin was obtained from tolerant 
CBA/Ca donors, hosts became non-permissive for the rejection of fresh 
B10.BR skin graft after transfusion of 107 non-tolerant spleen cells. However, 
when the tolerated B10.BR skin was derived from tolerant CP1-CBA donors, 
and the hosts depleted of all donor derived and recipient T cells by using 0.25 
mg CAMPATH-1H at the time of re-graft, grafts were rejected after the 
transfusion of naïve CBA/Ca splenocytes.  
 
6.2.5  T cells can expand from the tolerated B10.BR skin grafts  
 
We used RAG1-/- mice as hosts completely deficient in T cells to determine 
whether T cells infiltrating tolerated grafts could expand from the skin. These 
mice were grafted with tolerated B10.BR skin from either tolerant CBA/Ca or 
tolerant CP1-CBA, or autologous CBA/Ca skin from CBA/Ca mice tolerant to 
B10.BR  skin  grafts.  A  sample  of  peripheral  blood  was  collected 30 days 
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Figure 6.3 Tolerance is not due to microchimerism. Empty CP1-CBA mice were transplanted 
at day –30 with tolerated B10.BR skin grafts from tolerant CBA/Ca (?), (B10.BRxCBA/Ca)F1 
skin grafts (▼), or (B10.BRxCBA/Ca)F1 skin grafts transplanted 30 days before into 
syngeneic hosts (▲). A control group of mice did not receive any initial skin graft (?). All 
mice were transfused with 107 spleen cells from naïve CBA/Ca at day –1, and transplanted 
with a fresh B10.BR skin on the following day. Only recipients of tolerated skin grafts resisted 
the transfusion of non-tolerant splenocytes and accepted the B10.BR skin grafts indefinitely 
(?, n=5, MST>100d, P<0.002). In all other groups the B10.BR skin grafts were rejected at a 
similar rate. 
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Figure 6.4 Tolerance is due to regulatory T cells present in the skin graft. Empty CP1-CBA 
mice were transplanted at day –30 with tolerated B10.BR skin grafts from tolerant CBA/Ca 
(?), tolerated B10.BR skin grafts from tolerant CP1-CBA (▲), or (B10.BRxCBA/Ca)F1 skin 
(▼). A control group of mice did not receive any initial skin graft (?). All mice were 
transfused with 107 spleen cells from naïve CBA/Ca at day –1, and transplanted with a fresh 
B10.BR skin on the following day. Mice transplanted with tolerated B10.BR skin grafts from 
tolerant CP1-CBA (▲) were depleted of infiltrating T cells by treatment with 0.25 mg 
CAMPATH-1H at days –30 and –1. Recipients of tolerated B10.BR skin grafts from tolerant 
CBA/Ca were also treated with CAMPATH-1H as described.   Only recipients of tolerated 
skin grafts whose T cells had not been ablated resisted the transfusion of non-tolerant 
splenocytes and accepted B10.BR skin grafts indefinitely (?, n=5, MST>100d, P<0.002). In 
all other groups the B10.BR skin grafts were rejected at a similar rate. Note that one animal 
in the tolerated skin, T cell depleted group (▲) rejected the initial B10.BR graft before 
transfusion with CBA/Ca splenocytes. 
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 following transplantation, stained and analyzed by flow cytometry. Figure 
6.5A shows that CD4+ T cells can be detected in the peripheral blood of 
transplanted RAG1-/- mice 30 days following tolerated skin transplantation. 
Remarkably, the CD4+ T cell frequency was significantly increased in 
recipients of tolerated skin grafts when compared with recipients of 
autologous skin from tolerant mice. In all mice the majority of CD4+ cells that 
had expanded from the graft were CD4+CD25-, but a minority of CD4+CD25+ 
cells could also be detected (Figure 6.5B). The frequency of CD4+CD25+ T 
cells within the CD4+ T cell population derived from tolerated skins was not 
significantly different from the usual frequency in naïve CBA/Ca mice.  
 
One week after the blood sampling, all animals were transfused with 107 
spleen cells from naïve CBA/Ca mice, and challenged with a fresh B10.BR 
skin graft on the following day. In one group of mice transplanted with 
tolerated B10.BR skin from tolerant CP1-CBA donors, donor T cells were 
depleted with 0.25 mg CAMPATH-1H at the time of CBA/Ca cell transfusion. 
These mice became permissive for rejection by naïve CBA/Ca cells, with a 
rejection rate comparable to the group initially grafted with CBA/Ca skin from 
tolerant CBA/Ca mice (Figure 6.5C). In contrast, when the RAG1-/- mice were 
initially transplanted with tolerated B10.BR skin grafts, in the absence of T 
cell depletion, all mice became non-permissive for rejection, and 
consequently all B10.BR grafts were held indefinitely.  
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Figure 6.5 T cells expand from the tolerated B10.BR skin grafts. RAG1-/--CBA mice were 
grafted with tolerated B10.BR skin from tolerant CBA/Ca mice (?), CBA/Ca skin from 
CBA/Ca mice tolerant to B10.BR skin grafts (▲), and tolerated B10.BR skin grafts from 
tolerant CP1-CBA mice (▼ and ?). Tolerated B10.BR skin grafts in group ? were depleted 
of putative infiltrating T cells with 0.25 mg CAMPATH-1H at day –1. A, Blood samples were 
collected 30 days after skin grafting and analysed by FACS. The graph represents the 
percentage of CD4+ T cells within blood mononuclear cells. The percentage of CD4+ T cells 
that expanded from tolerated skin grafts is significantly higher than in the animals grafted 
with CBA/Ca skin from tolerant syngeneic donors (P<0.05, unpaired t test). B, FACS staining 
from a mouse of the tolerated skin group (▼), showing that expanded T cells are mainly 
CD4+CD25-. C, All mice were transfused with 107 spleen cells from naïve CBA/Ca one week 
following blood tests, and transplanted with a fresh B10.BR skin on the following day (day 0). 
Recipients of tolerated B10.BR skin grafts whose putative regulatory T cells had not been 
depleted resisted the challenge with transfused CBA/Ca splenocytes and accepted the 
B10.BR skin grafts indefinitely (? and ▼, MST>100d, P<0.05).  Mice that were recipients of 
tolerated B10.BR skin grafts depleted of T cells rejected the grafts shortly after transfusion of 
CBA/Ca splenocytes (▲, MST=22d). Recipients of CBA/Ca skin from CBA/Ca mice tolerated 
to B10.BR skin grafts also rejected B10.BR skin grafts (?, MST=20.5d). 
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 6.2.6 T cells from non-tolerated B10.BR skin allografts can also  
expand, but this does not lead to tolerance 
 
I wanted to exclude the possibility that the process of transplanting donor skin 
to RAG-/- recipients was not itself conducive to the development of dominant 
tolerance. I found that transfer of non-tolerated skin allografts indeed led to T 
cell expansion, but did not modify the rejection capacity of transfused 
splenocytes from naïve syngeneic mice. CBA/Ca mice were transplanted with 
B10.BR in the absence of antibody treatment. At day 8 following 
transplantation, when the skin grafts still appear healthy (rejection usually 
occurs at days 11 – 15), the skin grafts were removed from the initial hosts 
and re-transplanted onto RAG1-/- mice. These grafts were all rejected (n=6, 
MST=9d from the time of regraft). At day 30 following transplantation, blood 
samples were collected to confirm CD4+ T cell expansion (4.92% ± 0.37 
CD4+ T cells in peripheral blood). One week after the blood sample, all mice 
were transfused with 107 splenocytes from naïve CBA/Ca donors and 
transplanted with a second B10.BR skin on the following day. All skin grafts 
were readily rejected (n=6, MST=17d) confirming that the T cell expansion 
from non-tolerated allografts did not alter the rejection permissive state. This 
result reinforces the conclusion that the regulatory T cells pre-existed in 
tolerated skin prior to retransplantation onto RAG1-/- recipients. 
 
6.3  Discussion 
 
One outstanding issue concerning immune regulation concerns the location 
where regulatory T cells operate. It has been shown in different experimental 
systems that regulatory T cells can be isolated from the spleen of tolerant 
animals (Qin et al., 1993; Chen et al., 1996; Zhai and Kupiec-Weglinski, 
1999; Sawitzki et al., 2001; Waldmann and Cobbold, 2001). The results 
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 described in this chapter conclusively demonstrate that regulatory T cells can 
also be identified within the tolerated tissue itself. 
 
The experiments with (B10.BR x CBA/Ca)F1 skin grafts  exclude 
microchimerism as being sufficient to drive tolerance achieved by transferring 
tolerated skin grafts. In addition, they also exclude any requirement for the 
thymus in the maintenance of the tolerant state, as adult thymectomised 
recipient mice can be rendered tolerant following transplantation of a 
tolerated skin allograft. 
 
Studies concerning neonatal tolerance had implicated pro-tolerogenic 
properties of neonatal skin in achieving tolerance to skin antigens (Alferink et 
al., 1998; Alferink et al., 1999). The present findings exclude pro-tolerogenic 
properties of the tolerated skin allografts. In fact, when T cells (defined as 
transgenic cells that express hCD52) carried over with tolerated skin grafts 
are depleted, then tolerance is not imposed on the recipient. As a corollary, 
when recipients of tolerated skin allografts resist rejection mediated by 
transfused T cells, such a non-permissive state must be due to regulatory T 
cells which have infiltrated the tolerated skin grafts, and not to cells of a 
different type. 
 
I also established that tolerance cannot be achieved by transplantation of 
autologous skin from tolerised mice. The study of lymphocyte expansion from 
transplanted skins suggests that very few T cells infiltrate autologous skin of 
tolerised mice, when compared with tolerated allografts. In Chapter 5, I 
showed that B10.BR skin graft rejection mediated by 107 splenocytes 
transfused from naïve CBA/Ca into empty CP1-CBA mice, could be 
prevented by co-transfer of regulatory T cells. By titrating the number of 
transfused regulatory cells I concluded that abrogation of rejection requires 
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 co-transfer of 106 CD4+CD25+ cells or 107 CD4+CD25- cells from CBA/Ca 
tolerised to B10.BR skin grafts (Graca et al., 2002b; Chapter 5). Such 
observations, taken together with the present results, suggest that at the time 
107 splenocytes from naïve CBA/Ca mice were transfused, regulatory cells 
from tolerated allografts had expanded to evoke a regulatory function 
equivalent to 106 CD4+CD25+ cells from a tolerised spleen. 
 
The observations described in this chapter may in part explain the 
phenomenon of linked suppression (Davies et al., 1996a; Chen et al., 1996; 
Wong et al., 1997; Honey et al., 1999; Chapter 4).  When dominant 
transplantation tolerance is achieved, the tolerised animals accept 
subsequent grafts expressing third-party antigens when such tissues also 
express tolerated antigens. But third-party skin grafts are rejected when 
transplanted simultaneously with a skin graft of the tolerated type onto the 
same graft bed. The present study was designed as a way to investigate 
whether regulatory T cells capable of maintaining dominant tolerance could 
be demonstrated within the tolerated tissue. It is possible that the reason for 
the graft acceptance when tolerated and third-party antigens are linked within 
the same tissue, may be due to local effects of regulatory T cells. When the 
tolerated and third-party antigens are present in two different grafts that 
mainly drain into the same lymph nodes, the absence of tissue infiltrating 
regulatory T cells may result in graft rejection.  
 
The identification of regulatory T cells within tolerated allografts may relate to 
the recent identification of memory T cells that persist in non-lymphoid tissue 
(Sallusto et al., 1999; Lanzavecchia and Sallusto, 2000; Masopust et al., 
2001; Reinhardt et al., 2001; Tuma and Pamer, 2002; Sprent and Surh, 
2002). The memory T cells can be divided into two different populations 
based on their surface phenotype, localization pattern and effector function: 
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 the central-memory T cells (TCM) and effector-memory T cells (TEM). The 
TCM cells express the chemokine CCR7, are residents in secondary lymphoid 
tissue, and following subsequent interaction with antigen undergo 
proliferation and further differentiation acquiring effector function, some of 
them becoming TEM cells (Sallusto et al., 1999). The TEM are believed to be 
terminally differentiated effector T cells, with the capacity to deliver effector 
molecules (cytokines or lytic mediators) upon rechallenge with antigen. They 
also express CCR7, and recirculate through peripheral tissues. It is not clear 
why these TEM cells survive for long periods of time, but it has been 
suggested that they upregulate anti-apoptotic genes (Lanzavecchia and 
Sallusto, 2000). The best characterized regulatory T cells – the CD4+CD25+ 
cells – share many phenotypic characteristics with memory cells (for instance 
they are CD44+CD45RBlow – see Chapter 5). It may be that following initial 
activation of T cells, in the same way some CD4+ differentiate into TEM cells 
in the context of protective immune responses, some other CD4+ T cells can 
differentiate into regulatory TEM cells. It has been postulated that the 
functional relevance for TEM is a rapid effector function following antigen 
encounter in the peripheral tissues, while TCM would allow a rapid expansion 
and recruitment of new effector T cells following interaction with the antigen 
in the lymphoid tissue (Lanzavecchia and Sallusto, 2000). It is possible that 
regulatory T cells in tolerated allografts are a particular population of effector-
memory T cells, that unlike the TEM require the persistence of antigen. It is 
not clear at this time what makes regulatory T cells to accumulate 
preferentially within tolerated allografts, when compared with syngeneic skin 
from the same tolerised animal.  
 
Interestingly, a reverse transcription PCR (RT-PCR) analysis of genes 
expressed in tolerated and rejecting tissues showed that expression of genes 
associated with regulatory T cells were found to be differential (Zelenika et 
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 al., 2002). This was not, however, the case, when draining lymph nodes or 
spleens from the same animals were compared, suggesting that regulatory 
activity is concentrated in the graft (Zelenika et al., 2002). Surprisingly, the 
genes associated with regulatory T cells were also found to be 
overexpressed in syngeneic skin when compared with rejecting tissue 
(Zelenika et al., 2002). It is possible that regulatory T cells circulate through 
syngeneic skin although their number is below the threshold that we could 
identify with the described experimental system. 
 
 It is intriguing that, on a functional basis, regulatory cells with the capacity to 
prevent graft rejection can be demonstrated in both the spleen and tolerated 
skin grafts. It is not clear at this time, given the RT-PCR data, whether graft 
infiltrating regulatory cells constitute a special resident population different 
from splenic regulatory cells. The observation that T cells expand from graft 
infiltrating regulatory cells may imply that regulatory T cells in grafts result 
from a steady-state recirculation. Perhaps, regulatory cells recirculate 
through the body and accumulate preferentially at the sites where their target 
antigens are present. As a consequence it is possible they exert their 
regulatory activity on peripheral tissues by default, until inflammatory signals 
or other as yet unknown ligands turn off their suppressive function, so 
permitting a “normal” protective immune response to occur. Consistent with 
this hypothesis, it was recently reported that CD4+CD25+ regulatory T cells 
express glucocorticoid-induced tumor necrosis factor receptor family-related 
gene (GITR, also known as TNFRSF18) (Shimizu et al., 2002; McHugh et al., 
2002), and ligation of this molecule by agonistic Abs abrogates the 
suppressive capacity of the cells (Shimizu et al., 2002). In any case, the 
present observations strongly support the view that at least some of the 
suppressive activity of regulatory T cells occurs beyond secondary lymphoid 
tissues at the sites where their target antigens are present. 
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 CHAPTER 7 
 
“STEALTH ANTIBODIES” AS A STRATEGY TO ABOLISH  
IMMUNOGENICITY OF THERAPEUTIC ANTIBODIES 
 
 
Monoclonal antibodies have proven useful in the treatment of several 
human diseases. However, 25 years after their discovery, the clinical 
use of mAbs is still hampered by immune responses directed against 
them. Humanisation of mAbs reduced but did not abolish their 
immunogenicity. It has been reported that non cell-binding mAbs are 
not immunogenic, but instead can induce tolerance to the cell-binding 
form. When depleting T cells with CAMPATH-1H, as described in 
previous Chapters, it would be ideal to use a non-immunogenic mAb 
treatment. Based on the classical principles of Chiller and Weigle, we 
decided to test the biological effect of mAbs with their binding site 
occupied by an epitope-like peptide (mimotope). Such mAbs were 
found to be less immunogenic, and could induce partial to complete 
tolerance to their wild-type form. Surprisingly, the mimotope-bound 
mAbs retained biological effect suggesting that some antibody must 
have bound cells in vivo. As a consequence we called these mAbs 
“stealth antibodies”. We anticipate it may be possible to create 
“stealth” variations of therapeutic mAbs, that once administered can 
mediate the therapeutic effect (although with a delayed action) without 
eliciting an immune response. In addition to the possible clinical 
applications, such mAbs may prove more useful reagents to achieve 
long term depletion in experimental transplantation, as described in 
previous Chapters, without incurring the risk of any artefacts due to 
immunogenicity. 
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 7.1  Introduction 
 
The efficacy of mAbs to treat several human diseases is now well 
established. Shortly after the discovery of mAbs in 1975 (Kohler and Milstein, 
1975), they were adopted for biomedical research and clinical diagnosis. 
However, their therapeutic use has been slower to be established. In spite of 
the initial enthusiasm following the first report on the therapeutic use of mAb 
to treat a patient with lymphoma in 1982 (Miller et al., 1982), progress in their 
therapeutic application has been slow.  
 
A major limitation for clinical use of traditional mAbs was that they derive from 
rodents, with amino-acid sequences significantly different from human 
antibodies (Ab). As a result, murine therapeutic mAb often evoked the 
production of neutralising antiglobulins (Schroff et al., 1985; Shawler et al., 
1985). The turning point for clinical use of mAbs was the application of 
genetic engineering to mAb production.  First, the development of chimeric 
mAbs, whose constant regions were human while the variable regions were 
rodent (Figure 7.1), offered the provision of equivalent “human” effector 
function and reduced the Ab immunogenicity (Boulianne et al., 1984; 
Morrison et al., 1984). The heavy-chain constant region (in particular the CH2 
domain) contains sites recognised by innate effector systems of the body. 
Furthermore, humans are, of course, largely tolerant to human constant 
regions derived from other individuals. It has been formally shown (as might 
have been predicted) that immunogenicity of mAbs is greater when the 
sequence of the injected mAb is more dissimilar to host antibodies’ 
sequences (Bruggemann et al., 1989). Humanisation allowed the production 
of mAbs with an entirely human sequence except for the complementarity 
determining regions (CDR, Figure 7.1) (Jones et al., 1986). Humanised mAbs 
significantly reduced the immunogenicity of therapeutic mAbs, but were 
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 Rodent Chimeric
Humanised Human
 
Figure 7.1 Humanization of therapeutic mAbs. Murine sequences are represented in grey 
and human sequences in black. In chimeric mAbs the constant region of both light and heavy 
chains are human, while the variable regions are murine. In the humanised mAbs only the 
CDRs are murine. 
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 shown unlikely to abolish it completely (Isaacs et al., 1992; Weinblatt et al., 
1995). In the early 90s an approach was developed for the production of 
human mAbs in mice by construction of mice transgenic for human 
immunoglobulin (Ig) genes (Bruggemann et al., 1991) as well as through 
phage display technology (Clackson et al., 1991; Winter et al., 1994). These 
advances, although offering alternatives to engineering, are also unlikely to 
overcome immunogenicity based on the CDRs of the mAbs. In fact, even the 
Abs naturally produced in the human body frequently lead to the production 
of anti-idiotypic Abs (i.e. directed to the CDR of the target Ab) (Eichmann, 
1975; Trenkner and Riblet, 1975; Forni et al., 1980). Some authors even 
suggest that the emergence of such a network of interactions between 
natural Abs can be an important homeostatic mechanism governing the 
reactivity of the immune system (Jerne, 1974; Coutinho, 1989). As a 
consequence, a human mAb is probably not too different from a humanised 
one in terms of potential for immunogenicity. 
 
In chronic diseases such as rheumatoid arthritis (RA) where therapeutic 
mAbs are repeatedly administered, the emergence of neutralising Abs 
significantly affects the efficacy of therapeutic mAbs by reducing their half-life 
and their capacity to bind target antigen. As an example, in one of the first 
clinical trials of humanised mAbs, CAMPATH-1H was used to treat patients 
with RA, and 63% of the treated patients developed neutralising Abs which 
may have limited the clinical benefit (Weinblatt et al., 1995). Of the mAbs 
used currently to treat RA, the chimeric mAb InfliximabTM (anti – Tumour 
Necrosis Factor α (TNF-α)) is perhaps the most studied example, and 
requires the addition of immunosuppressive drugs to prevent the production 
of neutralising Abs. In fact, in a recent review, Feldmann and Maini discussed 
the immunogenicity of InfliximabTM, as well as of other therapeutic mAbs, and 
offered no solution other than co-administration of immunosuppressive drugs 
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 (Feldmann and Maini, 2001). Furthermore, formation of immune complexes 
and subsequent deposition in the tissues can lead to adverse consequences. 
Such formation of immune complexes is a clinical problem as it may generate 
a range of side effects as severe as serum sickness, and reduces efficacy of 
the therapeutic mAb. Similarly, artefacts associated with immunogenicity 
might also lead to misinterpretations of animal experiments of the type in this 
thesis which use mAb to manipulate cell populations. 
 
The amino-acid sequence of the mAbs, however, is only one of the several 
factors determining their immunogenicity (Table 7.1). From the early 70s it 
has been known that the same immunoglobulins can lead to the formation of 
antiglobulins or to tolerance depending on the way they are administered 
(Weigle, 1973). Chiller and Weigle reported that aggregated human Ig were 
very immunogenic in mice resulting in the production of antiglobulins, 
however, the same human Ig administered in the monomeric form not only 
fail to induce an immune response, but was tolerogenic preventing 
antiglobulin production following subsequent immunisations with aggregated 
human Ig (Chiller et al., 1970). More recently, it was shown that mAbs 
binding to cellular antigens tend to be immunogenic, while non-cell binding 
mAbs tend to be tolerogenic (Benjamin et al., 1986). Immunogenicity of Abs, 
as well as other foreign proteins (like therapeutic administration of factors VIII 
and IX in haemophilia), is a consequence of an immune response dependent 
on CD4+ T cells (Isaacs and Waldmann, 1994). This may be the explanation 
for the special characteristics of anti-CD4 mAbs as tolerogenic agents: 
although cell-binding, these mAbs induce tolerance to themselves and to 
other foreign antigens administered at the same time (Benjamin et al., 1986; 
Benjamin and Waldmann, 1986). This property makes CD4 mAbs very 
interesting for therapeutic induction of tolerance, namely to transplants 
(Waldmann and Cobbold, 1998; Graca and Waldmann, 2001).  
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mAb Structure Humanized fraction 
 Glycosylation 
mAb Specificity Soluble versus cellular antigen 
 Binding affinity 
 Multivalency of Ab and antigen 
mAb Function Binding to Fc receptors 
 Complement activation 
 Cell lysis 
 Cytokine release 
 Inflammation 
mAb administration Dose 
 Frequency of administration 
 Route of administration 
Patient Characteristics of the disease 
 Immunosuppression 
 
Table 7.1 Factors determining the immunogenicity of therapeutic mAbs.  
 
The observation that an immunogenic mAb can be made tolerogenic by 
preventing its binding to cells and formation of aggregates, offers the 
opportunity to develop a general mechanism to eliminate immunogenicity of 
therapeutic mAbs. The principle has recently been established by Gilliland 
and colleagues in the host laboratory (Gilliland et al., 1999). They evolved a 
strategy based on the humanised CAMPATH-1H mAb, recently approved for 
clinical use by the Food and Drug Administration, USA (FDA). Antiglobulins 
have been shown to be induced during clinical administration of CAMPATH-
1H in chronic diseases like RA and multiple sclerosis (G. Hale, personal 
communication), leading to a reduction of the therapeutic effect in some 
instances (Isaacs, 1990; Isaacs et al., 1992; Lockwood et al., 1993; Weinblatt 
et al., 1995; Isaacs et al., 1996). Gilliland and colleagues studied the 
immunogenicity of CAMPATH-1H and a series of mutants in CP1-CBA/Ca 
transgenic mice that express human-CD52 (hCD52), the target of 
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 CAMPATH-1H, under the control of the CD2 promoter (Gilliland et al., 1999). 
All T cells from this mouse strain express hCD52. When these mice were 
injected with CAMPATH-1H they produced antiglobulins. 
 
The mutants that were used above were identical to CAMPATH-1H, except 
that they possessed one or two amino-acid substitutions within the CDR2 of 
the heavy chain. In vitro tests identified some mutants with impaired binding 
to hCD52. Animals treated with non-binding mutants did not produce 
antiglobulins, not even following subsequent administration of CAMPATH-1H 
(Gilliland et al., 1999). However, with some of the mutants tolerogenicity to 
the wild-type was, as might be expected, incomplete with breakthrough 
responses specifically directed to the site selected for mutation (Gilliland et 
al., 1999). These experiments show that it is possible to eliminate 
immunogenicity of therapeutic mAbs by preventing their binding to cells. 
However, tolerisation in advance of treatment may not be logistically feasible 
for clinical use, and the possibility that immunogenicity can still be observed 
due to differences of the mutated residues could also become a problem.  
 
Aside from the therapeutic arena, immunologists have increasingly utilised 
mAbs to deplete cell populations or block specific functions in experimental 
studies. Any neutralising antiglobulins might well create artefactual outcomes 
to the experimental study. It would therefore be desirable to have antibody 
reagents capable of inducing long lasting cell depletion in experimental 
animals, without eliciting the production of anti-antibodies with their 
associated disadvantages. The two step process involving prior 
administration of a mutated non-cell binding mAb, although useful for short-
term studies, may still pose problems where longer-term “therapy” is 
anticipated, as antiglobulins can be generated against the non-mutated 
regions of the wild-type mAb (Gilliland et al., 1999).  
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 We decided to tackle the problem by creating a non-cell binding version of 
the CAMPATH-1H mAb without modifying its primary amino-acid sequence. 
This antibody was designed to have the advantages of a tolerogen, but retain 
(in part) the cell-binding capacity required for its function. An epitope-like 
peptide (mimotope) was convalently linked (by genetic engineering) to the 
variable region of the light chain, so as to interfere with the mAb binding 
capacity to hCD52. One such construct, the mimotope-IgG1 (MIM-IgG1) had 
impaired binding to its ligand both in vitro and in vivo. MIM-IgG1 was shown 
to be less immunogenic and even partially tolerogenic when administered 
into CP1-CBA transgenic mice. Despite this, the mAb could still deplete 
target T cells in vivo, albeit at a slower rate than with wild-type CAMPATH-
1H. These results suggest that around the time that the antibody is 
administered, the majority of MIM-IgG1 is unable to bind to cells and 
consequently can induce partial tolerance to itself. With time, increasing 
amounts of the MIM-IgG1 become bound to cells at sufficient levels to bring 
about cell depletion. We have coined such mAbs “stealth antibodies”.  
 
To determine whether “effector” function contributed to immunogenicity we 
also removed the glycosylation site (asp 297) from the Fc region (AG-MIM-
IgG1). This construct proved to be completely non-immunogenic and a far 
more effective tolerogen than MIM-IgG1. We conclude that the lack of 
“adjuvanticity” or “danger” associated with the loss of FcR-binding by AG-
MIM-IgG1 resulted in that outcome.  
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 7.2  Results 
 
7.2.1  MIM-IgG1 and AG-MIM-IgG1 have impaired binding activity in 
vitro 
 
Several constructs based on the CAMPATH-1H were made by Mark Frewin 
(see Table 7.2). I produced the AG-CAMPATH-1H construct.  
 
MIM-IgG1 and AG-MIM-IgG1 have a reduced binding capacity in vitro when 
compared with CAMPATH-1H by ELISA, flow cytometry and surface plasmon 
resonance (BIAcore). 
 
Figure 7.2A shows the binding ability of different constructs to HUT cells 
expressing hCD52. It is apparent that CAMPATH-1H binds HUT cells with an 
efficiency approximately 5 times superior to p61-IgG1, 2000 times superior to 
MIM-IgG1 and more than 10,000 times superior to AG-MIM-IgG1 (experiment 
performed by Mark Frewin and provided for clarification). Comparable results 
were obtained by ELISA, using plates coated with the antigen (Figure 7.2B). 
 
Results obtained with BIAcore were not as conclusive due to the large 
differences in binding capacities between the different constructs. However, 
such results confirmed a far superior binding capacity of CAMPATH-1H and 
p61-IgG1 when compared with MIM-IgG1, compatible with the results 
obtained with the other methods (Figure 7.2C). 
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CAMPATH-1H Wild type CAMPATH-1H light chain V-region + 
CAMPATH-1H heavy chain with wild type human IgG1 
constant region. Cloned into Wellcome expression 
vectors pRDN-1 and pBAN-2 for CHO produced Ab. 
AG-CAMPATH-1H Wild type CAMPATH-1H light chain V-region + 
CAMPATH-1H heavy chain with aglycosyl human IgG1 
constant region. Cloned into Celltech expression vector 
PEE12 for NSO produced Ab. 
MIM-IgG1 CD52 mimotope QTSSPSAD tethered to CAMPATH-
1H light chain V-region by flexible Glycine4 Serine2 
linker + CAMPATH-1H heavy chain with wild type 
human IgG1 constant region. Cloned into Celltech 
expression vector PEE12 for NSO produced Ab, and 
Wellcome pRDN-1 and pBAN-2 for CHO produced Ab. 
AG-MIM-IgG1 CD52 mimotope QTSSPSAD tethered to CAMPATH-
1H light chain V-region by flexible Glycine4 Serine2 
linker + CAMPATH-1H heavy chain with aglycosyl 
human IgG1 constant region. Cloned into Celltech 
expression vector PEE12 for NSO produced Ab. 
P61-IgG1 HLA P61 binding peptide SLLPAIVEL tethered to 
CAMPATH-1H light chain V-region by flexible Glycine4 
Serine2 linker + CAMPATH-1H heavy chain with wild 
type human IgG1 constant region. Cloned into 
Wellcome expression vectors pRDN-1 and pBAN-2 for 
CHO produced Ab. 
AG-P61-IgG1 HLA P61 binding peptide SLLPAIVEL tethered to 
CAMPATH-1H light chain V-region by flexible Glycine4 
Serine2 linker + CAMPATH-1H heavy chain with 
aglycosyl human IgG1 constant region. Cloned into 
Celltech expression vector PEE12 for NSO produced 
Ab. 
 
Table 7.2 mAb constructs based on CAMPATH-1H used in the present study. I only made 
AG-CAMPATH-1H. All other constructs were made by M. Frewin. 
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Figure 7.2 Binding activity of different mAb constructs in vitro. A, Binding capacity of different 
mAb constructs to HUT-78 cells expressing the hCD52 antigen, detected by flow cytometry. 
CAMPATH-1H is the most efficient mAb in binding to HUT cells, followed by both P61-IgG1 
and AG-P61-IgG1. MIM-IgG1 and AG-MIM-IgG1 have poor binding activity (data from M. 
Frewin). B, Similar results were obtained measuring Ab binding activity to BHK21.C13 by 
ELISA. C, BIAcore sensorgram showing binding of different mAbs to BHK21.C13. Binding 
activity of CAMPATH-1H and P61-IgG1 is significantly greater than MIM-IgG1. Binding of 
MIM-IgG1 is not significantly different than the control mAb. 
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 7.2.2 MIM-IgG1 and AG-MIM-IgG1 show delayed cell-binding activity in  
vivo 
 
The inferior in vivo binding capacity of MIM-IgG1 and AG-MIM-IgG1 
compared with CAMPATH-1H was confirmed by flow cytometric analysis of 
lymphocytes from CP1-CBA transgenic mice treated with the different mAbs. 
CP1-CBA mice express hCD52 under the control of the CD2 promoter on all 
T cells (Gilliland et al., 1999). Purified mAb was injected i.p. into CP1-CBA 
mice and spleen cells and peripheral blood were analysed for mAb binding to 
hCD52+ T cells 3 hours and 8 days following mAb treatment. 
 
Peripheral blood lymphocytes (PBL) stained three hours following mAb 
injection show that mice treated with CAMPATH-1H or AG-CAMPATH-1H 
were saturated with the mAb (mean fluorescent activity (MFI): 938 ± 237 and 
1729 ± 115 respectively) (Figure 7.3A, C), and a significant proportion of the 
CD3+ T cell population was already depleted (only 9% ± 2.9 and 32% ± 1.6 
respectively of the CD3+ cells were left). Both p61-IgG1 and AG-p61-IgG1 
which also stained strongly (MFI 528 ± 145 and 855 ± 42 respectively), 
achieved significant depletion at this same dose (10.9% ± 2.3 and 20.7% ± 
2.8 of CD3+ PBL). MIM-IgG1 could also be detected bound to CD3+ cells, 
although the intensity of staining was reduced by approximately two orders of 
magnitude (MFI = 191 ± 31), and almost no depletion could be observed 
(66.9% ± 4.2 of CD3+ PBL were present). Finally, AG-MIM-IgG1 bound very 
weakly to PBL (MFI = 23.1 ± 0.8), and virtually no depletion of T cells could 
be observed at this stage (71.8% ± 5.1 of CD3+ cells). Comparable results 
were obtained when splenocytes from the same animals were examined 
(Figure 7.3B and D). We can thus conclude that, in the first hours after 
treatment, both MIM-IgG1 and AG-MIM-IgG1 are significantly less efficient 
than all other constructs in binding to T cells in vivo and causing depletion. 
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Figure 7.3 Binding capacity of different mAb constructs to T cells in vivo. (see legend in the 
next page). 
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Figure 7.3 Binding capacity of different mAb constructs to T cells in vivo. Analysis by flow 
cytometry of mAb binding to T cells of CP1-CBA mice 3 hours following i.p. injection of 0.5 
mg of mAb. A, Analysis of peripheral blood lymphocytes. CD3+ T cells from mice treated with 
CAMPATH-1H or AG-CAMPATH-1H are coated with these mAbs as the cells are brightly 
stained with anti-human IgG1 mAb. Some depletion of T cells from the blood can already be 
seen at this time with both constructs. The P61-IgG1 and AG-P61-IgG1 also stain strongly, 
and achieve some depletion. MIM-IgG1 stains the blood T cells, although with lower intensity 
than the above constructs, and very little cell depletion is seen at this stage. Finally, AG-MIM-
IgG1 binds very weakly to blood lymphocytes, and is not associated with any cell depletion at 
this time. B, Analysis of splenocytes. Results are comparable to peripheral blood. C, 
Representation of the MFI of CD3+ T cells (left) and percentage of CD3+ T cells among the 
PBL (right) amongst the mice treated with different constructs as shown in A. Mean and 
standard deviation are shown. D, Representation of MFI (left) and percentage of CD3+ cells 
(right) amongst the splenocytes of the same mice. 
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 When PBLs and splenocytes from mice treated with MIM-IgG1 or AG-MIM-
IgG1 were analysed 8 days following mAb injection, it was apparent that 
there was an increase in the amount of the human mAb binding to T cells, as 
exemplified by AG-MIM-IgG1 when compared with that seen at 3 hours after 
treatment (Figure 7.4). Furthermore, depletion mediated by MIM-IgG1 was 
also increased. Animals treated with mAbs were observed to have near total 
T cell depletion at this time point. 
 
Taken together, these results suggest that AG-MIM-IgG1 and MIM-IgG1 have 
the capacity to bind the cells in vivo, although with delayed kinetics.  
 
7.2.3  MIM-IgG1 depletes T cells in a dose-dependent manner 
 
Since MIM-IgG1 has the capacity to bind cells in vivo, I determined whether 
this mAb could exert its biological function by depleting cells expressing their 
target antigen. I found this to be the case, with MIM-IgG1 being capable of 
cell depletion in a dose dependent fashion.  
 
CP1-CBA mice were treated with different doses of CAMPATH-1H or MIM-
IgG1. Blood samples were collected at different time points following mAb 
treatment and analysed for depletion of hCD52+ T cells (Figure 7.5). As 
expected, mice treated with CAMPATH-1H showed a marked depletion of T 
cells immediately following injection, while depletion in MIM-IgG1-treated 
mice took much longer to occur. It is also required a dose 10 to 50 times 
higher to achieve depletion comparable to CAMPATH-1H. Interestingly, it 
appears that depletion induced by MIM-IgG1 has a longer duration than that 
seen with CAMPATH-1H. In fact, 21 days following mAb treatment at the 
highest mAb doses, the percentage of hCD52+ cells was higher in 
CAMPATH-1H treated mice than in MIM-IgG1 treated mice. 
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Figure 7.4 Binding of MIM-IgG1 and AG-MIM-IgG1 to hCD52+ T cells increases with time. A, 
Analysis by flow cytometry of MIM-IgG1 and AG-MIM-IgG1 binding to T cells of CP1-CBA 
mice 8 days following i.p. injection of 0.5 mg of mAb. The injected AG-MIM-IgG1 mAb has 
bound to CD3+ T cells in the spleen and peripheral blood, and that the intensity of staining is 
higher that in the analysis at 3 hours post-treatment (Figure 7.3). Similar results were 
obtained following treatment with MIM-IgG1, but in this case a significant proportion of T cells 
has been depleted as the percentage of CD3+ cells is markedly reduced. B, Representation 
of the MFI (left) and percentage of CD3+ T cells from mice treated with the different mAb 
constructs. Mean and standard deviation are indicated. 
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Figure 7.5 Depletion of peripheral blood T lymphocytes by CAMPATH-1H and MIM-IgG1. 
Different groups of CP1-CBA mice were injected i.p. with several doses of CAMPATH-1H or 
MIM-IgG1. Blood samples were collected 24 hours, 8 days and 21 days following mAb 
treatment, and depletion of hCD52+ T cells was quantitated by flow cytometry. The left 
column shows the results of mice treated with 0.1 mg to 0.5 mg of mAb and the right column 
shows the results of a different experiment where mice were treated with 1 µg to 50 µg of 
mAb. CAMPATH-1H depletes host T cells within 24 hours at doses down to 5 µg/ml whereas 
MIM-IgG1 depletion is slower and requires doses of mAb 100 times greater. In contrast, at 
day 21 depletion achieved with 0.25 mg or 0.5 mg of MIM-IgG1 is similar to the one achieved 
with the same doses of CAMPATH-1H, where T cells are already expanding. 
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 These results suggest that treatment with MIM-IgG1 can achieve cell 
depletion, when given at appropriate dose, and that this has a slower onset 
but a longer duration than depletion by CAMPATH-1H. 
 
7.2.4 MIM-IgG1 and AG-MIM-IgG1 are less immunogenic than 
CAMPATH-1H 
 
To assess the immunogenicity of the different mAbs, serum samples were 
collected 21 or 28 days following mAb treatment of CP1-CBA mice. The 
presence of anti-human globulins in the serum samples was quantified by 
ELISA as described in Chapter 2, confirming high immunogenicity of 
CAMPATH-1H, but not MIM-IgG1 or AG-MIM-IgG1. 
 
CP1-CBA mice were injected with different doses of mAbs (Figure 7.6A). All 
doses of CAMPATH-1H tested were found to be significantly more 
immunogenic than any dose of MIM-IgG1 tested. Remarkably, mice treated 
with AG-MIM-IgG1 had no detectable anti-human globulin in the serum. The 
lack of immunogenicity of AG-MIM-IgG1 is not solely due to the amino-acid 
modification of the Fc region, as treatment with 0.5 mg AG-CAMPATH-1H or 
AG-p61-IgG1 leads to significant anti-human globulin titres (Figure 7.6B).  
 
7.2.5  MIM-IgG1 and AG-MIM-IgG1 can induce tolerance to CAMPATH-
1H 
 
In order to determine the tolerogenic capacity of different Ab constructs, CP1-
CBA mice were initially treated with the test mAbs, and subsequently 
challenged with an immunogenic dose of CAMPATH-1H as represented in 
Figure 7.7A. Treatment with MIM-IgG1 and AG-MIM-IgG1 severely impaired 
production of antiglobulins following subsequent challenge with CAMPATH-
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Figure 7.6 Immunogenicity of different mAb constructs. Sera was taken from CP1-CBA mice 
treated with different doses CAMPATH-1H or MIM-IgG1 mAbs on day 21 (A), or from mice 
treated with 0.5 mg of test mAbs on day 28 (B). The presence of anti-CAMPATH-1H Abs was 
assessed by ELISA. All doses of CAMPATH-1H were more immunogenic than equivalent 
doses of MIM-IgG1 (mean antiglobulin titres respectively 1:1.5x104 to 1:105 versus 1:45.9 to 
1:557, corresponding to differences of approximately 100 to 400-fold for equivalent doses). 
Interestingly, in any of the mice treated with 0.5 mg of AG-MIM-IgG1 no antiglobulins were 
detected (titres <1:20). Treatment with AG-CAMPATH-1H or AG-P61-IgG1 led to the 
production of antiglobulins (mean titres 1:2.9x104 and 1:6463). Differences between 
CAMPATH-1H and MIM-IgG1 treated mice, as well as AG-MIM-IgG1 treated mice compared 
with animals treated with AG-CAMPATH-1H or AG-p61-IgG1, are statistically significant 
(p<0.0005). Geometric mean and standard deviation for each group are represented in the 
graph. 
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 1H. In other words, treatment with MIM-IgG1 and AG-MIM-IgG1 induced 
partial (MIM-IgG1) and complete (AG-MIM-IgG1) tolerance to CAMPATH-1H. 
 
Groups of CP1-CBA mice were treated with different concentrations of mAbs. 
All animals were challenged with 5 daily doses of 50 µg CAMPATH-1H as 
described in Figure 7.7A. Such challenge with CAMPATH-1H is highly 
immunogenic leading to high serum levels of anti-human globulins readily 
detectable by ELISA 30 days following CAMPATH-1H administration (Figure 
7.7B). The antiglobulin titres of mice treated initially with CAMPATH-1H were 
even increased four-fold following the CAMPATH-1H challenge. However, 
mice initially treated with different doses of MIM-IgG1 showed partial 
tolerance to CAMPATH-1H, as they failed to produce more antiglobulins 
following challenge with CAMPATH-1H, or even subsequent challenge 30 
days after the first one (Figure 7.7C). Remarkably, mice initially treated with 
AG-MIM-IgG1 became completely tolerant to CAMPATH-1H with no 
detectable serum antiglobulins following any CAMPATH-1H challenge. The 
control group treated with p61-IgG1 showed a partial impairment in 
antiglobulin production following CAMPATH-1H treatment. Interestingly, one 
of these mice failed to produce antiglobulins following challenge with 
CAMPATH-1H. At the present we cannot explain this observation, which was 
not reproduced in a repeat experiment. 
 
Taken together these results confirm that MIM-IgG1 and particularly AG-MIM-
IgG1 have the capacity to induce degrees of tolerance to the wild-type 
CAMPATH-1H mAb. 
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Figure 7.7 Tolerogenicity of different mAb constructs. (see legend in the next page). 
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 Figure 7.7 Tolerogenicity of different mAb constructs. CP1-CBA mice were treated with 
different mAb constructs at day 0. A, At day 60 (left panels) or 21 (right panels) the mice 
were challenged with 250 µg CAMPATH-1H over five days. A blood sample was collected 3 
or 4 weeks following the CAMPATH-1H challenge (day 90 or 45, respectively) and analysed 
for the presence of antiglobulins. At this time another challenge with daily injections of 50 µg 
CAMPATH-1H over five days was performed. A final blood sample was collected 4 weeks 
following the last rechallenge (days 120 or 75). B, Quantitation by ELISA of serum 
antiglobulins after the initial challenge with CAMPATH-1H, on day 90 (left) or 45 (right). Mice 
initially treated with MIM-IgG1 shown a reduced capacity to mount an immune response to 
the injected CAMPATH-1H, suggesting some level of tolerisation. None of the mice initially 
treated with AG-MIM-IgG1 had detectable antiglobulins in circulation, suggesting they were 
completely tolerised to CAMPATH-1H. C, Quantitation of serum antiglobulins, from the same 
animals represented in (B), after secondary challenge with CAMPATH-1H, on day 120 (left) 
or 75 (right). Mice initially treated with CAMPATH-1H, P61-IgG1, or without any initial 
treatment demonstrated an even higher antiglobulin titre. That was not the case of animals 
initially treated with MIM-IgG1, that maintained low titres of antiglobulin, or mice initially 
treated with AG-MIM-IgG1, that still had no detectable antiglobulin in the circulation. 
Differences between CAMPATH-1H and MIM-IgG1 treated mice, as well as AG-MIM-IgG1 
treated mice compared with animals treated with p61-IgG1 or without an initial mAb 
treatment, are statistically significant at the two studied time points (A and B) (p<0.005). 
Geometric mean and standard deviation for each group are represented in the graph. 
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 7.2.6  Tolerance with AG-MIM-IgG1 is complete by two weeks 
 
To assess the time that is necessary for tolerance to be complete, groups of 
mice treated with the tolerogenic dose of 0.5 mg AG-MIM-IgG1 were 
subsequently injected with an immunogenic dose of 50 µg CAMPATH-1H at 
different time points thereafter (Figure 7.8). Quantification of serum anti-
human globulins was performed 21 days following the administration of the 
immunogenic mAb. Remarkably, when the time interval between tolerogenic 
and immunogenic treatment was greater than 24 hours, the amount of 
antiglobulins detected in the sera was lower, being smaller the longer the 
time interval from administration of tolerogen. When the immunogenic stimuli 
was given two weeks following the tolerogenic mAb, only 1 out of 6 mice had 
any detectable serum antiglobulins and this was at a very low titre (<1:40). I 
can therefore conclude that 1 week is sufficient to prevent the generation of 
high antiglobulin titres, and 2 weeks permits virtually complete tolerance. 
 
7.2.7  An immunogenic dose of CAMPATH-1H can be overriden by 
tolerance processes if co-administered with an excess of AG-
MIM-IgG1 
 
I decided to establish whether an immunogenic dose of CAMPATH-1H could 
be overriden by tolerance if sufficient AG-MIM-IgG1 was co-administered. 
Such result would be important to determine whether any cell-bound antibody 
accumulating immediately after injection could abrogate the tolerogenic 
capacity of the stealth construct. 
 
CP1-CBA mice were treated with the tolerogenic dose of 0.5 mg AG-MIM-
IgG1 mixed with different immunogenic doses of CAMPATH-1H (Figure 
7.9A). An immune response to CAMPATH-1H was abrogated when a ratio of 
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Figure 7.8 How much time is needed for tolerance to develop. All mice were treated with 0.5 
mg AG-MIM-IgG1 at time 0. An immunogenic dose of 50 µg CAMPATH-1H was given at 
different time points following the Ag-MIM-IgG1 treatment. Blood samples were collected 21 
days following immunogenic challenge and the presence of antiglobulins quantified by 
ELISA. Serum antiglobulin levels were significantly reduced when the immunogenic 
challenged was given three days following the tolerogenic treatment (geometric mean: 3.6 ± 
0.87, p=0.0226 compared with time 0 (7.4 ± 1.03)). And even further reduced at day 7 and 
day 14 (1.8 ± 0.37 and 0.2 ± 0.2 respectively). 
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 CAMPATH-1H / AG-MIM-IgG1 of 1:100 or 1:1,000 was injected (Figure 
7.9B). Furthermore, when mice that failed to mount an immune response to 
the initial injection of CAMPATH-1H were challenged with 5 daily doses of 50 
µg CAMPATH-1H they did not produce detectable levels of antiglobulins. I 
can therefore conclude that an appropriate mixture of the immunogenic with 
the tolerogenic Ab can result in tolerance or immunity depending on the 
injected ratios. 
 
7.2.8  Tolerance correlates with higher serum concentration / half-life of 
human mAb 
 
As antiglobulins can lead to increased clearance of their target Abs, I 
determined whether induction of tolerance leads to increased half-life of the 
injected mAbs. An inverse correlation between antiglobulin titre and serum 
concentration of human Abs was found. 
 
CP1-CBA mice were treated with a mixture of AG-MIM-IgG1 and CAMPATH-
1H, and challenged at day 21 with a further injection of 250 µg CAMPATH-1H 
over 5 days, as described above (Figure 7.9A). At day 42 the concentration 
of human Abs (both injected CAMPATH-1H and AG-MIM-IgG1) in the serum 
was determined by ELISA (Figure 7.9C). Interestingly, mice tolerant to 
CAMPATH-1H demonstrated higher titres of human Abs in the serum than 
mice that were not tolerant. In fact, there is an inverse correlation between 
the presence of antiglobulins and the presence of human Ab in the serum 
(Figure 7.9B and C). These results confirm the hypothesis that tolerance 
induction, by reducing the production of antiglobulins, allows a greater half-
life of the injected mAbs. 
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Figure 7.9 A mixture of CAMPATH-1H and AG-MIM-IgG1 at the appropriate ratio can result 
in tolerance. A, CP1-CBA mice were injected at day 0 with 0.5 mg AG-MIM-IgG1, alone or in 
combination with 0.5 mg, 50 µg, 5 µg or 0.5 µg CAMPATH-1H. All mice were bled at day 21, 
and antiglobulin titles measured by ELISA (white bars). All mice were then challenged with 5 
doses of 50µg CAMPATH-1H between day 21 and 25. Another blood sample was collected 
at day 42, and antiglobulin titres determined as before (grey bars). B, Comparison of 
antiglobulin titres from mice injected with different mAb mixtures. White and grey bars 
correspond to samples from day 21 or 42 respectively. The titres were not significantly 
different between day 21 and 42 in any group except the one treated with 5 µg CAMPATH-
1H (p=0.0338). There was a significant reduction in antiglobulin titres, both at days 21 and  
42 between the groups injected with 50 µg and 500 µg CAMPATH-1H compared with any 
other group (p<0.0005). C, At day 42 the serum concentration of human antibody was 
determined in all mice by ELISA. Mice with higher antiglobulin titres had lower concentration 
of human mAb in the sera, being the difference between any of those two groups and any 
other group statistically significant (p<0.01). 
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 7.2.9 Tolerance to CAMPATH-1H correlates with a longer biological  
effect of the mAb 
 
Initial experiments suggested that treatment with MIM-IgG1 could result in a 
more prolonged T cell depletion than the use of an equal dose of CAMPATH-
1H (Figure 7.5). I confirmed that a longer biological effect of this type is 
dependent on tolerance induction. 
 
Different groups of CP1-CBA mice were treated with 0.5 mg of MIM-IgG1, 
CAMPATH-1H, or a control mAb. An additional group of mice were pre-
tolerised by treatment with 0.5 mg AG-MIM-IgG1 21 days prior to CAMPATH-
1H treatment (Figure 7.10). Remarkably, the two groups treated with the 
same dose of CAMPATH-1H showed a very different result in terms of long-
term depletion. The tolerant mice maintained a very low level of T cells up to 
60 days following CAMPATH-1H treatment, while in the non-tolerant group T 
cells started to expand in the first 3 weeks. Mice treated with MIM-IgG1 
showed an intermediate effect: such treatment does not lead to near absolute 
cell depletion as obtained following CAMPATH-1H treatment. However, low 
levels of T cells are maintained for a long period of time, probably as a result 
of low antiglobulin levels. 
 
7.3  Discussion 
 
The present study was prompted by the need in animal models for non-
immunogenic mAbs as reagents for in vivo experimental work. I used, as a 
starting point, the previous observation that non-cell binding mAbs can 
induce tolerance to the binding form (Benjamin et al., 1986). Gilliland and 
colleagues have shown that by mutating HCDR2 of CAMPATH-1H one can 
prevent its binding, being the mutant Ab capable of inducing tolerance to 
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Figure 7.10 Tolerance correlates with long-term depletion. Mice were injected with 0.5 mg of 
different mAb at day 0. One group of mice treated with CAMPATH-1H at day 0, had been 
tolerised by treatment with 0.5 mg AG-MIM-IgG1 at day –30. Depletion of T cells among 
peripheral blood lymphocytes was monitored by flow cytometry. Tolerised mice treated with 
CAMPATH-1H showed a much longer depletion than mice injected with the same 
CAMPATH-1H dose in the absence of pre-tolerisation. At day 60, the percentage of hCD52+ 
cells in the peripheral blood of mice treated with CAMPATH-1H (57.8 ± 1.60) was 
significantly higher than in animals treated with the same mAb but tolerised in advance with 
AG-MIM-IgG1 (1.80 ± 1.72; p<0.0001) or mice treated with MIM-IgG1 (17.3 ± 5.7; p<0.0001). 
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 CAMPATH-1H (Gilliland et al., 1999). With the present experiments I 
confirmed that by constructing a mAb variant lacking cell binding activity, one 
can obtain an mAb capable of inducing tolerance to the cell binding form. 
 
We decided to prevent cell-binding capacity of CAMPATH-1H using a CD52 
mimotope convalently linked to the V region of its light chain. We anticipated 
that such a strategy would have three important advantages. First, the 
complete primary sequence and structure of CAMPATH-1H would be 
preserved in the tolerogenic mAb. Second, the process offered a new and 
general method for creating non-cell binding variations of different mAbs. 
Third, it might, in time, be possible to remove the linked mimotope once 
tolerance had been induced, so releasing a functional mAb. 
 
In vitro studies confirmed that the MIM-IgG1 had a poor binding capacity 
when compared with CAMPATH-1H or P61-IgG1 (a control with an irrelevant 
peptide). Remarkably, when injected in vivo, MIM-IgG1 could bind to cells 
and even mediate cell depletion. However, MIM-IgG1 took more time to bind 
to cells than CAMPATH-1H, and does not seem to saturate cellular sites in 
the manner of CAMPATH-1H (Figures 7.3 and 7.4). It is therefore likely that a 
large fraction of MIM-IgG1 remained in the plasma, in spite of some cell 
binding activity. In the case of CAMPATH-1H treatment it is certain that the 
proportion of the injected mAb that remained in the circulation was lower. 
Such differences in the cell binding capacity offer an explanation for the 
distinct pattern in cell depletion observed following treatment with MIM-IgG1 
or CAMPATH-1H (Figure 7.5). A larger dose of MIM-IgG1 than of CAMPATH-
1H was required to achieve substantial T cell depletion, possibly due to a 
significant fraction of MIM-IgG1 that remained unbound. Depletion with MIM-
IgG1, at the highest tested doses, had a slower onset than by CAMPATH-1H, 
and a “near complete” depletion, as follows CAMPATH-1H treatment, was 
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 never observed with MIM-IgG1. Interestingly, the depletion achieved with 
MIM-IgG1 was maintained for a longer period than deletion by CAMPATH-1H 
(Figures 7.5 and 7.10). 
 
As predicted, MIM-IgG1 was significantly less immunogenic than CAMPATH-
1H and could prevent the generation of antiglobulins following subsequent 
treatment with CAMPATH-1H (Figures 7.6 and 7.7). Remarkably, AG-MIM-
IgG1 was not immunogenic and could induce complete tolerance to 
CAMPATH-1H. Although the antigen binding properties of AG-MIM-IgG1 and 
MIM-IgG1 are slightly different (Figures 7.2 and 7.3), we believe that such 
differences are probably insufficient to explain the differences in 
immunogenicity and tolerogenicity. It is likely that a mAb capable of causing 
cell deletion will generate some pro-inflammatory “danger” signals. As a 
consequence, a similar mAb unable to activate effector function would not 
generate such “danger” signals and would be less immunogenic. Indeed AG-
MIM-IgG1 lacked cell depleting activity altogether.  
 
We also established that tolerance with AG-MIM-IgG1 took time to reach 
completion. Three days following the tolerogenic treatment, the capacity to 
produce antiglobulins following administration of the immunogenic wild-type 
mAb was clearly compromised, but not totally (Figure 7.8). It is interesting to 
compare this time-scale with the kinetics of cell binding in vivo (Figures 7.3 
and 7.4). It is likely that in the initial days when tolerance is becoming 
established most of the MIM-IgG1 or AG-MIM-IgG1 is unbound, with 
progressively more Ab being deposited on T cells with time. However, 
depletion with MIM-IgG1 only becomes significant 8 days after treatment, at a 
time partial tolerance was already established.  Furthermore, when a mixture 
of AG-MIM-IgG1 and CAMPATH-1H was injected at different ratios we 
confirmed that 5 µg of CAMPATH-1H could be co-administered with 0.5 mg 
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 of AG-MIM-IgG1 without compromising tolerance induction (Figure 7.9). Such 
a result suggests that some cell binding mAb present at the time of tolerance 
induction need not prevent tolerance if an excess of unbound tolerising mAb 
is also present.  
 
Taken together, these results suggest that the bulk of MIM-IgG1 and AG-
MIM-IgG1, due to their slow accumulation on cells, remain mostly in the 
unbound form, in the circulation, during the initial days following treatment. 
About 1 week following mAb injection, more mAbs accumulate on T cells, 
resulting in greater cell depletion with MIM-IgG1. However, as tolerance is 
already partially established, the cell-bound mAb is less able to evoke an 
immune response. 
 
It is important to stress that all in vivo experiments were performed using 
humanised mAbs in transgenic mice. As a consequence, the immunogenic 
challenge was much greater than that which might be expected in clinical 
situations where humanised mAbs are used. It may well be possible that the 
incomplete tolerogenic effect of MIM-IgG1 in the mouse could be sufficient to 
induce complete tolerance in a less stringent human – human situation. It is 
even likely that the partial tolerance effect obtained following MIM-IgG1 
treatment could be adequate, as animals treated with MIM-IgG1 showed 
prolonged cell depletion (Figure 7.10), and maintained the low level of 
antiglobulins in spite of subsequent administrations of CAMPATH-1H (Figure 
7.7). 
 
The finding that MIM-IgG1 binds to target cells at a slower rate than 
CAMPATH-1H may offer important clinical benefits. One frequent problem of 
mAbs that target lymphocytes is the deleterious effect of cytokines released 
as a result, a complication known as cytokine release syndrome (Cosimi et 
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 al., 1981; Group, 1985). By diminishing the speed of cell depletion in may be 
possible to reduce or even eliminate cytokine release syndrome when a 
therapeutic mAb with an obstructed binding site is used. Additionally, it is 
frequently difficult to remove efficiently large solid tumours with mAbs. In part 
this may be due to the cells at the periphery acquiring most of the available 
mAb, so that insufficient mAb accumulates in the central tumour cells. If so, 
then this might be improved with a mAb like MIM-IgG1 that binds slowly and 
maintains efficacy for longer than CAMPATH-1H. This way it may be possible 
to progressively reduce the tumour mass without “wasting” therapeutic mAb 
on the peripheral cells. Finally, the process of reducing immunogenicity and 
achieving tolerogenic capacity by interfering with cell binding with a linked 
peptide may prove useful for other molecules apart from therapeutic mAbs. 
When foreign molecules are introduced in patients, either directly, like factors 
VIII and IX in haemophilia and therapeutic enzymes in storage diseases, or 
by gene therapy, their immunogenicity can limit their effectiveness. A similar 
strategy to create non-cell binding tolerogenic molecules may be possible in 
this context. 
 
A natural development from our experimental system will be to design 
“linkers” that can be cleaved at specific sites or particular time. Such 
“cleavable” linkers may allow a better control of the site and time for 
therapeutic activity, while allowing the maintenance of a large proportion of 
soluble mAb to induce tolerance to the cell binding form. 
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 CHAPTER 8 
 
DISCUSSION 
 
 
There is now compelling evidence for active regulation of immune responses 
by T cells. The mechanisms responsible for such active regulation remain 
largely unknown, and it is not inconceivable that multiple redundant 
regulatory strategies are operating.  
 
The suggestion that antibody-induced transplantation tolerance, as well as 
self-tolerance may in part be maintained by CD4+ regulatory T cells (Powrie 
and Mason, 1990; Qin et al., 1993; Sakaguchi et al., 1995; Chen et al., 1996; 
Onodera et al., 1996; Asano et al., 1996; Hall et al., 1998; Thornton and 
Shevach, 1998) sparked interest in the characterisation of mechanisms by 
which T cells regulate in these model systems. When compared with other 
cells that have been shown capable of suppressing T cell responses (at least 
in vitro) CD4+CD25+ T cells seem to be the most potent.  
 
It is still not known whether regulatory T cells implicated in self-tolerance 
have any relationship with the CD4+ regulatory T cells involved in 
transplantation tolerance. By understanding the characteristics and 
mechanisms of action of regulatory T cells it may be possible to develop 
rational methods for the induction of tolerance both in transplantation and 
autoimmunity. In addition, the precise characterisation of specific markers of 
regulatory function may allow the biology of regulatory cells to be studied in 
greater detail, as well as the development of useful diagnostic tools for 
clinical use. 
 
   165 
 The starting point for this thesis was the study of whether tolerance induced 
with co-stimulation blockade lead to the development of regulatory T cells 
that could maintain a state of dominant tolerance and recruit new regulatory 
cells through infectious tolerance (Chapter 3). Indeed, long held assumptions 
postulated that co-stimulation blockade would lead to tolerance by 
inactivation or deletion of alloreactive clones (see Matzinger, 1999). I was 
able to demonstrate that indeed co-stimulation blockade induced the 
emergence of CD4+ regulatory T cells (Graca et al., 2000; Chapter 3), adding 
to the body of knowledge that has also implicated reduction of alloreactive 
clones as part of the tolerisation process (Wells et al., 1999; Li et al., 1999; Li 
et al., 2001).  
 
I therefore argue that the regulatory mechanisms induced following co-
receptor blockade (with non-depleting anti-CD4 and anti-CD8 mAbs) are 
similar to the mechanisms triggered by tolerisation with co-stimulation 
blockade (with non-depleting anti-CD40L). In fact the properties of tolerance 
achieved with either one or the other strategy are remarkably similar: in both 
cases they involve dominant tolerance (Qin et al., 1990; Graca et al., 2000), 
infectious tolerance (Qin et al., 1993; Graca et al., 2000), and linked 
suppression (Davies et al., 1996a; Chen et al., 1996; Honey et al., 1999). In 
both cases tolerance is maintained by CD4+ T cells (Qin et al., 1993; Graca 
et al., 2000), while AICD is probably involved during the induction phase (Li 
et al., 1999; Wells et al., 1999; Phillips et al., 2000). 
 
Given the finding that both co-receptor or co-stimulation blockade can result 
in dominant tolerance, I decided to investigate whether the two strategies can 
be combined to induce tolerance more effectively. In Chapter 4 I show that 
combined co-stimulation and co-receptor blockade can enable induction of 
tolerance to fully mismatched skin allografts, which is not feasible with either 
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 strategy alone. Tolerance so achieved was shown to be dominant, and 
dependent on CD4+ T cells. Linked suppression was also observed. It is 
important to note that fully mismatched skin is considered to be the most 
stringent test for transplantation tolerance (Trambley et al., 2000), and that 
non-depleting mAbs targeting co-stimulation or co-receptors have generally 
failed to induce tolerance to fully mismatched skin allografts when given 
alone.  
 
Given the results described above, it appears that CD4+ regulatory T cells 
may be a final common pathway for a range of different strategies to induce 
transplantation tolerance. I decided therefore to study whether such CD4+ 
regulatory T cells carried the CD25 marker which is characteristic of natural 
regulatory T cells in self-tolerance (Sakaguchi, 2000; Shevach, 2000; Maloy 
and Powrie, 2001). I have shown that naturally occurring CD4+CD25+ T cells 
from “naïve” mice, which had never experienced the transplantation antigens, 
can still prevent skin graft rejection if given in sufficient numbers together with 
normal splenocytes (Graca et al., 2002b; Chapter 5). However, CD4+CD25+ T 
cells from tolerised mice seemed more potent as a lower number were 
required to suppress allograft rejection. This result can be explained by any 
of: (1) a selective expansion of regulatory T cells from pre-existing 
precursors, (2) by de novo formation of CD4+CD25+ regulatory cells, or (3) by 
selective inactivation of putative non-tolerant cells from the CD4+CD25+ T cell 
population. 
 
These observations question the antigen specificity of regulatory CD4+CD25+ 
T cells, one of the most important outstanding issues concerning regulatory T 
cell biology. Transplantation studies offer the opportunity to study antigen 
specificity of regulation in a more controlled way than animal models of 
autoimmunity. But a proper study of specificity will require a criss-cross 
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 analysis, testing whether regulatory T cells which can prevent rejection of one 
type of allograft are permissive for rejection of a third-party allograft, and vice-
versa. Until such experiments are performed, the question of antigen 
specificity of regulatory T cells remains unresolved.  
 
In these same studies I have also observed regulatory capacity among the 
CD4+CD25- population from tolerised mice, albeit 10-fold less potent than 
equivalent numbers of CD4+CD25+ T cells (Graca et al., 2002b; Chapter 5). 
However, as the proportion of CD25+ cells among the CD4+ T lymphocytes is 
~10%, the overall regulatory capacity within the whole of CD4+CD25+ and 
CD4+CD25- T cell populations is likely to be similar. Furthermore, by titrating 
unseparated CD4+ T cells from tolerised mice, I concluded that the potency of 
the unseparated CD4+ T cells was greater than the potency of equivalent 
numbers of sorted CD4+CD25+ or CD4+CD25- T cells. Given these results it 
is possible that the two populations can synergise in the maintenance of 
tolerance. 
 
It is interesting that the CD4+CD25- population is only seen to regulate if 
derived from tolerised, but not naïve mice. This may not be surprising as the 
CD4+CD25- population in naïve animals is thought to carry the potential 
“aggressor cells”. It may be that, in tolerance, some CD4+CD25+ regulatory 
cells loose the expression of CD25 and endow the CD4+CD25- population 
with new regulatory powers, as has been suggested following homeostatic 
expansion of CD4+CD25+ T cells (Gavin et al., 2002). Alternatively, AICD 
previously reported to occur in the induction of transplantation tolerance 
(Wells et al., 1999; Li et al., 1999), may selectively remove effector cells from 
the CD4+CD25- population so unmasking residual regulatory cell activity.  
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 It is also an unresolved issue whether regulatory T cells (both CD4+CD25- 
and CD4+CD25+ T cells) represent a specific lineage exported from the 
thymus, or whether peripheral T cells can differentiate into regulatory cells in 
the context of a particular microenvironment.  
 
In support of the “lineage” hypothesis, the thymus was shown to contain 
potent regulatory cells that are CD4+CD25+CD45RClow (Saoudi et al., 1996; 
Itoh et al., 1999). Furthermore, CD4+CD25- thymocytes, unlike CD4+CD25- 
peripheral T cells, seem to lack any suppressive capacity (Stephens and 
Mason, 2000). It has been shown that thymocytes from double transgenic 
mice, bearing both a high affinity TCR and its target antigen (a peptide 
derived from influenza hemaglutinin (HA)), can produce functional 
CD4+CD25+ T cells. However, double transgenic mice expressing a low 
affinity HA specific TCR fail to sustain the development of CD4+CD25+ T cells 
(Jordan et al., 2001). The authors suggest that thymocytes whose TCRs 
have high affinity for self-peptides being presented in the thymus, but not 
high enough to be committed towards negative selection, become 
CD4+CD25+ regulatory T cells.  
 
This, however, is not conclusive evidence supporting lineage commitment. 
Our results have shown that dominant tolerance, mediated by CD4+ T cells, 
can be induced in either euthymic or adult thymectomised animals (see 
Chapters 3 and 4). In such experiments tolerance is induced to non-self 
antigens. Although, such results are consistent with the hypothesis that T 
cells can become regulatory following peripheral “tolerisation”, they are also 
insufficient for the conclusion that they derive de novo. It was recently shown 
that peripheral CD4+CD25+ or CD4+CD25- T cells, when injected into RAG2-/- 
mice proliferate yielding a mixed population where in both cases ~20% of the 
cells are CD4+CD25+ (Annacker et al., 2001b). The authors suggested that, 
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 on the one hand, peripheral T cells are heterogeneous with regulatory cells, 
derived from CD4+CD25+ thymocytes, contained within both the CD25+ and 
CD25- T cell pool (Annacker et al., 2001a). On the other hand, single positive 
thymocytes are considered to be more homogeneous for the presence of 
regulatory T cells, with all regulatory activity contained in the CD4+CD25+ 
subpopulation, while the CD4+CD25- thymocytes are apparently devoid of 
any regulatory cells (Annacker et al., 2001a). Given the evidence suggesting 
that in single positive thymocytes CD25 expression defines two separate 
populations – regulatory and non-regulatory cells – it may be possible to 
further investigate the plasticity of thymic emigrants for developing into 
aggressive or regulatory T cells, by adoptive transfers of CD4+CD8-CD25- 
thymocytes into syngeneic thymectomised RAG-/- hosts. In such 
circumstances it may be possible to observe CD4+CD25- T cells becoming 
effectors of skin graft rejection or regulatory T cells (even CD4+CD25+ 
regulatory T cells) if “tolerised” with non-depleting mAbs, or following co-
existence with regulatory T cells (infectious tolerance). Such a result would 
strongly argue against a deterministic lineage of regulatory T cells, identified 
by the CD25 molecule, being exported from the thymus. 
 
The effect of homeostatic-driven proliferation of transfused cells into T cell 
deficient hosts needs some discussion. It has been shown that both 
CD4+CD25- and a fraction of the CD4+CD25+ T cells do expand when 
injected into RAG2-/- mice (Annacker et al., 2001b). Such in vivo results 
contrast with the poor proliferative capacity of CD4+CD25+ cells in vitro 
(Takahashi et al., 1998; Thornton and Shevach, 1998). However, it is 
important to note that in the in vivo experiments only ~10% of the injected 
CD4+CD25+ T cells underwent proliferation, involving 10 – 11 rounds of 
division, such that the progeny contributed to more than 99% of the cell pool 
once a steady state was reached (Annacker et al., 2001b). Nonetheless, 
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 CD4+CD25+ T cells were shown capable of controlling the expansion of 
CD4+CD45RBhigh T cells, suggesting a role in the control of homeostatic 
driven proliferation (Annacker et al., 2001b). Such findings raise the 
possibility that in animal models of gut immunopathology and autoimmune 
disease where pathology is associated with homeostatic proliferation of 
CD4+CD45RBhigh T cells, the protective effect of CD4+CD25+ T cells may be 
due to control of homeostatic expansion rather than antigen-specific 
suppression.  
 
It has been suggested that once activated, CD4+CD25+ T cells mediate 
suppression in an antigen non-specific way (Takahashi et al., 1998; Thornton 
and Shevach, 2000). One can speculate that under lymphopenic conditions, 
the CD4+CD25+ T cells have a competitive advantage over CD25- cells. 
Under such circumstances, the CD4+CD25+ T cells would benefit from 
homeostatic expansion, while simultaneously preventing the CD25- cells from 
expanding. As was shown by Gavin et al, under lymphopenic conditions 
homeostatic expansion is largely antigen non-specific, but MHC dependent – 
a situation similar to thymic positive selection (Gavin et al., 2002). It is likely 
that T cell competition for expansion in T cell replete animals is considerably 
tougher. In such conditions, it is improbable that simple interactions with 
MHC will support expansion. In a replete immune system it is therefore more 
likely that antigen specificity play an important role in the competition for 
expansion, and conversely in its inhibition. It will be important to develop in 
vivo experimental systems where the function of different cell populations can 
be assessed in the absence of homeostatic proliferation. 
 
The finding that regulatory T cells can be identified in tolerated skin allografts 
but not, at least to the same extent, within the syngeneic skin of the same 
tolerised mice (Graca et al., 2002a; Chapter 6), bears some discussion. This 
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 may in part explain the phenomenon of linked suppression (Davies et al., 
1996a; Chen et al., 1996; Wong et al., 1997; Honey et al., 1999; Chapter 4). 
It is possible that the reason for graft acceptance when the tolerated and 
third-party antigens are linked in the same tissue, may be due to local effects 
of regulatory T cells. Whether the regulatory T cells present in tolerated 
allografts are resident peripheral regulatory cells or cells preferentially re-
circulating through that tissue is presently unknown. 
 
In some experiments, such as those where infectious tolerance is being 
investigated, it is desirable to use depleting mAbs to eliminate a particular T 
cell sub-population (host or donor). In euthymic mice, the long-term 
maintenance of non-detectable levels of the target lymphocytes can be 
difficult when anti-globulins start to neutralize the injected mAb. This problem 
is obviously one also encountered in the clinic when patients are treated with 
multiple doses of therapeutic mAb over a long period of time. In Chapter 7 I 
described how the immunogenicity of therapeutic mAbs can be circumvented 
when they are prevented from binding to cells with a mimotope that occupies 
their binding site. This strategy was based on previous observations that non-
cell binding mAbs are not immunogenic and can induce tolerance to the 
binding form (Benjamin et al., 1986; Gilliland et al., 1999). Indeed I confirmed 
that by preventing CAMPATH-1H from binding to cells when its binding site is 
occupied by a mimotope, the immunogenicity is significantly reduced and at 
least partial tolerance to subsequent administrations of CAMPATH-1H is 
obtained.  
 
It came as a surprise that such binding inhibition is not absolute, as with time 
MIM-IgG1 accumulates on the cell surface. Remarkably, MIM-IgG1 was 
found to be capable of cell depletion, although with a delayed onset when 
compared with wild-type CAMPATH-1H. I can therefore conclude that it is 
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 possible to obtain two different actions from the same mAb construct: first, 
the MIM-IgG1 induces tolerance to itself while the majority of the mAb is 
unbound. Later, the mAb starts to accumulate on the cell surface leading to 
cell deletion once a threshold is reached. However, it no longer elicits a 
strong anti-globulin response as tolerance, at least partial, has already been 
established. As a consequence MIM-IgG1 achieves a better long-term effect, 
as seen by sustained cell depletion, than the wild-type CAMPATH-1H.  
 
Such mAb variants may be useful in situations where antiglobulin responses 
may be undesirable. For example, when I investigated whether infectious 
tolerance leads to the emergence of CD4+CD25+ regulatory T cells in naive 
splenocytes, I used AG-MIM-IgG1 to induce tolerance to CAMPATH-1H. 
Subsequently, it became possible to achieve a long-term depletion of hCD52+ 
T cells in the euthymic mice, so eliminating any experimental artefacts that 
might arise from anti-globulin responses (see Chapter 5). 
 
Another finding described in Chapter 7 concerns the distinct immunogenic 
and tolerogenic properties of MIM-IgG1 and AG-MIM-IgG1. In spite of some 
minor differences in cell binding capacity between the two constructs, I 
believe the explanation must relate to the differences in pro-inflammatory 
signals that the two mAbs induce. As AG-MIM-IgG1 lacks cell depleting 
activity altogether, it is likely that in the absence of “danger” the outcome 
shifts the balance between effector and regulatory systems more towards the 
latter. 
 
One can explain the results described in this thesis by considering a model 
where persistence of foreign antigen in the absence of danger would result in 
dominant tolerance mediated by regulatory CD4+ T cells. Both in 
transplantation tolerance and tolerance to therapeutic mAbs that seems to be 
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 the case. In tolerance induced to allografts it has been previously shown that 
the persistence of alloantigen is required for tolerance maintenance (Scully et 
al., 1994). Furthermore, the results described in Chapter 4 suggest that when 
tolerance is induced to fully mismatched skin grafts, dominant tolerance is 
only maintained towards alloantigens derived by the indirect pathway. As 
direct presentation to CD4+ host T cells is necessarily transitory in the 
experimental system tested, regulatory T cells specific for that pathway are 
probably not maintained. It is possible that a major effect of tolerogenic 
mAbs, such as non-depleting anti-CD4, anti-CD8 and anti-CD40L, is to 
induce a cease-fire, therefore permitting interaction between CD4+ T cells 
and alloantigens in the absence of “danger”. Results described in Chapter 7 
support this model: AG-MIM-IgG1 and MIM-IgG1 are two mAbs with 
essentially the same characteristics, except that the first is not lytic. I 
confirmed that the non-lytic mAb is a better tolerogen that the lytic one. 
 
In the absence of “danger” it is unlikely that persistent non-self antigens 
(either transplantation antigens or therapeutic mAbs) would lead to 
presentation by fully mature DCs. It is most likely that in those circumstances 
tolerance is reinforced by antigen recognition in the context of immature DCs 
or a pro-tolerogenic set of DCs (Roncarolo et al., 2001; Higgins et al., 2002). 
It is not clear at this time whether CD4+ regulatory T cells can drive DCs 
towards an alternative maturation pathway, forcing them to remain immature 
or “decommissioned”. With time, through “infectious tolerance” the pool of 
regulatory CD4+ T cells will increase, at the expense of naïve alloreactive 
cells. As a consequence, when alloantigens persist in the absence of 
“danger”, tolerance becomes more robust with time due to the “infectious 
tolerance” recruitment of new regulatory cells. At a later time point dominant 
tolerance is robust enough to resist a challenge where “danger” is present. 
This has been repeatedly observed when a fresh skin graft of the tolerated 
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 type is transplanted onto tolerised animals. But even more remarkable is the 
experiment described in Chapter 7, where after treatment with the tolerogenic 
mAb AG-MIM-IgG1, mice resist an immunogenic challenge with the lytic 
“danger”-inducing mAb CAMPATH-1H. Furthermore, the longer we wait until 
injecting the immunogenic mAb, the more robust tolerance has become 
(Chapter 7, Figure 7.8). 
 
In immunology, as in human conflicts, it is likely that lasting “tolerance” does 
not rely on segregation, ignorance or indifference. Tolerance can only be 
achieved after a relatively long and peaceful coexistence, that may require 
active intervention from a peace-keeping force. Given enough time of 
peaceful coexistence tolerance may no longer be broken by “dangerous” 
situations. 
 
Although many major issues in transplantation tolerance and T cell regulation 
remain unsolved, I anticipate that a significant advance in the field will be the 
development of diagnostic markers of the tolerant state in vivo. There are 
currently no reliable tests capable of distinguishing a tolerised animal from a 
primed one. The transfer of current knowledge of tolerogenic protocols to the 
clinic would be greatly facilitated if diagnostic tests for tolerance were 
available. 
 
One possible strategy for the development of diagnostic tests, that is being 
pursued in the host laboratory, involves the characterization of genes 
uniquely expressed in regulatory cells. By comparing the genes expressed by 
different T cell sub-populations it may be possible to identify unique genes 
whose level of expression may correlate with tolerance (see Chapter 5). 
Together, with the observation that tolerated allografts harbour regulatory T 
cells (Chapter 6), one may predict that transplant tolerance correlates with 
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 high tissue expression of regulatory T cell-specific genes. It may therefore be 
possible, although speculative, that by monitoring the level of such 
regulatory-specific transcripts in the patients blood or urine (in the case of 
kidney grafts) one may be able to monitor the tolerant status of the patients, 
and act accordingly. 
 
In summary, this thesis demonstrates that transplantation tolerance induced 
by co-stimulation blockade leads to a dominant and infectious form of 
tolerance maintained by CD4+ T cells (Chapter 3). It was consequently 
possible to achieve a synergy when co-stimulation blockade was combined 
with co-receptor blockade, leading to robust tolerance of fully mismatched 
skin allografts (Chapter 4). Such tolerance was also dominant, manifest by 
linked-suppression and dependent on regulatory CD4+ T cells. By studying 
the phenotype of T cells maintaining dominant tolerance, I concluded that 
these could be found within the CD4+CD25+ and CD4+CD25- populations of 
tolerised mice, but only among the CD4+CD25+ T cells of naïve animals 
(Chapter 5). Such regulatory cells were found not only in the spleen of 
tolerised mice, but also in the tolerated tissue (Chapter 6). Finally, I describe 
a strategy to eliminate the immunogenicity of therapeutic mAbs by interfering 
with their capacity to bind to cells by occupying the binding-site with a 
mimotope (Chapter 7). Further elucidation of mechanisms of transplantation 
tolerance, namely the identification of specific markers for regulatory T cells, 
may lead to significant advances on our understanding of T cell suppression 
and may greatly facilitate the clinical application of tolerogenic strategies. 
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